



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|------------------------------|--|---|---------------|-------------------------|----|---------------|------------------------------|----|---------------|------------------------------|----|---------------|------------------------------|----|---------------|----------------------------|----|---------------|----------------------------|----|------------|-----------------------------|----|------------|-----------------------------|----|------------|-----------------------------|----|---------------|----------------------------|----|---------------|----------------------------|----|----------|-------------------------|--|----------|-------------------------|--|----------|-------------------------|--|----------|-------------------------|--|----------|------------------------------|--|----------|------------------------------|--|----------|------------------------------|--|----------|------------------------------|--|----------|----------------------------|--|----------|----------------------------|--|----------|----------------------------|--|----------|----------------------------|--|----------|----------------------------|--|----------|----------------------------|--|----------|-----------------------------|--|----------|-----------------------------|--|----------|-----------------------------|--|----------|-----------------------------|--|----------|----------------------------|--|----------|----------------------------|--|----------|----------------------------|--|---|----------------------------|--|---|--|--|--|
| <p>(51) International Patent Classification 7 : C12N 15/12, C07K 14/47, C12N 9/12, 5/10, C07K 16/18, A61K 38/17</p> | A2 | <p>(11) International Publication Number: WO 00/06728</p> <p>(43) International Publication Date: 10 February 2000 (10.02.00)</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>(21) International Application Number: PCT/US99/17132</p> <p>(22) International Filing Date: 28 July 1999 (28.07.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">09/123,494</td> <td style="width: 30%;">28 July 1998 (28.07.98)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>Not furnished</td> <td>28 July 1998 (28.07.98)</td> <td>US</td> </tr> <tr> <td>09/152,814</td> <td>14 September 1998 (14.09.98)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>14 September 1998 (14.09.98)</td> <td>US</td> </tr> <tr> <td>09/173,482</td> <td>14 October 1998 (14.10.98)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>14 October 1998 (14.10.98)</td> <td>US</td> </tr> <tr> <td>60/106,889</td> <td>3 November 1998 (03.11.98)</td> <td>US</td> </tr> <tr> <td>60/109,093</td> <td>19 November 1998 (19.11.98)</td> <td>US</td> </tr> <tr> <td>60/113,796</td> <td>22 December 1998 (22.12.98)</td> <td>US</td> </tr> <tr> <td>09/229,005</td> <td>12 January 1999 (12.01.99)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>12 January 1999 (12.01.99)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">US</td> <td style="width: 30%;">Not furnished (CIP)</td> <td style="width: 40%;"></td> </tr> <tr> <td>Filed on</td> <td>28 July 1998 (28.07.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/123,494 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>28 July 1998 (28.07.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/152,814 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 September 1998 (14.09.98)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 September 1998 (14.09.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/173,482 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 October 1998 (14.10.98)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 October 1998 (14.10.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/106,889 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>3 November 1998 (03.11.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/109,093 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 November 1998 (19.11.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/113,796 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>22 December 1998 (22.12.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/229,005 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>12 January 1999 (12.01.99)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>12 January 1999 (12.01.99)</td> <td></td> </tr> </table> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> </td> <td style="width: 50%; vertical-align: top;"> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94709 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Drive, Sunnyvale, CA 94086 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). SHIH, Leo, L. [US/US]; Apt. B, 1081 Tanland Drive, Palo Alto, CA 94303 (US).</p> <p>(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p> </td> </tr> <tr> <td colspan="3" style="vertical-align: top;"> <p>(54) Title: PHOSPHORYLATION EFFECTORS</p> <p>(57) Abstract</p> <p>The invention provides human phosphorylation effectors (PHSP) and polynucleotides which identify and encode PHSP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PHSP.</p> </td> </tr> </table> | | | <p>(21) International Application Number: PCT/US99/17132</p> <p>(22) International Filing Date: 28 July 1999 (28.07.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">09/123,494</td> <td style="width: 30%;">28 July 1998 (28.07.98)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>Not furnished</td> <td>28 July 1998 (28.07.98)</td> <td>US</td> </tr> <tr> <td>09/152,814</td> <td>14 September 1998 (14.09.98)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>14 September 1998 (14.09.98)</td> <td>US</td> </tr> <tr> <td>09/173,482</td> <td>14 October 1998 (14.10.98)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>14 October 1998 (14.10.98)</td> <td>US</td> </tr> <tr> <td>60/106,889</td> <td>3 November 1998 (03.11.98)</td> <td>US</td> </tr> <tr> <td>60/109,093</td> <td>19 November 1998 (19.11.98)</td> <td>US</td> </tr> <tr> <td>60/113,796</td> <td>22 December 1998 (22.12.98)</td> <td>US</td> </tr> <tr> <td>09/229,005</td> <td>12 January 1999 (12.01.99)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>12 January 1999 (12.01.99)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">US</td> <td style="width: 30%;">Not furnished (CIP)</td> <td style="width: 40%;"></td> </tr> <tr> <td>Filed on</td> <td>28 July 1998 (28.07.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/123,494 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>28 July 1998 (28.07.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/152,814 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 September 1998 (14.09.98)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 September 1998 (14.09.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/173,482 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 October 1998 (14.10.98)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 October 1998 (14.10.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/106,889 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>3 November 1998 (03.11.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/109,093 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 November 1998 (19.11.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/113,796 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>22 December 1998 (22.12.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/229,005 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>12 January 1999 (12.01.99)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>12 January 1999 (12.01.99)</td> <td></td> </tr> </table> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> | 09/123,494 | 28 July 1998 (28.07.98) | US | Not furnished | 28 July 1998 (28.07.98) | US | 09/152,814 | 14 September 1998 (14.09.98) | US | Not furnished | 14 September 1998 (14.09.98) | US | 09/173,482 | 14 October 1998 (14.10.98) | US | Not furnished | 14 October 1998 (14.10.98) | US | 60/106,889 | 3 November 1998 (03.11.98) | US | 60/109,093 | 19 November 1998 (19.11.98) | US | 60/113,796 | 22 December 1998 (22.12.98) | US | 09/229,005 | 12 January 1999 (12.01.99) | US | Not furnished | 12 January 1999 (12.01.99) | US | US | Not furnished (CIP) | | Filed on | 28 July 1998 (28.07.98) | | US | 09/123,494 (CIP) | | Filed on | 28 July 1998 (28.07.98) | | US | 09/152,814 (CIP) | | Filed on | 14 September 1998 (14.09.98) | | US | Not furnished (CIP) | | Filed on | 14 September 1998 (14.09.98) | | US | 09/173,482 (CIP) | | Filed on | 14 October 1998 (14.10.98) | | US | Not furnished (CIP) | | Filed on | 14 October 1998 (14.10.98) | | US | 60/106,889 (CIP) | | Filed on | 3 November 1998 (03.11.98) | | US | 60/109,093 (CIP) | | Filed on | 19 November 1998 (19.11.98) | | US | 60/113,796 (CIP) | | Filed on | 22 December 1998 (22.12.98) | | US | 09/229,005 (CIP) | | Filed on | 12 January 1999 (12.01.99) | | US | Not furnished (CIP) | | Filed on | 12 January 1999 (12.01.99) | | <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94709 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Drive, Sunnyvale, CA 94086 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). SHIH, Leo, L. [US/US]; Apt. B, 1081 Tanland Drive, Palo Alto, CA 94303 (US).</p> <p>(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p> | <p>(54) Title: PHOSPHORYLATION EFFECTORS</p> <p>(57) Abstract</p> <p>The invention provides human phosphorylation effectors (PHSP) and polynucleotides which identify and encode PHSP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PHSP.</p> | | |
| <p>(21) International Application Number: PCT/US99/17132</p> <p>(22) International Filing Date: 28 July 1999 (28.07.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">09/123,494</td> <td style="width: 30%;">28 July 1998 (28.07.98)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>Not furnished</td> <td>28 July 1998 (28.07.98)</td> <td>US</td> </tr> <tr> <td>09/152,814</td> <td>14 September 1998 (14.09.98)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>14 September 1998 (14.09.98)</td> <td>US</td> </tr> <tr> <td>09/173,482</td> <td>14 October 1998 (14.10.98)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>14 October 1998 (14.10.98)</td> <td>US</td> </tr> <tr> <td>60/106,889</td> <td>3 November 1998 (03.11.98)</td> <td>US</td> </tr> <tr> <td>60/109,093</td> <td>19 November 1998 (19.11.98)</td> <td>US</td> </tr> <tr> <td>60/113,796</td> <td>22 December 1998 (22.12.98)</td> <td>US</td> </tr> <tr> <td>09/229,005</td> <td>12 January 1999 (12.01.99)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>12 January 1999 (12.01.99)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">US</td> <td style="width: 30%;">Not furnished (CIP)</td> <td style="width: 40%;"></td> </tr> <tr> <td>Filed on</td> <td>28 July 1998 (28.07.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/123,494 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>28 July 1998 (28.07.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/152,814 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 September 1998 (14.09.98)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 September 1998 (14.09.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/173,482 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 October 1998 (14.10.98)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>14 October 1998 (14.10.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/106,889 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>3 November 1998 (03.11.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/109,093 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 November 1998 (19.11.98)</td> <td></td> </tr> <tr> <td>US</td> <td>60/113,796 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>22 December 1998 (22.12.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/229,005 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>12 January 1999 (12.01.99)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>12 January 1999 (12.01.99)</td> <td></td> </tr> </table> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> | 09/123,494 | 28 July 1998 (28.07.98) | US | Not furnished | 28 July 1998 (28.07.98) | US | 09/152,814 | 14 September 1998 (14.09.98) | US | Not furnished | 14 September 1998 (14.09.98) | US | 09/173,482 | 14 October 1998 (14.10.98) | US | Not furnished | 14 October 1998 (14.10.98) | US | 60/106,889 | 3 November 1998 (03.11.98) | US | 60/109,093 | 19 November 1998 (19.11.98) | US | 60/113,796 | 22 December 1998 (22.12.98) | US | 09/229,005 | 12 January 1999 (12.01.99) | US | Not furnished | 12 January 1999 (12.01.99) | US | US | Not furnished (CIP) | | Filed on | 28 July 1998 (28.07.98) | | US | 09/123,494 (CIP) | | Filed on | 28 July 1998 (28.07.98) | | US | 09/152,814 (CIP) | | Filed on | 14 September 1998 (14.09.98) | | US | Not furnished (CIP) | | Filed on | 14 September 1998 (14.09.98) | | US | 09/173,482 (CIP) | | Filed on | 14 October 1998 (14.10.98) | | US | Not furnished (CIP) | | Filed on | 14 October 1998 (14.10.98) | | US | 60/106,889 (CIP) | | Filed on | 3 November 1998 (03.11.98) | | US | 60/109,093 (CIP) | | Filed on | 19 November 1998 (19.11.98) | | US | 60/113,796 (CIP) | | Filed on | 22 December 1998 (22.12.98) | | US | 09/229,005 (CIP) | | Filed on | 12 January 1999 (12.01.99) | | US | Not furnished (CIP) | | Filed on | 12 January 1999 (12.01.99) | | <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). AU-YOUNG, Janice [US/US]; 1419 Kains Avenue, Berkeley, CA 94709 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). AZIMZAI, Yalda [US/US]; 2045 Rock Springs Drive, Hayward, CA 94545 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Drive, Sunnyvale, CA 94086 (US). LU, Dyung, Aina, M. [US/US]; 55 Park Belmont Place, San Jose, CA 95136 (US). SHIH, Leo, L. [US/US]; Apt. B, 1081 Tanland Drive, Palo Alto, CA 94303 (US).</p> <p>(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p> | | | | | | |
| 09/123,494 | 28 July 1998 (28.07.98) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Not furnished | 28 July 1998 (28.07.98) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 09/152,814 | 14 September 1998 (14.09.98) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Not furnished | 14 September 1998 (14.09.98) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 09/173,482 | 14 October 1998 (14.10.98) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Not furnished | 14 October 1998 (14.10.98) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 60/106,889 | 3 November 1998 (03.11.98) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 60/109,093 | 19 November 1998 (19.11.98) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 60/113,796 | 22 December 1998 (22.12.98) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 09/229,005 | 12 January 1999 (12.01.99) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Not furnished | 12 January 1999 (12.01.99) | US | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | Not furnished (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 28 July 1998 (28.07.98) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | 09/123,494 (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 28 July 1998 (28.07.98) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | 09/152,814 (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 14 September 1998 (14.09.98) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | Not furnished (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 14 September 1998 (14.09.98) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | 09/173,482 (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 14 October 1998 (14.10.98) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | Not furnished (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 14 October 1998 (14.10.98) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | 60/106,889 (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 3 November 1998 (03.11.98) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | 60/109,093 (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 19 November 1998 (19.11.98) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | 60/113,796 (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 22 December 1998 (22.12.98) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | 09/229,005 (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 12 January 1999 (12.01.99) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| US | Not furnished (CIP) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Filed on | 12 January 1999 (12.01.99) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>(54) Title: PHOSPHORYLATION EFFECTORS</p> <p>(57) Abstract</p> <p>The invention provides human phosphorylation effectors (PHSP) and polynucleotides which identify and encode PHSP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PHSP.</p> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Larvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

PHOSPHORYLATION EFFECTORS

TECHNICAL FIELD

5 This invention relates to nucleic acid and amino acid sequences of phosphorylation effectors and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, immune, and neuronal disorders.

 Kinases and phosphatases are critical components of intracellular signal transduction mechanisms. Kinases catalyze the transfer of high energy phosphate groups from adenosine triphosphate (ATP) to various target proteins. Phosphatases, in contrast, remove phosphate groups from proteins. Reversible protein phosphorylation is the main strategy for regulating protein activity in eukaryotic cells. In general, proteins are activated by phosphorylation in response to extracellular signals such as hormones, neurotransmitters, and growth and differentiation factors.

15 Protein dephosphorylation occurs when down-regulation of a signaling pathway is required. The coordinate activities of kinases and phosphatases regulate key cellular processes such as proliferation, differentiation, and cell cycle progression. Kinases comprise the largest known enzyme superfamily and are widely varied in their substrate specificities. Kinases may be categorized based on the specific amino acid residues that are phosphorylated in their substrates:

20 protein tyrosine kinases (PTK) phosphorylate tyrosine residues, and protein serine/threonine kinases (STK) phosphorylate serine and/or threonine residues. Almost all kinases contain a conserved 250-300 amino acid catalytic domain. This domain can be further divided into 11 subdomains. N-terminal subdomains I-IV fold into a two-lobed structure which binds and orients the ATP donor molecule, and subdomain V spans the two lobes. C-terminal subdomains VIA-XI

25 bind the protein substrate and transfer the gamma phosphate from ATP to the hydroxyl group of a serine, threonine, or tyrosine residue. Each of the 11 subdomains contains specific catalytic residues or amino acid motifs characteristic of that subdomain. For example, subdomain I contains an 8-amino acid glycine-rich ATP binding consensus motif, subdomain II contains a critical lysine residue required for maximal catalytic activity, and subdomains VI and IX comprise

30 the highly conserved catalytic core. Kinases may also be categorized by additional amino acid sequences, generally between 5 and 100 residues, which either flank or occur within the kinase domain. These additional amino acid sequences regulate kinase activity and determine substrate specificity. (Reviewed in Hardie, G. and Hanks, S. (1995) The Protein Kinase Facts Books, Vol I:7-20 Academic Press, San Diego, CA.)

35 STKs include both protein kinase A (PKA) and calcium-dependent protein kinase C

(PKC), both of which transduce signals from plasma membrane receptors. The activities of PKA and PKC are directly regulated by second messenger signaling molecules such as cyclic AMP and diacylglycerol, respectively. A novel kinase identified by genetic analysis in the fission yeast Schizosaccharomyces pombe is encoded by the *cek1*⁺ gene and is related to both PKA and PKC
5 (Samejima, I. and Yanagida, M. (1994) Mol. Cell. Biol. 14:6361-6371). *cek1*⁺ encodes an unusually large kinase of 1309 amino acids. The kinase domain spans residues 585 to 987, and 112 additional amino acids are present in this domain between subdomains VII and VIII. Overexpression of *cek1*⁺ suppresses mutations in *cut8*⁺, a gene required for chromosome segregation during mitosis. Therefore, *cek1*⁺ may encode a unique member of the PKA/PKC
10 protein family with a role in mitotic signaling and cell cycle progression.

PTKs may be classified as either transmembrane or nontransmembrane proteins.

Transmembrane tyrosine kinases function as receptors for most growth factors. Binding of growth factor to the receptor activates the transfer of a phosphate group from ATP to selected tyrosine side chains of the receptor itself and other specific second messenger proteins. Growth factors
15 (GF) that associate with receptor PTKs include epidermal GF, platelet-derived GF, fibroblast GF, hepatocyte GF, insulin and insulin-like GFs, nerve GF, vascular endothelial GF, and macrophage colony stimulating factor. Nontransmembrane PTKs form signaling complexes with the cytosolic domains of plasma membrane receptors. Receptors that signal through nontransmembrane PTKs include cytokine, hormone, and antigen-specific lymphocytic receptors. Many PTKs were first
20 identified as oncogene products in cancer cells in which PTK activation was no longer subject to normal cellular controls. In fact, about one third of the known oncogenes encode PTKs. Furthermore, cellular transformation (oncogenesis) is often accompanied by increased tyrosine phosphorylation activity (Charbonneau, H. and Tonks, N. K. (1992) Annu. Rev. Cell Biol. 8:463-93). Regulation of PTK activity may therefore be an important strategy in controlling some
25 types of cancer.

Some kinases utilize carbohydrates as their substrates and are important for glucose metabolism. For example, glycolysis employs four distinct kinases to effect the conversion of glucose to pyruvate, a key metabolite in the production of ATP. One of these enzymes is phosphofructokinase (PFK) which catalyzes the transfer of phosphate from ATP to fructose 6-
30 phosphate. PFK is an allosteric enzyme and a key regulator of glycolysis. In certain genetic muscle disorders, such as muscle phosphofructokinase deficiency type VII, phosphofructokinase activity is absent in muscle and deficient in red blood cells. As a result, afflicted individuals suffer from mild hemolytic anemia and muscle pain (Isselbacher, K.J. et al. (1994) Harrison's Principles of Internal Medicine, McGraw-Hill, New York, NY, p. 2102).

35 Kinase-mediated phosphorylation is antagonized by the activity of phosphatases, which

remove phosphate groups by hydrolysis. Phosphatases are classified into one of three evolutionarily distinct families: the protein serine/threonine phosphatases (PPs), the protein tyrosine phosphatases, and the acid/alkaline phosphatases. PPs may be further categorized into four distinct groups: PP-I, PP-IIA, PP-IIB, and PP-IIC. (Cohen, P. (1989) *Annu. Rev. Biochem.* 58:453-508). PP-I, in particular, dephosphorylates many of the proteins phosphorylated by PKA and is therefore an important regulator of signal transduction pathways. Kinase-activated proteins which bind to and inhibit PP-I have been identified. These inhibitors potentiate the activity of kinases such as PKA by allowing protein substrates to remain in their phosphorylated, activated state. A novel inhibitor of PP-1 has been purified from porcine aorta (Eto, M. et al. (1995) *J. Biochem.* 118:1104-1107; Eto, M. et al. (1997) *FEBS Lett.* 410:356-360). This inhibitor, called CPI17, is 147 amino acids in length and is activated by PKC. CPI17 expression is restricted to smooth muscle tissues such as aorta and bladder, suggesting that CPI17 functions in PKC-mediated signal transduction pathways in these tissues, possibly through a calcium-dependent mechanism.

15 The discovery of new phosphorylation effectors and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, immune, and neuronal disorders.

SUMMARY OF THE INVENTION

20

The invention features substantially purified polypeptides, phosphorylation effectors, referred to collectively as "PHSP" and individually as "PHSP-1 to PHSP-31". In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

25

The invention further provides a substantially purified variant having at least 90% amino acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-31, and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof. The invention also includes an

30 isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising

35 an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments

thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample
5 containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.
10 The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62, and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62, and fragments thereof. The invention also provides an
15 isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62, and fragments thereof.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the
20 group consisting of SEQ ID NO:1-31, and fragments thereof. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the expression of the polypeptide; and
25 (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected
30 from the group consisting of SEQ ID NO:1-31, and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of PHSP, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a
35 substantially purified polypeptide having the amino acid sequence selected from the group

consisting of SEQ ID NO:1-31, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of PHSP, the method comprising administering to a subject in
5 need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.

BRIEF DESCRIPTION OF THE TABLES

Table 1 shows nucleotide and polypeptide sequence identification numbers (SEQ ID NO),
10 clone identification numbers (clone ID), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding PHSP.

Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods and algorithms used for identification of PHSP.

Table 3 shows the tissue-specific expression patterns of each nucleic acid sequence as
15 determined by northern analysis, diseases, disorders, or conditions associated with these tissues, and the vector into which each cDNA was cloned.

Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding PHSP were isolated.

Table 5 shows the tools, programs, and algorithms used to analyze PHSP, along with
20 applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods
25 described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for
30 example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention
35 belongs. Although any machines, materials, and methods similar or equivalent to those described

herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"PHSP" refers to the amino acid sequences of substantially purified PHSP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which, when bound to PHSP, increases or prolongs the duration of the effect of PHSP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of PHSP.

An "allelic variant" is an alternative form of the gene encoding PHSP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding PHSP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as PHSP or a polypeptide with at least one functional characteristic of PHSP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding PHSP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding PHSP. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent PHSP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of PHSP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine,

and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

The terms "amino acid" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of PHSP which are preferably at least 5 to about 15 amino acids in length, most preferably at least 14 amino acids, and which retain some biological activity or immunological activity of PHSP. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term "antagonist" refers to a molecule which, when bound to PHSP, decreases the amount or the duration of the effect of the biological or immunological activity of PHSP. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of PHSP.

The term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind PHSP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell,

the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

The term "biologically active," refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic PHSP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding PHSP or fragments of PHSP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, extended using the XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding PHSP, by northern analysis is indicative of the presence of nucleic acids encoding PHSP in a sample, and

thereby correlates with expression of the transcript from the polynucleotide encoding PHSP.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" and "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR, Madison WI) which creates alignments between two or more sequences according to methods selected by the user, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988) Gene 73:237-244.) The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A

and sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) Methods Enzymol. 183:626-645.) Identity between
5 sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

“Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

10 The term “humanized antibody” refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

15 The term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate
20 substrate to which cells or their nucleic acids have been fixed).

The words “insertion” or “addition” refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

“Immune response” can refer to conditions associated with inflammation, trauma, immune
25 disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term “microarray” refers to an arrangement of distinct polynucleotides on a substrate.

The terms “element” or “array element” in a microarray context, refer to hybridizable
30 polynucleotides arranged on the surface of a substrate.

The term “modulate” refers to a change in the activity of PHSP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PHSP.

The phrases “nucleic acid” or “nucleic acid sequence,” as used herein, refer to a
35 nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to

DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which, comprise a region of unique polynucleotide sequence that specifically identifies

5 SEQ ID NO:32-62, for example, as distinct from any other sequence in the same genome. For example, a fragment of SEQ ID NO:32-62 is useful in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:32-62 from related polynucleotide sequences. A fragment of SEQ ID NO:32-62 is at least about 15-20 nucleotides in length. The precise length of the fragment of SEQ ID NO:32-62 and the region of SEQ ID

10 NO:32-62 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment. In some cases, a fragment, when translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or structural domain characteristic, e.g., ATP-binding site, of the full-length polypeptide

The terms "operably associated" or "operably linked" refer to functionally related nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if

15 the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator sequences that control expression of the polypeptide.

20 The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or microarray. "Oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

25 "Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

30 The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding PHSP, or fragments thereof, or PHSP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" or "specifically binding" refer to that interaction between a

35 protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon

the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds
5 to the antibody.

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the
10 concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with
15 which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers,
20 microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of
25 foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host
30 chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of PHSP polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with
35 isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of

glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

5 The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to PHSP. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The
10 corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide
15 polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

THE INVENTION

 The invention is based on the discovery of new human phosphorylation effectors (PHSP),
20 the polynucleotides encoding PHSP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, immune, and neuronal disorders.

 Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding PHSP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte
25 clones in which nucleic acids encoding each PHSP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. The clones in column 5 were used to assemble the consensus nucleotide sequence of each PHSP and are useful as fragments in hybridization technologies.

30 The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO and column 2 shows the number of amino acid residues in each polypeptide. Columns 3 and 4 show potential phosphorylation sites and potential glycosylation sites, respectively. Column 5 shows the amino acid residues comprising signature sequences and motifs. Column 6 shows homologous sequences as identified by BLAST analysis,
35 while column 7 shows analytical methods used to identify each polypeptide through sequence

homology and protein motifs.

The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding PHSP. The first column of Table 3 lists the SEQ ID NOs. Column 2 lists tissue categories which express PHSP as a fraction of total tissue

5 categories expressing PHSP. Column 3 lists diseases, disorders, or conditions associated with those tissues expressing PHSP. Column 4 lists the vectors used to subclone the cDNA library.

The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries from which cDNA clones encoding PHSP were isolated. Column 1 references the SEQ ID NO, column 2 shows the cDNA libraries from which these clones were isolated, and column 3
10 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

The following fragments of the nucleotide sequences encoding PHSP are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:32-62 and to distinguish between SEQ ID NO:32-62 and related polynucleotide sequences. The useful
15 fragments include, the fragment of SEQ ID NO:32 from about nucleotide 81 to about nucleotide 110; the fragment of SEQ ID NO:33 from about nucleotide 323 to about nucleotide 352; the fragment of SEQ ID NO:34 from about nucleotide 83 to about nucleotide 112; the fragment of SEQ ID NO:35 from about nucleotide 524 to about nucleotide 553; the fragment of SEQ ID NO:36 from about nucleotide 275 to about nucleotide 346; the fragment of SEQ ID NO:37 from
20 about nucleotide 1328 to about nucleotide 1396; the fragment of SEQ ID NO:38 from about nucleotide 245 to about nucleotide 304; the fragment of SEQ ID NO:39 from about nucleotide 1253 to about nucleotide 1312; the fragment of SEQ ID NO:41 from about nucleotide 117 to about nucleotide 170; the fragments of SEQ ID NO:42 from about nucleotide 109 to about nucleotide 153, and from about nucleotide 325 to about nucleotide 369; the fragments of SEQ ID NO:43 from
25 about nucleotide 380 to about nucleotide 424, and from about nucleotide 1190 to about nucleotide 1234; the fragment of SEQ ID NO:44 from about nucleotide 1 to about nucleotide 46; the fragment of SEQ ID NO:45 from about nucleotide 533 to about nucleotide 577; the fragments of SEQ ID NO:46 from about nucleotide 109 to about nucleotide 153, and from about nucleotide 379 to about nucleotide 423; the fragment of SEQ ID NO:47 from about nucleotide 1730 to about
30 nucleotide 1774; the fragment of SEQ ID NO:48 from about nucleotide 433 to about nucleotide 477; the fragment of SEQ ID NO:49 from about nucleotide 1117 to about nucleotide 1155; the fragment of SEQ ID NO:50 from about nucleotide 166 to about nucleotide 213; the fragment of SEQ ID NO:51 from about nucleotide 60 to about nucleotide 95; the fragment of SEQ ID NO:52 from about nucleotide 326 to about nucleotide 370; the fragment of SEQ ID NO:53 from about
35 nucleotide 25 to about nucleotide 66; the fragment of SEQ ID NO:54 from about nucleotide 55 to

about nucleotide 102; the fragment of SEQ ID NO:55 from about nucleotide 138 to about nucleotide 167; the fragment of SEQ ID NO:56 from about nucleotide 29 to about nucleotide 58; the fragment of SEQ ID NO:57 from about nucleotide 455 to about nucleotide 484; the fragment of SEQ ID NO:58 from about nucleotide 226 to about nucleotide 255; the fragment of SEQ ID NO:59 from about nucleotide 557 to about nucleotide 598; the fragment of SEQ ID NO:60 from about nucleotide 284 to about nucleotide 325; the fragment of SEQ ID NO:61 from about nucleotide 1043 to about nucleotide 1090; and the fragment of SEQ ID NO:62 from about nucleotide 84 to about nucleotide 132. The polypeptides encoded by the fragments of SEQ ID NO:32-62 are useful, for example, as immunogenic peptides.

10 The invention also encompasses PHSP variants. A preferred PHSP variant is one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the PHSP amino acid sequence, and which contains at least one functional or structural characteristic of PHSP.

15 The invention also encompasses polynucleotides which encode PHSP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:32-62, which encodes PHSP.

20 The invention also encompasses a variant of a polynucleotide sequence encoding PHSP. In particular, such a variant polynucleotide sequence will have at least about 80%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding PHSP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:32-62 which has at least about 80%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:32-62. Any one of the polynucleotide variants described above can encode 25 an amino acid sequence which contains at least one functional or structural characteristic of PHSP.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding PHSP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could 30 be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring PHSP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode PHSP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring PHSP under appropriately 35 selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding

PHSP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide
5 sequence encoding PHSP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode PHSP and PHSP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the
10 synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding PHSP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID
15 NO:32-62 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low
20 stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the
25 concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35%
30 formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

The washing steps which follow hybridization can also vary in stringency. Wash stringency
35 conditions can be defined by salt concentration and by temperature. As above, wash stringency can

be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include temperature of at least about 25°C, more preferably of at least about 42°C, and most preferably of at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art.

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 (Hamilton, Reno NV), Peltier thermal cycler 200 (PTC200; MJ Research, Watertown MA) and the ABI CATALYST 800 (Perkin-Elmer). Sequencing is then carried out using the ABI 373 or 377 DNA sequencing systems (Perkin-Elmer), or the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding PHSP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions

and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) *Nucleic Acids Res.* 19:3055-306). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode PHSP may be cloned in recombinant DNA molecules that direct expression of PHSP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express PHSP.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter PHSP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction

sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding PHSP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.)

5 Alternatively, PHSP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of PHSP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other
10 proteins, or any part thereof, to produce a variant polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New
15 York NY.)

In order to express a biologically active PHSP, the nucleotide sequences encoding PHSP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and
20 inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding PHSP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding PHSP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding PHSP and its initiation codon and upstream regulatory sequences are inserted into
25 the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion
30 of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding PHSP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and
35 in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory

Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding PHSP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

10 In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding PHSP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding PHSP can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or pSPORT1 plasmid (Life Technologies). Ligation of sequences encoding PHSP into the vector's multiple cloning site
15 disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) *J. Biol. Chem.* 264:5503-5509.) When large quantities of PHSP are needed, e.g. for the production of antibodies,
20 vectors which direct high level expression of PHSP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of PHSP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct
25 either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Grant et al. (1987) *Methods Enzymol.* 153:516-54; and Scorer, C. A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of PHSP. Transcription of sequences encoding PHSP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in
30 combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See,
35 e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY,

pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding PHSP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader
5 sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses PHSP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

10 Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355.)

15 For long term production of recombinant proteins in mammalian systems, stable expression of PHSP in cell lines is preferred. For example, sequences encoding PHSP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before
20 being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These
25 include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *apr* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides, neomycin and G-418; and *als* or *pat*
30 confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP;
35 Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may

be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding PHSP is inserted within a marker gene sequence, transformed cells containing sequences encoding PHSP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding PHSP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding PHSP and that express PHSP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of PHSP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PHSP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul MN, Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding PHSP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding PHSP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for

ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding PHSP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein
5 produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode PHSP may be designed to contain signal sequences which direct secretion of PHSP through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the
10 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational
15 activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Bethesda MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding PHSP may be ligated to a heterologous sequence resulting in translation of a
20 fusion protein in any of the aforementioned host systems. For example, a chimeric PHSP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of PHSP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST),
25 maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity
30 purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the PHSP encoding sequence and the heterologous protein sequence, so that PHSP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch 10). A variety of commercially available kits may also be used to facilitate expression and purification of
35 fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled PHSP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract systems (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably ³⁵S-methionine.

Fragments of PHSP may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra, pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Various fragments of PHSP may be synthesized separately and then combined to produce the full length molecule.

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of PHSP and protein phosphatases. In addition, the expression of PHSP is closely associated with reproductive tissue, nervous tissue, gastrointestinal tissue, cell proliferation, cancer, inflammation, and immune response. Therefore, PHSP appears to play a role in cell proliferative, immune, and neuronal disorders. In the treatment of disorders associated with increased PHSP expression or activity, it is desirable to decrease the expression or activity of PHSP. In the treatment of disorders associated with decreased PHSP expression or activity, it is desirable to increase the expression or activity of PHSP.

Therefore, in one embodiment, PHSP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PHSP. Examples of such disorders include, but are not limited to, a cell proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis,

hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner
5 syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a neuronal disorder, such as akathisia, Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, dementia, depression, diabetic neuropathy, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, peripheral neuropathy, multiple sclerosis, neurofibromatosis, Parkinson's
10 disease, paranoid psychoses, postherpetic neuralgia, schizophrenia, and Tourette's disorder.

In another embodiment, a vector capable of expressing PHSP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PHSP including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified
15 PHSP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of PHSP including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of PHSP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity
20 of PHSP including, but not limited to, those listed above.

In a further embodiment, an antagonist of PHSP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PHSP. Examples of such disorders include, but are not limited to, those described above. In one aspect, an antibody which specifically binds PHSP may be used directly as an antagonist or indirectly as a targeting or delivery
25 mechanism for bringing a pharmaceutical agent to cells or tissue which express PHSP.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding PHSP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of PHSP including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary
30 sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic
35 efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of PHSP may be produced using methods which are generally known in the art. In particular, purified PHSP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PHSP. Antibodies to PHSP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with PHSP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PHSP have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of PHSP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to PHSP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce PHSP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton

D.R. (1991) Proc. Natl. Acad. Sci. 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; 5 Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for PHSP may also be generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and 10 easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such 15 immunoassays typically involve the measurement of complex formation between PHSP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering PHSP epitopes is preferred, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay 20 techniques may be used to assess the affinity of antibodies for PHSP. Affinity is expressed as an association constant, K_a , which is defined as the molar concentration of PHSP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_a determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple PHSP epitopes, represents the average affinity, or avidity, of the antibodies for 25 PHSP. The K_a determined for a preparation of monoclonal antibodies, which are monospecific for a particular PHSP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_a ranging from about 10^9 to 10^{12} L/mole are preferred for use in immunoassays in which the PHSP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_a ranging from about 10^6 to 10^7 L/mole are preferred for use in immunopurification and similar 30 procedures which ultimately require dissociation of PHSP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington, DC; Liddell, J. E. and Cryer, A. (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to 35 determine the quality and suitability of such preparations for certain downstream applications. For

example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is preferred for use in procedures requiring precipitation of PHSP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra,
5 and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding PHSP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding PHSP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary
10 to polynucleotides encoding PHSP. Thus, complementary molecules or fragments may be used to modulate PHSP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding PHSP.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or
15 from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding PHSP. (See, e.g., Sambrook, supra; Ausubel, 1995, supra.)

Genes encoding PHSP can be turned off by transforming a cell or tissue with expression
20 vectors which express high levels of a polynucleotide, or fragment thereof, encoding PHSP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the
25 vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding PHSP. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly,
30 inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A
35 complementary sequence or antisense molecule may also be designed to block translation of mRNA

by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding PHSP.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding PHSP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such

therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of PHSP, antibodies to PHSP, and mimetics, agonists, antagonists, or inhibitors of PHSP. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.

5 Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, 15 or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be 20 permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many 25 acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

30 After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of PHSP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The 35 determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for
5 administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example PHSP or fragments thereof, antibodies of PHSP, and agonists, antagonists or inhibitors of PHSP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by
10 calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD_{50}/ED_{50} ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such
15 compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the
20 active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular
25 formulation.

Normal dosage amounts may vary from about 0.1 μg to 100,000 μg , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their
30 inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind PHSP may be used for the diagnosis of disorders characterized by expression of PHSP, or in assays to monitor patients being
35 treated with PHSP or agonists, antagonists, or inhibitors of PHSP. Antibodies useful for diagnostic

purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for PHSP include methods which utilize the antibody and a label to detect PHSP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter
5 molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring PHSP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PHSP expression. Normal or standard values for PHSP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to PHSP under conditions suitable
10 for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of PHSP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding PHSP may be used for
15 diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of PHSP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of PHSP, and to monitor regulation of PHSP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide
20 sequences, including genomic sequences, encoding PHSP or closely related molecules may be used to identify nucleic acid sequences which encode PHSP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high,
25 intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding PHSP, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably have at least 50% sequence identity to any of the PHSP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:32-
30 62 or from genomic sequences including promoters, enhancers, and introns of the PHSP gene.

Means for producing specific hybridization probes for DNAs encoding PHSP include the cloning of polynucleotide sequences encoding PHSP or PHSP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA
35 polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a

variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding PHSP may be used for the diagnosis of disorders associated with expression of PHSP. Examples of such disorders include, but are not limited to, a cell
5 proliferative disorder, such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall
10 bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an immune disorder, such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-
15 candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation,
20 osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and a neuronal disorder, such as akathisia,
25 Alzheimer's disease, amnesia, amyotrophic lateral sclerosis, bipolar disorder, catatonia, dementia, depression, diabetic neuropathy, Down's syndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease, peripheral neuropathy, multiple sclerosis, neurofibromatosis, Parkinson's disease, paranoid psychoses, postherpetic neuralgia, schizophrenia, and Tourette's disorder. The polynucleotide sequences encoding PHSP may be used in Southern or northern analysis, dot blot, or
30 other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered PHSP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PHSP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide
35 sequences encoding PHSP may be labeled by standard methods and added to a fluid or tissue sample

from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding PHSP in the sample
5 indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of PHSP, a normal or standard profile for expression is established. This may be accomplished by combining
10 body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PHSP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples
15 from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from
20 successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance
25 of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding PHSP may involve the use of PCR. These oligomers may be chemically synthesized, generated
30 enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding PHSP, or a fragment of a polynucleotide complementary to the polynucleotide encoding PHSP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

35 Methods which may also be used to quantify the expression of PHSP include radiolabeling

or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in
5 various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene
10 function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) *Proc. Natl. Acad. Sci.* 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al.
15 (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) *Proc. Natl. Acad. Sci.* 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding PHSP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to
20 artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) *Nat Genet.* 15:345-355; Price, C.M. (1993) *Blood Rev.* 7:127-134; and Trask, B.J. (1991) *Trends Genet.* 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome
25 mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the location of the gene encoding PHSP on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide
30 sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may
35 reveal associated markers even if the number or arm of a particular human chromosome is not known.

New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that
5 area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, PHSP, its catalytic or immunogenic fragments, or
10 oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between PHSP and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds
15 having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with PHSP, or fragments thereof, and washed. Bound PHSP is then detected by methods well known in the art. Purified PHSP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively,
20 non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PHSP specifically compete with a test compound for binding PHSP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PHSP.

25 In additional embodiments, the nucleotide sequences which encode PHSP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding
30 description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 09/173,482, 09/123,494, 09/152,814, 09/229,005, 60/106,889, 60/109,093,
35 and 60/113,796, are hereby expressly incorporated by reference.

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some
5 tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized
and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a
monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged
over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either
isopropanol or sodium acetate and ethanol, or by other routine methods.

10 Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA
purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated
using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN,
Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was
isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA
15 purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA
libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP
vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the
recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units
20 5.1-6.6). Reverse transcription was initiated using oligo d(T) or random primers. Synthetic
oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the
appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000
bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column
chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs
25 were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g.,
PBLUESCRIPT plasmid (Stratagene), pSPORT1 plasmid (Life Technologies), or pINCY (Incyte
Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells
including XL1-BLUE, XL1-BLUERF, or SOLR from Stratagene or DH5 α , DH10B, or
ELECTROMAX DH10B from Life Technologies.

30 II. Isolation of cDNA Clones

Plasmids were recovered from host cells by in vivo excision, using the UNIZAP vector
system (Stratagene) or cell lysis. Plasmids were purified using at least one of the following: a Magic
or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit
(Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid,
35 QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid kit from QIAGEN.

Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal
5 cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a Fluoroskan II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

10 cDNA sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Perkin-Elmer) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing
15 kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing systems (Perkin-Elmer) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading
20 frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the
25 art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other
30 parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR).

The polynucleotide sequences were validated by removing vector, linker, and polyA
35 sequences and by masking ambiguous bases, using algorithms and programs based on BLAST,

dynamic programing, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases, such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences
5 using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, Prosite, and Hidden Markov Model (HMM)-based
10 protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S.R. (1996) Curr. Opin. Str. Biol. 6:361-365.)

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:32-62. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and
15 amplification technologies were described in The Invention section above.

IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel,
20 1995, supra, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ database (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as
25 exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within
30 a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding PHSP occurred. Analysis involved the categorization of cDNA libraries by
35 organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic,

developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation/trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories.

- 5 Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

V. Extension of PHSP Encoding Polynucleotides

The full length nucleic acid sequences of SEQ ID NO:32-62 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this
10 fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer, to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in
15 hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction
20 mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg^{2+} , $(NH_4)_2SO_4$, and β -mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the
25 alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100 μ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE
30 and 0.5 μ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose mini-gel to determine which reactions were successful in extending
35 the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulphoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer).

In like manner, the nucleotide sequences of SEQ ID NO:32-62 are used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for such extension, and an appropriate genomic library.

VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:32-62 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 µCi of [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon

membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are compared.

5 VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array elements on the surface of a substrate. (See, e.g., Baldeschweiler, *supra*.) An array analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by hand
10 or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the scanned images.

15 Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an
20 appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) *Science* 270:467-470; Shalon, D. et al. (1996) *Genome Res.* 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The substrate is analyzed by procedures described above.

25 VIII. Complementary Polynucleotides

Sequences complementary to the PHSP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring PHSP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are
30 designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of PHSP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the PHSP-encoding transcript.

IX. Expression of PHSP

35 Expression and purification of PHSP is achieved using bacterial or virus-based expression

systems. For expression of PHSP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express PHSP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of PHSP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding PHSP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, PHSP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from PHSP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch 10 and 16). Purified PHSP obtained by these methods can be used directly in the following activity assay.

X. Demonstration of PHSP Activity

PHSP protein kinase is measured by the phosphorylation of a substrate in the presence of gamma-labeled ^{32}P -ATP. PHSP is incubated with an appropriate substrate and ^{32}P -ATP in a buffered solution. ^{32}P -labeled product is separated from free ^{32}P -ATP by gel electrophoresis or chromatographic procedures, and the incorporated ^{32}P is quantified by phosphorimage analysis or using a scintillation counter. The amount of ^{32}P detected is proportional to the activity of PHSP in this assay. The specific amino acid residue phosphorylated by PHSP may be determined by

phosphoamino acid analysis of the labeled, hydrolyzed protein.

PHSP phosphatase activity is measured by the removal of phosphate from a [^{32}P]-labelled substrate. PHSP is incubated with an appropriate [^{32}P]-labelled substrate in a buffered solution. Reaction products are separated by gel electrophoresis or chromatographic procedures, and the level of ^{32}P associated with the substrate molecule is quantified by phospho-image analysis or scintillation counting. The difference in ^{32}P associated with untreated substrate versus PHSP-treated substrate is a measure of phosphatase activity and is proportional to PHSP activity.

XI. Functional Assays

PHSP function is assessed by expressing the sequences encoding PHSP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate properties, for example, their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of PHSP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding PHSP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art.

Expression of mRNA encoding PHSP and other genes of interest can be analyzed by northern analysis or microarray techniques.

XII. Production of PHSP Specific Antibodies

PHSP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g.,
5 Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the PHSP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for
10 selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase
15 immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XIII. Purification of Naturally Occurring PHSP Using Specific Antibodies

20 Naturally occurring or recombinant PHSP is substantially purified by immunoaffinity chromatography using antibodies specific for PHSP. An immunoaffinity column is constructed by covalently coupling anti-PHSP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

25 Media containing PHSP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PHSP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/PHSP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and PHSP is collected.

30 XIV. Identification of Molecules Which Interact with PHSP

PHSP, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) *Biochem. J.* 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled PHSP, washed, and any wells with labeled PHSP complex are assayed. Data obtained using different concentrations of PHSP are used to
35 calculate values for the number, affinity, and association of PHSP with the candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific
5 embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

TABLE I

| Protein SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|-----------------------|--------------------------|----------|-----------|---|
| 1 | 32 | 132240 | BMARNOT02 | 132240H1 and 132240R1 (BMARNOT02), 3254142H1 (OVRTUT01), 1453821X14F1 and 1453821F6 (PENITUT01) |
| 2 | 33 | 2180116 | SININOT01 | 2180116H1 and 2180116T6 (SININOT01), 3046645H1 (HEAANOT01), 1918183H1 (PROSNOT06), and 1482405F1 (CORPNOT02) |
| 3 | 34 | 2197671 | SPLNFET02 | 2197671H1 (SPLNFET02), 666366X22R1 (SCORNOT01), 693783X14 (SYNORAT03), 824265X33F1 (PROSNOT06), 039482R1 and 039482F1 (HUVENOB01), 1453984T6 (PENITUT01), 1663987H1 (BRSTNOT09), and 125901R1 (LUNGNOT01) |
| 4 | 35 | 2594943 | OVRTUT02 | 2594943H1 (OVRTUT02), 3617557H1 (EPIPNOT01), 2269005R6 (UTRSNOT02), 1307764F6 (COLNFET02), 1377794F6 (LUNGNOT10), and 1286608H1 (BRAINOT11) |
| 5 | 36 | 1513871 | PANCTUT01 | 754239R6 (BRAITUT02), 1513871H1 (PANCTUT01), 2414420F6 (HNT3AZT01), 3291775F6 (BONRFET01), 3821451F6 (BONSTUT01) |
| 6 | 37 | 156108 | THP1PLB02 | 156108F1 and 156108H1 (THP1PLB02), 336346R6 (EOSIHET02), 1319528F1 (BLADNOT04), 2375549F6 (ISLTNOT01), SBFA04563F1, SBFA04977F1 |
| 7 | 38 | 2883243 | UTRSTUT05 | 1342082F6 (COLNTUT03), 1933387T6 (COLNNOT16), 2766460F6 (BRSTNOT12), 2883243H1 (UTRSTUT05), 3524262H1 (ESOGTUN01), 3766487F6 (BRSTNOT24) |

TABLE 1 cont.

| Protein SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|-----------------------|--------------------------|----------|-----------|---|
| 8 | 39 | 3173355 | UTRSTUT04 | 1300803F6 and 1300803T6 (BRSTNOT07), 2477542F6 (SMCANOT01), 2477542T6 (SMCANOT01), 2875968H1 (THYRNOT10), 3173355F6 and 3173355H1 (UTRSTUT04), 3290825H1 (BONRFET01), 5192561H1 (OVARBIT06) |
| 9 | 40 | 5116906 | SMCBUNT01 | 267517F1 (HNT2NOT01), 263823R1 (HNT2AGT01), 5116906H1 (SMCBUNT01) |
| 10 | 41 | 940589 | ADRENOT03 | 029801R6 (SPLNFET01), 940589H1 (ADRENOT03), 1737403T6 (COLNNOT22), 1805477F6 and 1805477T6 (SINTNOT13), 2447613H1 (THPINOT03), 3408563H1 (PROSTUS08), 3519506H1 (LUNGNOT03), 3637343T6 (LUNGNOT30) |
| 11 | 42 | 304421 | TESTNOT04 | 304421H1, 304421X318B2, and 304421X323B2 (TESTNOT04), 2639579F6 (BONTNOT01), 2951859H1 (KIDNFET01) |
| 12 | 43 | 1213802 | BRSTTUT01 | 894574R1 (BRSTNOT05), 1213802H1 (BRSTTUT01), 1233414F1 and 1234238H1 (LUNGFET03), 1255782F2 and 1255782T1 (MENITUT03), 1455429F1 (COLNFET02), 1576102T1 (LNODNOT03), 2189267F6 (PROSNOT26), 2748179F6 (LUNGTTUT11), 2831667H1 (TLYMNOT03), 3031229H1 (TLYMNOT05), 3054893H1 (LNODNOT08), 3797030F6 (SPLNNOT12), 3880154H1 (SPLNNOT11), 4852525H1 (TESTNOT10), 5514137H1 (BRADDIR01), 5518378H1 (LIVDIR01) |
| 13 | 44 | 1378134 | LUNGNOT10 | 1378134H1 and 1378134X11 (LUNGNOT10), 2205185F6 (SPLNFET02), 4959694H1 (TLYMNOT05), SAMA00107F1, SAMA00160F1, SAMA00020F1 |

TABLE I cont.

| Protein SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|-----------------------|--------------------------|----------|-----------|--|
| 14 | 45 | 1490070 | UCMCL5T01 | 432218H1 (BRAVUNT02), 1490070H1 (UCMCL5T01), 1535394F1 (SPLNNOT04), 1616509F6 and 1616509T6 (BRAITUT12), 2490845H1 (EOSITXT01), 2723789F6 (LUNGUT01), SAOA00263F1 |
| 15 | 46 | 1997814 | BRSTTUT03 | 855350R1 (NGANNOT01), 875417R1 (LUNGAST01), 895096R1 (BRSTNOT05), 1271348F1 (TESTTUT02), 1331289F6 (PANCNOT07), 1359243F1 (LUNGNOT12), 1540824T1 (SINTTUT01), 1839828H1 (EOSITXT01), 1997814H1 (BRSTTUT03), 2170638F6 (ENDCNOT03), 3751363F6 (UTRSNOT18) |
| 16 | 47 | 2299715 | BRSTNOT05 | 637354R6 and 637354T6 (NEUTGMT01), 1852144P6 (LUNGFET03), 2172576F6 (ENDCNOT03), 2232449F6 (PROSNOT16), 2299715H1 (BRSTNOT05), 2509737X325D2 (CONUTUT01), 2606210F6 (LUNGUT07), 2692024F6 (LUNGNOT23), 2805893F6 (BLADTUT08), 2986160H1 (CARGDIT01), 3085382H1 (HEAONOT03), 3136101F6 and 3136587H1 (SMCCNOT01), 4249977H1 (BRADDIR01) |
| 17 | 48 | 209854 | SPLNNOT02 | 209854H1 and 209854T6 (SPLNNOT02), 3152165R6 and 3152165T6 (ADRENON04) |
| 18 | 49 | 1384286 | BRAITUT08 | 676123R6 and 676123T6 (CRBLNOT01), 989218X11 and 989218X12 (LVENNOT03), 1384286H1 (BRAITUT08), 3099868H1 (PROSBPT03), 4693167H1 (BRAENOT02) |
| 19 | 50 | 1512656 | PANCTUT01 | 322847X5 (EOSIHET02), 1253795T6 (LUNGFET03), 1512656H1 (PANCTUT01), 1561686X303D1 (SPLNNOT04), 2212305H1 (SINTFET03), 2697679H1 (UTRSNOT12), 3205172H1 (PENCNOT03), 5313318H1 (KIDETXS02) |

TABLE 1 cont.

| Protein SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|-----------------------|--------------------------|----------|-----------|---|
| 20 | 51 | 2098635 | BRAITUT02 | 1268848T1, 1268848X301F1, and 2157157H1 (BRAINOT09), 2098635H1 and 2098635R6 (BRAITUT02), 2198819F6, 2198819X301D4, 2198819X303D1, 2198819X309B2, and 2198819X309D4 (SPLNFET02), 2784975H2 (BRSTNOT13), 3320340H1 (PROSBPT03) |
| 21 | 52 | 2446646 | THP1NOT03 | 000297R6 and 000297X61 (U937NOT01), 2446646H1 (THP1NOT03), 2557274F6 (THYMNOT03) |
| 22 | 53 | 2764911 | BRSTNOT12 | 678618T6 and 678618X14 (UTRSNOT02), 2304126R6 (BRSTNOT05), 2764911H1 (BRSTNOT12), 2834475F6 (TLYMNOT03), 2915803F6 (THYMFET03), 3035012F6 (TLYMNOT05), SAFC00027F1, SAFC00254F1, SAFC02376F1, SAFC01609F1 |
| 23 | 54 | 3013946 | MUSCNOT07 | 673753H1 (CRBLNOT01), 989218X11 and 989218X14 (LVENNOT03), 2821720F6 (ADRETUT06), 3013946F6, 3013946H1, and 3013946T6 (MUSCNOT07), 4693167H1 (BRAENOT02) |
| 24 | 55 | 067967 | HUVESTB01 | 067967X92, 067966R1, and 067967H1 (HUVESTB01), SAIA02074F1, SAIA03254F1, SAIA03603F1, and SAIA02259F1 |
| 25 | 56 | 346275 | THYMNOT02 | 346275H1 (THYMNOT02), 609792X12 (COLNNOT01), SAGA03543F1, SAGA02528F1, and SAGA00285F1 |
| 26 | 57 | 283746 | CARDNOT01 | 283746H1 and 283746X10 (CARDNOT01), 4903108H1 (TLYMNOT08), 557918X15 (MPHGLPT02), and 2379045F6 (ISLTNOT01) |
| 27 | 58 | 2696537 | UTRSNOT12 | 2696537H1 (UTRSNOT12), 3173337F6 (UTRSTUT04), 082658X100 (HUVESTB01), and 603219T6 (BRSTTUT01) |

TABLE 1 cont.

| Protein SEQ ID NO: | Nucleotide SEQ ID NO: | Clone ID | Library | Fragments |
|-----------------------|--------------------------|----------|-----------|--|
| 28 | 59 | 551178 | BEPINOT01 | 551178H1 (BEPINOT01), 861522R1 (BRAITUT03), 965838R1 (BRSTNOT05), 1574007F1 and 1574007T1 (LNODNOT03), 1830083T6 and 1831194T6 (THP1AZT01), 3098496H1 (CERVNOT03), 3293481H1 (TLYJINT01) |
| 29 | 60 | 619292 | PGANNOT01 | 613165F1 (COLNTUT02), 619292H1 and 619292X13 (PGANNOT01) |
| 30 | 61 | 2054049 | BEPINOT01 | 1736355F6 (COLNNOT22), 2054049H1 (BEPINOT01), 2379092T6 (ISLTNOT01), 3127284T3 (LUNGUT12), 3136377F6 (SMCCNOT01), SBMA00545F1, SBMA00827F1, SBMA02930F1, SBMA02853F1 |
| 31 | 62 | 2843910 | DRGLNOT01 | 036294X71 (HUVENOB01), 066017X102, 068399R1, and 068399X3 (HUVESTB01), 1527276H1 (UCMCL5T01), 1846570T6 (COLNNOT09), 2843910H1 (DRGLNOT01) |

TABLE 2

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Homologous sequences | Analytical Methods |
|---------------------------|---------------------------|---|-------------------------------------|---|--|---|
| 1 | 300 | S3 S15 S19 S20 S24 T98 S125 S231 T238 S257 S282 S12 S41 S70 T120 T143 S146 T242 | N85 N88 N96 | Protein kinase motifs: G161-F256 catalytic tk domain IX: V180-E202 | Protein kinase | BLAST PFAM PRINTS |
| 2 | 147 | S85 T38 S90 | | Calcium-binding repeat motifs: G28-L115 | PKC- potentiated inhibitory protein of PPI (CPI17) | BLAST PRINTS BLOCKS |
| 3 | 431 | T178 S282 T25 S34 S75 S106 S194 S198 T208 T264 S299 S303 S304 S308 T328 S345 S388 T46 S137 S260 | N44 N242 | PTK signatures: A18-Y283 ATP-binding site: I30-K53, E127-G164 Y196-H219 PK catalytic subdomains: M99-E112, Y134-L152 G181-I191, Y243- A265 | Ste20-like protein kinase | BLOCKS PRINTS PROFILES SCAN BLAST |
| 4 | 218 | S108 S68 S90 T133 T170 S172 T34 T123 T207 | | Phosphofructokinase domains: I47, V177-Q195 L148-Y164 | | PRINTS |

TABLE 2 cont.

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Homologous sequences | Analytical Methods |
|---------------------------|---------------------------|--|-------------------------------------|--|---|--|
| 5 | 474 | S14 S89 S98 S132 S472 T22 S26 S62 S66 T204 T320 T345 T359 S427 S443 S94 S128 T211 T336 S443 Y155 | | Protein kinase family signature: Y144-F425 | serine /threonine protein kinase | MOTIFS PFAM BLOCKS PRINTS ProfileScan BLAST |
| 6 | 540 | S102 S183 S267 T296 T301 S442 S34 S58 S180 S207 S224 T360 S374 S401 S428 S478 T484 Y23 | N100 N391 N457 N537 | Protein kinase family signature: L18-L287 | serine /threonine protein kinase | MOTIFS PFAM BLOCKS PRINTS PROFILESCAN BLAST |
| 7 | 454 | S57 S69 S130 T203 T212 S338 S420 S91 T101 T220 S271 S295 T315 S359 S381 Y197 | N55 N140 N218 N403 N437 N441 | SH2 domain: W63-Y138, W354-Y428 PI 3 kinase P85 regulator: K153-G176, A216- N257, R287-N332 | phosphatidyl- inositol 3- kinase | PFAM BLOCKS PRINTS BLAST |
| 8 | 502 | S246 T498 T21 S65 S76 T193 T203 S275 S312 S355 T484 S106 T222 S323 T498 Y347 | N302 N414 | Signal peptide: M1-T21 SH2 domain: V70-E80 ER targeting signal: K499-L502 | tyrosine kinase | SigPept BLOCKS MOTIFS BLAST |

TABLE 2 (cont.)

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Homologous sequences | Analytical Methods |
|---------------------------|---------------------------|--|-------------------------------------|---|---|--|
| 9 | 281 | T66 T140 T141 T182 S210 | N117 N139 | Signal peptide: M1-I76 | calcium /calmodulin- dependent protein kinase | PFAM BLAST |
| 10 | 510 | T297 S323 S358 S51 T312 S323 T325 S329 T377 T390 T483 S24 S152 T201 S210 S247 T292 T406 T407 | N185 N349 N381 N405 | Protein kinase family signature: R52-V261 | Serine /threonine protein kinase | PFAM BLOCKS PRINTS MOTIFS BLAST |
| 11 | 248 | S5 S20 S36 T210 T245 | N208 | Tyrosine specific phosphatase active site: F166-A220 Dual specificity phosphatase: H95-R240 | Tyrosine phosphatase or Dual specificity phosphatase | BLAST, MOTIFS, BLOCKS, PRINTS PROFILES SCAN PFAM |

TABLE 2 cont.

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Homologous sequences | Analytical Methods |
|---------------------------|---------------------------|---|-------------------------------------|--|---|--|
| 12 | 810 | S62 S290 T429 S758 T17 T104 S108 T216 S279 T316 S330 T360 S386 T405 S425 S465 T473 S497 T547 T561 T715 S733 S738 S768 S196 S222 S229 S267 T281 T321 T347 S370 T400 T512 S534 T609 S617 S663 S751 T754 T762 Y67 | N33 | | Protein kinase | BLAST, MOTIFS |
| 13 | 549 | S6 T502 T21 T116 S125 S320 T417 S46 S87 T240 S390 S397 S405 S430 S497 | N238 | ATP/GTP-binding site (p-loop): G58-T65 Protein kinase signature: I176-K199 I292-L304 Y347-L370 F456-L483 | Dual specificity tyrosine /serine protein kinase | BLAST, MOTIFS BLOCKS, PRINTS PFAM |
| 14 | 416 | S312 T20 T97 S104 S183 T185 T211 T274 S381 S411 S72 S79 S140 S318 Y53 | | SH3 domain: A366-D384 N402-E414 | PEST phosphatase interacting protein | BLAST, MOTIFS BLOCKS, PRINTS PFAM |

TABLE 2 cont.

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Homologous sequences | Analytical Methods |
|---------------------------|---------------------------|---|-------------------------------------|--|---|--|
| 15 | 425 | T34 S233 S234 S25 S107 T144 T198 T250 S251 S258 S282 S300 S324 S345 T390 T51 T133 S365 S383 Y71 | N23 N176 N362 | | SH3 binding protein | BLAST, MOTIFS |
| 16 | 1135 | S77 T187 S259 S554 S815 S9 S17 T59 S112 T124 T222 S264 T319 S324 S326 S550 T572 S625 S681 S682 T688 T689 S706 S720 T931 S958 S978 S999 S255 T309 T351 T543 S550 S624 S632 S726 T811 S898 S1012 S1113 Y321 Y323 Y467 | N33 N570 N718 N1067 | Protein kinase signature: V31-K54 V149-L161 W129-V182 Tyrosine kinase catalytic site: G190-I200 S214-M236 NIK1-like kinase domain: Y836-R1115 | NIK kinase | BLAST, MOTIFS PROFILES SCAN BLOCKS, PRINTS PFAM |
| 17 | 228 | T163 S60 T78 T68 S88 S147 | N19 N100 N114 | | Interferon- induced PK regulator (P52rIPK) | BLAST |

TABLE 2 cont.

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Homologous sequences | Analytical Methods |
|---------------------------|---------------------------|---|-------------------------------------|--|---|--|
| 18 | 503 | S51 T262 T36 S79 T94 S109 T361 T362 T403 S472 T47 S334 S343 Y17 | N313 N333 N360 | Protein kinase signature: I20-K43 V132-L144 V195-E217 Protein kinase domain: Y14-V272 | calcium /calmodulin- dependent protein kinase II, beta 3 isoform | BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILES CAN |
| 19 | 433 | S12 S77 S124 S131 S255 S290 T327 S365 S402 T70 Y88 | | | Choline kinase isolog 384D8_3 | BLAST, MOTIFS |
| 20 | 527 | S417 S154 S199 T367 S453 T120 S178 S413 T447 S473 | N470 | Protein kinase signature: I144-K167 I260-V172 ATP-binding site: Q247-G284 Y318-F341 Protein kinase domain: I138-L427 | MAP-related protein kinase | BLAST, BLOCKS MOTIFS, PFAM, PROFILES CAN |

TABLE 2 cont.

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Homologous sequences | Analytical Methods |
|---------------------------|---------------------------|--|-------------------------------------|--|--|--|
| 21 | 322 | S19 S122 T198 T200 T236 S251 T260 S264 T301 S14 S52 T181 T225 | N196 N249 | Protein kinase signature: L163-I175 ATP-binding site: M150-V187 I224-H247 Protein kinase domain: S32-E316 | Protein tyrosine kinase | BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILES CAN |
| 22 | 802 | S70 T87 S750 T14 T98 S144 T150 S230 S263 T353 T465 T470 S517 S633 T751 S758 T27 T74 T100 T207 S268 S368 S458 | N36 N655 | Protein kinase signature: L55-K81, L432-K455 ATP-binding site: E160-G197, H232-F255 PTK catalytic domain: H534-F552, C603-H625 Protein kinase domains: F49-F318, L427-L687 Protein kinase C domain: Q319-I382 | Ribosomal S6 protein kinase | BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILES CAN |
| 23 | 641 | S51 T262 S398 S436 S479 T36 S79 T94 S109 T375 T376 T541 S610 T47 S315 S333 S342 S393 S422 S431 S465 S474 S508 Y17 | N313 N332 N374 | Protein kinase signature: I20-K43 V132-L144 ATP-binding site: Q119-A156 Y191-F214 Protein kinase domain: Y14-V272 | Ca ²⁺ /calmodulin dependent protein kinase | BLAST, BLOCKS, PRINTS, MOTIFS, PFAM, PROFILES CAN |

TABLE 2 cont.

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Homologous sequences | Analytical Methods |
|---------------------------|---------------------------|---|-------------------------------------|---|-------------------------------------|---|
| 24 | 588 | S106 T155 S359 T388 T456 T531 T4, S58 S108 T126 S132 T279 S350 S436 S469 S508 S537 Y32 | N63 N130 N574 | Protein kinase catalytic domain: Y209-S445, F495-I522 ATP-binding site: I215-K238 STK core catalytic motif: I331-L343 | Protein kinase Dyrk2 | MOTIFS PFAM BLOCKS PRINTS BLAST |
| 25 | 389 | S31 T301 S56 S96 S134 T149 S186 S201 S283 S358 S375 Y148 Y165 | N257 N343 N364 | Protein kinase catalytic domain: E73-I311 STK core catalytic motif: I172-Y184 PTK core domain: D152-D208 | CaM-like protein kinase | BLAST PFAM MOTIFS BLOCKS PRINTS PROFILESAN |
| 26 | 343 | S68 S81 S137 S184 T219 S276 S297 T29 T125 Y86 Y211 | N332 | EF hand calcium-binding signature: D176-L188 | protein phosphatase 2A (PR72) | BLAST MOTIFS BLOCKS |
| 27 | 184 | S36 T105 S40 S70 T117 Y50 | N62 | Tyrosine phosphatase active site domain: L63-V118 | MAP kinase phosphatase (X17C) | BLAST PROFILESAN BLOCKS PRINTS MOTIFS |

TABLE 2 cont.

| Polypeptide SEQ ID NO: | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequence | Homologous sequences | Analytical Methods |
|---------------------------|---------------------------|---|-------------------------------------|---|--|---|
| 28 | 367 | S10 S21 S44 S103 T116 T267 T309 S191 S213 S218 S256 T305 S352 Y159 Y344 | N16 N17 | | protein phosphatase 2A, A-subunit | BLAST |
| 29 | 118 | S34 S84 | N43 | Signal peptide: M1-A27 PDZ domain: H8-S73 | tyrosine phosphatase | SPScan PFAM BLAST |
| 30 | 356 | S9 S94 T209 T220 S259 S337 S5 S26 S75 S121 T154 S282 S332 S339 Y15 Y84 | N333 | tyrosine-specific protein phosphatase active site: I108-K164 | tyrosine phosphatase (myotubularin) | PROFILES MOTIFS BLOCKS PRINTS BLAST |
| 31 | 453 | S38 S73 S119 S131 S193 S200 T236 S293 S341 T379 T124 S173 T214 S252 T256 S282 S302 S313 S391 S397 | N43 N67 N357 | protein phosphatase 2A p55 subunit: P10-K451 | protein phosphatase 2A p55 regulatory subunit, alpha isoform | PFAM MOTIFS BLOCKS PRINTS BLAST |

TABLE 3

| Nucleotide SEQ ID NO: | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|---|--|-------------|
| 32 | Hematopoietic/Immune (0.333) Reproductive (0.333) | Cell proliferation (0.500) Inflammation (0.333) | PBLUESCRIPT |
| 33 | Nervous (0.216) Reproductive(0.235) Cardiovascular (0.118) | Cell proliferation (0.530) Inflammation (0.352) | pINCY |
| 34 | Reproductive (0.293) Gastrointestinal (0.192) | Cell proliferation (0.641) Inflammation (0.335) | pINCY |
| 35 | Reproductive (0.284) Nervous (0.210) Cardiovascular (0.1213) | Cell proliferation (0.729) Inflammation (0.272) | pINCY |
| 36 | Nervous (0.529) Developmental (0.118) Gastrointestinal (0.118) | Cell proliferation (0.588) Neurological (0.118) Inflammation (0.118) | pINCY |
| 37 | Hematopoietic/Immune (0.268) Reproductive (0.244) Nervous (0.122) | Inflammation (0.488) Cell Proliferative (0.415) | PBLUESCRIPT |
| 38 | Reproductive (0.400) Hematopoietic/Immune (0.160) Nervous (0.160) | Cell proliferation (0.600) Inflammation (0.320) | pINCY |
| 39 | Cardiovascular (0.312) Reproductive (0.312) Developmental (0.188) | Cell proliferation (0.938) Inflammation (0.125) | pINCY |
| 40 | Nervous (0.400) Gastrointestinal (0.267) Developmental (0.133) | Cell proliferation (0.733) Neurological (0.133) Inflammation (0.133) | pINCY |
| 41 | Gastrointestinal (0.267) Nervous (0.233) Reproductive (0.167) | Inflammation (0.533) Cell proliferation (0.534) | pSPORT1 |

Table 3 cont.

| Nucleotide SEQ ID NO: | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|--|--|-------------|
| 42 | Musculoskeletal (0.500) Developmental (0.167) Gastrointestinal (0.167) | Cancer (0.834) Inflammation (0.167) | PBLUESCRIPT |
| 43 | Reproductive (0.240) Nervous (0.151) Gastrointestinal (0.135) | Cell proliferation (0.536) Inflammation (0.417) | PSPORT1 |
| 44 | Hematopoietic/Immune (0.278) Nervous (0.222) Dermatologic (0.111) | Cell proliferation (0.444) Inflammation (0.389) | pINCY |
| 45 | Hematopoietic/Immune (0.500) Gastrointestinal (0.125) Nervous (0.125) | Inflammation (0.500) Cell proliferative (0.500) | PBLUESCRIPT |
| 46 | Nervous (0.220) Reproductive (0.213) Hematopoietic/Immune (0.140) | Cell proliferation (0.573) Inflammation (0.380) | PSPORT1 |
| 47 | Hematopoietic/Immune (0.190) Gastrointestinal (0.165) Nervous (0.139) | Cell proliferation (0.582) Inflammation (0.354) | PSPORT1 |

Table 3 cont.

| Nucleotide SEQ ID NO: | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | Vector |
|--------------------------|--|---|-------------|
| 48 | Nervous (0.333) Reproductive (0.333) Hematopoietic/Immune (0.111) | Cancer (0.444) Inflammation (0.222) Neurological (0.111) | PBLUESCRIPT |
| 49 | Nervous (0.724) Cardiovascular (0.103) | Inflammation (0.276) Cancer (0.241) Neurological (0.172) | pINCY |
| 50 | Reproductive (0.235) Hematopoietic/Immune (0.188) Gastrointestinal (0.129) | Cancer (0.447) Inflammation (0.282) Fetal (0.153) | pINCY |
| 51 | Nervous (0.368) Developmental (0.158) Gastrointestinal (0.105) | Cancer (0.368) Fetal (0.211) Inflammation (0.105) | pSPORT1 |
| 52 | Cardiovascular (0.312) Hematopoietic/Immune (0.312) Reproductive (0.158) | Fetal (0.688) Cancer (0.421) Inflammation (0.125) | pINCY |
| 53 | Reproductive (0.412) Nervous (0.235) Developmental (0.118) | Cancer (0.471) Fetal (0.235) Inflammation (0.235) | pINCY |
| 54 | Nervous (0.714) Cardiovascular (0.107) | Cancer (0.250) Inflammation (0.250) Neurological (0.179) | pINCY |

Table 3 cont.

| Nucleotide SEQ ID NO: | Tissue Expression (Fraction of Total) | Disease or Condition (Fraction of Total) | PBLUESCRIPT |
|--------------------------|---|---|-------------|
| 55 | Reproductive (0.533) Nervous (0.133) | Cell proliferation (0.601) Inflammation (0.270) | PBLUESCRIPT |
| 56 | Hematopoietic/Immune (0.278) Nervous (0.222) Reproductive (0.154) | Cell proliferation (0.388) Inflammation (0.333) Neurological (0.111) | PBLUESCRIPT |
| 57 | Hematopoietic/Immune (0.211) Cardiovascular (0.193) Nervous (0.175) | Cell proliferation (0.474) Inflammation (0.491) | PBLUESCRIPT |
| 58 | Reproductive (0.286) Cardiovascular (0.229) Musculoskeletal (0.143) | Cell proliferation (0.715) Inflammation (0.200) | pINCY |
| 59 | Reproductive (0.253) Gastrointestinal (0.211) Nervous (0.147) | Cancer and Cell proliferation (0.684) Inflammation and Immune Response (0.242) | pSPORT1 |
| 60 | Nervous (0.667) Reproductive (0.333) | Cancer (1.000) | pSPORT1 |
| 61 | Reproductive (0.357) Cardiovascular (0.179) Nervous (0.125) | Cancer and Cell proliferation (0.642) Inflammation and Immune Response (0.232) | pSPORT1 |
| 62 | Nervous (0.228) Reproductive (0.175) Cardiovascular (0.158) Hematopoietic/Immune (0.158) | Cancer (0.368) Inflammation and Immune Response (0.263) Fetal (0.211) | pINCY |

TABLE 4

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|------------------------------|------------|---|
| 32 | BMARNOT02 | Library was constructed using RNA isolated from the bone marrow of 24 male and female Caucasian donors, 16 to 70 years old. |
| 33 | SININOT01 | Library was constructed using RNA isolated from ileum tissue removed from the small intestine of a 4-year-old Caucasian female, who died from a closed head injury. Patient history included jaundice as a baby. Previous surgeries included a double hernia repair |
| 34 | SPLNPFET02 | Library was constructed using RNA isolated from spleen tissue removed from a Caucasian male fetus, who died at 23 weeks' gestation from premature birth. Family history included diabetes. |
| 35 | OVARTUT02 | Library was constructed using RNA isolated from ovarian tumor tissue removed from a 51-year-old Caucasian female during an exploratory laparotomy, total abdominal hysterectomy, salpingo-oophorectomy, and an incidental appendectomy. Pathology indicated mucinous cystadenoma presenting as a multiloculated neoplasm involving the entire left ovary. The right ovary contained a follicular cyst and a hemorrhagic corpus luteum. The uterus showed proliferative endometrium and a single intramural leiomyoma. The peritoneal biopsy indicated benign glandular inclusions consistent with endosalpingiosis. The patient presented with abnormal weight gain and ascites. Patient history included depressive disorder, joint pain, allergies, alcohol use, and a normal delivery. Family history included atherosclerotic coronary artery disease, benign hypertension, breast cancer and uterine cancer. |

TABLE 4 cont.

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|------------------------------|-----------|--|
| 36 | PANCTUT01 | Library was constructed using RNA isolated from pancreatic tumor tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology indicated an invasive grade 2 adenocarcinoma. Patient history included type II diabetes, osteoarthritis, cardiovascular disease, and benign neoplasm in the large bowel. Previous surgeries included a total splenectomy, cholecystectomy, and abdominal hysterectomy. Family history included cardiovascular disease, type II diabetes, and stomach cancer. |
| 37 | SMCBUNT01 | Library was constructed using RNA isolated from bronchial smooth muscle cell tissue removed from a 21-year-old Caucasian male. |
| 38 | UTRSTUT05 | Library was constructed using RNA isolated from uterine tumor tissue removed from a 41-year-old Caucasian female during a vaginal hysterectomy with dilation and curettage. Pathology indicated uterine leiomyoma. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Patient history included a ventral hernia and a benign ovarian neoplasm. |
| 39 | UTRSTUT04 | Library was constructed using RNA isolated from uterine tumor tissue removed from a 34-year-old Caucasian female during a hysteroscopy and an exploratory laparotomy with dilation and curettage. Pathology indicated an endometrial polyp, subserosal leiomyoma, and fragments of leiomyoma. Family history included hyperlipidemia, depressive disorder, benign hypertension, cerebrovascular disease, arteriosclerotic cardiovascular disease, and type II diabetes. |

TABLE 4 cont.

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|------------------------------|-----------|---|
| 40 | SMCBUNT01 | library was constructed using RNA isolated from bronchial smooth muscle cell tissue removed from a 21-year-old Caucasian male. |
| 41 | ADRENOT03 | library was constructed using RNA isolated from the adrenal tissue of a 17-year-old Caucasian male, who died from cerebral anoxia. |
| 42 | TESTNOT04 | library was constructed using RNA isolated from testicular tissue removed from a 37-year-old Caucasian male who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure. |
| 43 | BRSTTUT01 | library was constructed using RNA isolated from breast tumor tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated invasive grade 4 mammary adenocarcinoma of mixed lobular and ductal type, extensively involving the left breast. The tumor was identified in the deep dermis near the lactiferous ducts with extracapsular extension. Seven mid and low and five high axillary lymph nodes were positive for tumor. Proliferative fibrocystic changes were characterized by apocrine metaplasia, sclerosing adenosis, cyst formation, and ductal hyperplasia without atypia. Patient history included atrial tachycardia, blood in the stool, and a benign breast neoplasm. Family history included benign hypertension, atherosclerotic coronary artery disease, cerebrovascular disease, and depressive disorder. |
| 44 | LUNGNOT10 | library was constructed using RNA isolated from the lung tissue of a Caucasian male fetus who died at 23 weeks' gestation. |
| 45 | UCMCL5T01 | library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of 12 individuals. The cells were cultured for 12 days with IL-5 before RNA was isolated from the pooled lysates. |

TABLE 4 cont.

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|------------------------------|-----------|---|
| 46 | BRSTTUT03 | Library was constructed using RNA isolated from breast tumor tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated multicentric invasive grade 4 lobular carcinoma. The mass was identified in the upper outer quadrant, and three separate nodules were found in the lower outer quadrant of the left breast. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular disease, coronary artery aneurysm, breast cancer, prostate cancer, atherosclerotic coronary artery disease, and type I diabetes. |
| 47 | BRSTNOT05 | Library was constructed using RNA isolated from breast tissue removed from a 58-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated multicentric invasive grade 4 lobular carcinoma. Patient history included skin cancer, rheumatic heart disease, osteoarthritis, and tuberculosis. Family history included cerebrovascular and cardiovascular disease, breast and prostate cancer, and type I diabetes. |

TABLE 4 cont.

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|------------------------------|-----------|--|
| 48 | SPLNNOT02 | The library was constructed using RNA isolated from the spleen tissue of a 29-year-old Caucasian male, who died from head trauma. Serologies were positive for cytomegalovirus (CMV). Patient history included alcohol, marijuana, and tobacco use. |
| 49 | BRAITUT08 | The library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 47-year-old Caucasian male during excision of cerebral meningeal tissue. Pathology indicated grade 4 fibrillary astrocytoma with focal tumoral radionecrosis. Patient history included cerebrovascular disease, deficiency anemia, hyperlipidemia, epilepsy, and tobacco use. Family history included cerebrovascular disease and a malignant prostate neoplasm. |
| 50 | PANCTUT01 | The library was constructed using RNA isolated from pancreatic tumor tissue removed from a 65-year-old Caucasian female during radical subtotal pancreatectomy. Pathology indicated an invasive grade 2 adenocarcinoma. Patient history included type II diabetes, osteoarthritis, cardiovascular disease, benign neoplasm in the large bowel, and a cataract. Previous surgeries included a total splenectomy, cholecystectomy, and abdominal hysterectomy. Family history included cardiovascular disease, type II diabetes, and stomach cancer. |
| 51 | BRAITUT02 | The library was constructed using RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Family history included a malignant neoplasm of the kidney. |

TABLE 4 cont.

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|------------------------------|-----------|--|
| 52 | THP1NOT03 | The library was constructed using RNA isolated from untreated THP-1 cells. THP-1 (ATCC TIB 202) is a human promonocyte line derived from the peripheral blood of a 1-year-old Caucasian male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171). |
| 53 | BRSTNOT12 | The library was constructed using RNA isolated from diseased breast tissue removed from a 32-year-old Caucasian female during a bilateral reduction mammoplasty. Pathology indicated nonproliferative fibrocystic disease. Family history included cardiovascular disease. |
| 54 | MUSCNOT07 | The library was constructed using RNA isolated from muscle tissue removed from the forearm of a 38-year-old Caucasian female during a soft tissue excision. Pathology for the associated tumor tissue indicated intramuscular hemangioma. Family history included breast cancer, benign hypertension, cerebrovascular disease, colon cancer, and type II diabetes. |
| 55 | HUVESTB01 | Library was constructed using RNA isolated from shear-stressed HUV-EC-C (ATCC CRL 1730) cells. HUV-EC-C is an endothelial cell line derived from the vein of a normal human umbilical cord (ref:PNAS 81:6413). |
| 56 | THYMNOT02 | Library was constructed using polyA RNA isolated from thymus tissue removed from a 3-year-old Caucasian male, who died from drowning. |
| 57 | CARDNOT01 | Library was constructed using RNA isolated from the cardiac muscle of a 65-year-old Caucasian male, who died from a self-inflicted gunshot wound. |

TABLE 4 cont.

| Polynucleotide SEQ ID NO: | Library | Library Comment |
|------------------------------|-----------|--|
| 58 | UTRSNOT12 | Library was constructed using RNA isolated from uterine myometrial tissue removed from a 41-year-old Caucasian female during a vaginal hysterectomy with a dilatation and curettage. The endometrium was secretory and contained fragments of endometrial polyps. Benign endo- and ectocervical mucosa were identified in the endocervix. Pathology for the associated tumor tissue indicated uterine leiomyoma. The patient presented with an unspecified menstrual disorder. Patient history included ventral hernia, normal delivery, a benign ovarian neoplasm, and tobacco abuse. Previous surgeries included a bilateral destruction of fallopian tubes, removal of a solitary ovary, and an exploratory laparotomy. |
| 59 | BEPINOT01 | Library was constructed using RNA isolated from a bronchial epithelium primary cell line derived from a 54-year-old Caucasian male. |
| 60 | PGANNOT01 | Library was constructed using RNA isolated from paraganglionic tumor tissue removed from the intra-abdominal region of a 46-year-old Caucasian male during exploratory laparotomy. Pathology indicated a benign paraganglioma and association with a grade 2 renal cell carcinoma, clear cell type. |
| 61 | BEPINOT01 | Library was constructed using RNA isolated from a bronchial epithelium primary cell line derived from a 54-year-old Caucasian male. |
| 62 | DRGLNOT01 | Library was constructed using RNA isolated from dorsal root ganglion tissue removed from the low thoracic/high lumbar region of a 32-year-old Caucasian male who died from acute pulmonary edema and bronchopneumonia, bilateral pleural and pericardial effusions, and malignant lymphoma (natural killer cell type). Patient history included probable cytomegalovirus infection, hepatic congestion and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, and Bell's palsy. |

Table 5

| Program | Description | Reference | Parameter Threshold |
|-------------------|---|---|--|
| ABI FACTURA | A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA. | |
| ABI/PARACEL FDF | A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA. | Mismatch <50% |
| ABI AutoAssembler | A program that assembles nucleic acid sequences. | Perkin-Elmer Applied Biosystems, Foster City, CA. | |
| BLAST | A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx. | Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402. | ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less |
| FASTA | A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises as least five functions: fasta, tfasta, fastx, tfastx, and ssearch. | Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489. | ESTs: fasta E value= 1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value= 1.0E-8 or less Full Length sequences: fastx score= 100 or greater |
| BLIMPS | A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions. | Henikoff, S and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424. | Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and, if applicable, Probability value= 1.0E-3 or less |
| HMMER | An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM. | Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322. | Score= 10-50 bits for PFAM hits, depending on individual protein families |

Table 5 (cont.)

| Program | Description | Reference | Parameter Threshold |
|-------------|---|--|--|
| ProfileScan | An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite. | Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221. | Normalized quality score \geq GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1. |
| Phred | A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability. | Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194. | |
| Phrap | A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences. | Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA. | Score= 120 or greater; Match length= 56 or greater |
| Consed | A graphical tool for viewing and editing Phrap assemblies | Gordon, D. et al. (1998) Genome Res. 8:195-202. | |
| SPScan | A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides. | Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439. | Score=3.5 or greater |
| Motifs | A program that searches amino acid sequences for patterns that matched those defined in Prosite. | Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI. | |

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-31, and fragments thereof.
- 5 2. A substantially purified variant having at least 90% amino acid sequence identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide of claim 3.
- 10 5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
 - 15 (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
 - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
8. The method of claim 7 further comprising amplifying the polynucleotide prior to
20 hybridization.
9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:32-62 and fragments thereof.
10. An isolated and purified polynucleotide variant having at least 80% polynucleotide sequence identity to the polynucleotide of claim 9.
- 25 11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.
12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.
13. A host cell comprising the expression vector of claim 12.
- 30 14. A method for producing a polypeptide, the method comprising the steps of:
 - a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.
15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction
35 with a suitable pharmaceutical carrier.
16. A purified antibody which specifically binds to the polypeptide of claim 1.

17. A purified agonist of the polypeptide of claim 1.
18. A purified antagonist of the polypeptide of claim 1.
19. A method for treating or preventing a disorder associated with decreased expression or activity of PHSP, the method comprising administering to a subject in need of such treatment an
5 effective amount of the pharmaceutical composition of claim 15.
20. A method for treating or preventing a disorder associated with increased expression or activity of PHSP, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.

SEQUENCE LISTING

<110> INYCTE PHARMACEUTICALS, INC.
 HILLMAN, Jennifer L.
 LAL, Preeti
 TANG, Y. Tom
 CORLEY, Neil C.
 GUEGLER, Karl J.
 BAUGHN, Mariah R.
 PATTERSON, Chandra
 BANDMAN, Olga
 AU-YOUNG, Janice
 GORGONE, Gina A.
 YUE, Henry
 AZIMZAI, Yalda
 REDDY, Roopa
 LU, Dyung Aina M.
 SHIH, Leo L.

<120> PHOSPHORYLATION EFFECTORS

<130> PF-0565 PCT

<140> To Be Assigned

<141> Herewith

<150> 09/123,494; unassigned; 09/152,814; unassigned; 09/173,482;
 unassigned; 60/106,889; 60/109,093; 60/113,796;

<151> 1998-07-28; 1998-07-28; 1998-09-14; 1998-09-14; 1998-10-14;
 1998-10-14; 1998-11-03; 1998-11-19; 1998-12-22

<160> 61

<170> PERL Program

<210> 1

<211> 300

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 132240

<400> 1

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Ser | Pro | Leu | Glu | Ser | Gln | Pro | Leu | Asp | Ser | Asp | Arg | Ser |
| 1 | | | | 5 | | | | | 10 | | | | | 15 |
| Ile | Lys | Glu | Ser | Ser | Phe | Glu | Glu | Ser | Asn | Ile | Glu | Asp | Pro | Leu |
| | | | | 20 | | | | | 25 | | | | | 30 |
| Ile | Val | Thr | Pro | Asp | Cys | Gln | Glu | Lys | Thr | Ser | Pro | Lys | Gly | Val |
| | | | | 35 | | | | | 40 | | | | | 45 |
| Glu | Asn | Pro | Ala | Val | Gln | Glu | Ser | Asn | Gln | Lys | Met | Leu | Gly | Pro |
| | | | | 50 | | | | | 55 | | | | | 60 |
| Pro | Leu | Glu | Val | Leu | Lys | Thr | Leu | Ala | Ser | Lys | Arg | Asn | Ala | Val |
| | | | | 65 | | | | | 70 | | | | | 75 |

```
<210> 2
<211> 147
<212> PRT
<213> Homo sapiens
```

```

<400> 2
Met Ala Ala Gln Arg Leu Gly Lys Arg Val Leu Ser Lys Leu Gln
  1                    5                10                15
Ser Pro Ser Arg Ala Arg Gly Pro Gly Gly Ser Pro Gly Gly Met
      20                25                30
Gln Lys Arg His Ala Arg Val Thr Val Lys Tyr Asp Arg Arg Glu
      35                40                45
Leu Gln Arg Arg Leu Asp Val Glu Lys Trp Ile Asp Gly Arg Leu
      50                55                60
Glu Glu Leu Tyr Arg Gly Met Glu Ala Asp Met Pro Asp Glu Ile
      65                70                75
Asn Ile Asp Glu Leu Leu Glu Leu Glu Ser Glu Glu Glu Arg Ser
      80                85                90
Arg Lys Ile Gln Gly Leu Leu Lys Ser Cys Gly Lys Pro Val Glu
      95                100               105

```

```

Asp Phe Ile Gln Glu Leu Leu Ala Lys Leu Gln Gly Leu His Arg
      110                      115                      120
Gln Pro Gly Leu Arg Gln Pro Ser Pro Ser His Asp Gly Ser Leu
      125                      130                      135
Ser Pro Leu Gln Asp Arg Ala Arg Thr Ala His Pro
      140                      145

```

<210> 3

<211> 431

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2197671

<400> 3

```

Met Ala His Ser Pro Val Gln Ser Gly Leu Pro Gly Met Gln Asn
  1          5          10          15
Leu Lys Ala Asp Pro Glu Glu Leu Phe Thr Lys Leu Glu Lys Ile
      20          25          30
Gly Lys Gly Ser Phe Gly Glu Val Phe Lys Gly Ile Asp Asn Arg
      35          40          45
Thr Gln Lys Val Val Ala Ile Lys Ile Ile Asp Leu Glu Glu Ala
      50          55          60
Glu Asp Glu Ile Glu Asp Ile Gln Gln Glu Ile Thr Val Leu Ser
      65          70          75
Gln Cys Asp Ser Pro Tyr Val Thr Lys Tyr Tyr Gly Ser Tyr Leu
      80          85          90
Lys Asp Thr Lys Leu Trp Ile Ile Met Glu Tyr Leu Gly Gly Gly
      95          100          105
Ser Ala Leu Asp Leu Leu Glu Pro Gly Arg Leu Asp Glu Thr Gln
      110          115          120
Ile Ala Thr Ile Leu Arg Glu Ile Leu Lys Gly Leu Asp Tyr Leu
      125          130          135
His Ser Glu Lys Lys Ile His Arg Asp Ile Lys Ala Ala Asn Val
      140          145          150
Leu Leu Ser Glu His Gly Glu Val Lys Leu Ala Asp Phe Gly Val
      155          160          165
Ala Gly Gln Leu Thr Asp Thr Gln Ile Lys Arg Asn Thr Phe Val
      170          175          180
Gly Thr Pro Phe Trp Met Ala Pro Glu Val Ile Lys Gln Ser Ala
      185          190          195
Tyr Asp Ser Lys Ala Asp Ile Trp Ser Leu Gly Ile Thr Ala Ile
      200          205          210
Glu Leu Ala Arg Gly Glu Pro Pro His Ser Glu Leu His Pro Met
      215          220          225
Lys Val Leu Phe Leu Ile Pro Lys Asn Asn Pro Pro Thr Leu Glu
      230          235          240
Gly Asn Tyr Ser Lys Pro Leu Lys Glu Phe Val Glu Ala Cys Leu
      245          250          255
Asn Lys Glu Pro Ser Phe Arg Pro Thr Ala Lys Glu Leu Leu Lys
      260          265          270
His Lys Phe Ile Leu Arg Asn Ala Lys Lys Thr Ser Tyr Leu Thr
      275          280          285

```

| | | |
|---|-----|---------|
| Glu Leu Ile Asp Arg Tyr Lys Arg Trp Lys Ala Glu Gln Ser His | | |
| | 290 | 295 300 |
| Asp Asp Ser Ser Ser Glu Asp Ser Asp Ala Glu Thr Asp Gly Gln | | |
| | 305 | 310 315 |
| Ala Ser Gly Gly Ser Asp Ser Gly Asp Trp Ile Phe Thr Ile Arg | | |
| | 320 | 325 330 |
| Glu Lys Asp Pro Lys Asn Leu Glu Asn Gly Ala Leu Gln Pro Ser | | |
| | 335 | 340 345 |
| Asp Leu Asp Arg Asn Lys Met Lys Asp Ile Pro Lys Arg Pro Phe | | |
| | 350 | 355 360 |
| Ser Gln Cys Leu Ser Thr Ile Ile Ser Pro Leu Phe Ala Glu Leu | | |
| | 365 | 370 375 |
| Lys Glu Lys Ser Gln Ala Cys Gly Gly Asn Leu Gly Ser Ile Glu | | |
| | 380 | 385 390 |
| Glu Leu Arg Gly Ala Ile Tyr Leu Ala Glu Glu Ala Cys Pro Gly | | |
| | 395 | 400 405 |
| Ile Ser Asp Thr Met Val Ala Gln Leu Val Gln Arg Leu Gln Arg | | |
| | 410 | 415 420 |
| Tyr Ser Leu Ser Gly Gly Gly Thr Ser Ser His | | |
| | 425 | 430 |

<210> 4

<211> 218

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2594943

<400> 4

| | | |
|---|-----|---------|
| Met Asn Cys Arg Ser Glu Val Leu Glu Val Ser Val Glu Gly Arg | | |
| 1 | 5 | 10 15 |
| Gln Val Glu Glu Ala Met Leu Ala Val Leu His Thr Val Leu Leu | | |
| | 20 | 25 30 |
| His Arg Ser Thr Gly Lys Phe His Tyr Lys Lys Glu Gly Thr Tyr | | |
| | 35 | 40 45 |
| Ser Ile Gly Thr Val Gly Thr Gln Asp Val Asp Cys Asp Phe Ile | | |
| | 50 | 55 60 |
| Asp Phe Thr Tyr Val Arg Val Ser Ser Glu Glu Leu Asp Arg Ala | | |
| | 65 | 70 75 |
| Leu Arg Lys Val Val Gly Glu Phe Lys Asp Ala Leu Arg Asn Ser | | |
| | 80 | 85 90 |
| Gly Gly Asp Gly Leu Gly Gln Met Ser Leu Glu Phe Tyr Gln Lys | | |
| | 95 | 100 105 |
| Lys Lys Ser Arg Trp Pro Phe Ser Asp Glu Cys Ile Pro Trp Glu | | |
| | 110 | 115 120 |
| Val Trp Thr Val Lys Val His Val Val Ala Leu Ala Thr Glu Gln | | |
| | 125 | 130 135 |
| Glu Arg Gln Ile Cys Arg Glu Lys Val Gly Glu Lys Leu Cys Glu | | |
| | 140 | 145 150 |
| Lys Ile Ile Asn Ile Val Glu Val Met Asn Arg His Glu Tyr Leu | | |
| | 155 | 160 165 |
| Pro Lys Met Pro Thr Gln Ser Glu Val Asp Asn Val Phe Asp Thr | | |
| | 170 | 175 180 |

Gly Leu Arg Asp Val Gln Pro Tyr Leu Tyr Lys Ile Ser Phe Gln
 185 190 195
 Ile Thr Asp Ala Leu Gly Thr Ser Val Thr Thr Thr Met Arg Arg
 200 205 210
 Leu Ile Lys Asp Thr Leu Ala Leu
 215

<210> 5

<211> 474

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 1513871

<400> 5

Met Ile Met Asn Lys Met Lys Asn Phe Lys Arg Arg Phe Ser Leu
 1 5 10 15
 Ser Val Pro Arg Thr Glu Thr Ile Glu Glu Ser Leu Ala Glu Phe
 20 25 30
 Thr Glu Gln Phe Asn Gln Leu His Asn Arg Arg Asn Glu Asn Leu
 35 40 45
 Gln Leu Gly Pro Leu Gly Arg Asp Pro Pro Gln Glu Cys Ser Thr
 50 55 60
 Phe Ser Pro Thr Asp Ser Gly Glu Glu Pro Gly Gln Leu Ser Pro
 65 70 75
 Gly Val Gln Phe Gln Arg Arg Gln Asn Gln Arg Arg Phe Ser Met
 80 85 90
 Glu Asp Val Ser Lys Arg Leu Ser Leu Pro Met Asp Ile Arg Leu
 95 100 105
 Pro Gln Glu Phe Leu Gln Lys Leu Gln Met Glu Ser Pro Asp Leu
 110 115 120
 Pro Lys Pro Leu Ser Arg Met Ser Arg Arg Ala Ser Leu Ser Asp
 125 130 135
 Ile Gly Phe Gly Lys Leu Glu Thr Tyr Val Lys Leu Asp Lys Leu
 140 145 150
 Gly Glu Gly Thr Tyr Ala Thr Val Phe Lys Gly Arg Ser Lys Leu
 155 160 165
 Thr Glu Asn Leu Val Ala Leu Lys Glu Ile Arg Leu Glu His Glu
 170 175 180
 Glu Gly Ala Pro Cys Thr Ala Ile Arg Glu Val Ser Leu Leu Lys
 185 190 195
 Asn Leu Lys His Ala Asn Ile Val Thr Leu His Asp Leu Ile His
 200 205 210
 Thr Asp Arg Ser Leu Thr Leu Val Phe Glu Tyr Leu Asp Ser Asp
 215 220 225
 Leu Lys Gln Tyr Leu Asp His Cys Gly Asn Leu Met Ser Met His
 230 235 240
 Asn Val Lys Ile Phe Met Phe Gln Leu Leu Arg Gly Leu Ala Tyr
 245 250 255
 Cys His His Arg Lys Ile Leu His Arg Asp Leu Lys Pro Gln Asn
 260 265 270
 Leu Leu Ile Asn Glu Arg Gly Glu Leu Lys Leu Ala Asp Phe Gly
 275 280 285

```

Leu Ala Arg Ala Lys Ser Val Pro Thr Lys Thr Tyr Ser Asn Glu
290                      295                      300
Val Val Thr Leu Trp Tyr Arg Pro Pro Asp Val Leu Leu Gly Ser
305                      310                      315
Thr Glu Tyr Ser Thr Pro Ile Asp Met Trp Gly Val Gly Cys Ile
320                      325                      330
His Tyr Glu Met Ala Thr Gly Arg Pro Leu Phe Pro Gly Ser Thr
335                      340                      345
Val Lys Glu Glu Leu His Leu Ile Phe Arg Leu Leu Gly Thr Pro
350                      355                      360
Thr Glu Glu Thr Trp Pro Gly Val Thr Ala Phe Ser Glu Phe Arg
365                      370                      375
Thr Tyr Ser Phe Pro Cys Tyr Leu Pro Gln Pro Leu Ile Asn His
380                      385                      390
Ala Pro Arg Leu Asp Thr Asp Gly Ile His Leu Leu Ser Ser Leu
395                      400                      405
Leu Leu Tyr Glu Ser Lys Ser Arg Met Ser Ala Glu Ala Ala Leu
410                      415                      420
Ser His Ser Tyr Phe Arg Ser Leu Gly Glu Arg Val His Gln Leu
425                      430                      435
Glu Asp Thr Ala Ser Ile Phe Ser Leu Lys Glu Ile Gln Leu Gln
440                      445                      450
Lys Asp Pro Gly Tyr Arg Gly Leu Ala Phe Gln Gln Pro Gly Arg
455                      460                      465
Gly Lys Asn Arg Arg Gln Ser Ile Phe
470

```

<210> 6

<211> 540

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 156108

<400> 6

```

Met Asn Gly Glu Ala Ile Cys Ser Ala Leu Pro Thr Ile Pro Tyr
1                      5                      10                      15
His Lys Leu Ala Asp Leu Arg Tyr Leu Ser Arg Gly Ala Ser Gly
20                      25                      30
Thr Val Ser Ser Ala Arg His Ala Asp Trp Arg Val Gln Val Ala
35                      40                      45
Val Lys His Leu His Ile His Thr Pro Leu Leu Asp Ser Glu Arg
50                      55                      60
Lys Asp Val Leu Arg Glu Ala Glu Ile Leu His Lys Ala Arg Phe
65                      70                      75
Ser Tyr Ile Leu Pro Ile Leu Gly Ile Cys Asn Glu Pro Glu Phe
80                      85                      90
Leu Gly Ile Val Thr Glu Tyr Met Pro Asn Gly Ser Leu Asn Glu
95                      100                     105
Leu Leu His Arg Lys Thr Glu Tyr Pro Asp Val Ala Trp Pro Leu
110                     115                     120
Arg Phe Arg Ile Leu His Glu Ile Ala Leu Gly Val Asn Tyr Leu

```


| | | | | | |
|-----------------|---------------------|---------------------|-----|--|-----|
| | 125 | | 130 | | 135 |
| His Asn Met Thr | Pro Pro Leu Leu His | His Asp Leu Lys Thr | Gln | | |
| | 140 | | 145 | | 150 |
| Asn Ile Leu Leu | Asp Asn Glu Phe His | Val Lys Ile Ala Asp | Phe | | |
| | 155 | | 160 | | 165 |
| Gly Leu Ser Lys | Trp Arg Met Met Ser | Leu Ser Gln Ser Arg | Ser | | |
| | 170 | | 175 | | 180 |
| Ser Lys Ser Ala | Pro Glu Gly Gly Thr | Ile Ile Tyr Met Pro | Pro | | |
| | 185 | | 190 | | 195 |
| Glu Asn Tyr Glu | Pro Gly Gln Lys Ser | Arg Ala Ser Ile Lys | His | | |
| | 200 | | 205 | | 210 |
| Asp Ile Tyr Ser | Tyr Ala Val Ile Thr | Trp Glu Val Leu Ser | Arg | | |
| | 215 | | 220 | | 225 |
| Lys Gln Pro Phe | Glu Asp Val Thr Asn | Pro Leu Gln Ile Met | Tyr | | |
| | 230 | | 235 | | 240 |
| Ser Val Ser Gln | Gly His Arg Pro Val | Ile Asn Glu Glu Ser | Leu | | |
| | 245 | | 250 | | 255 |
| Pro Tyr Asp Ile | Pro His Arg Ala Arg | Met Ile Ser Leu Ile | Glu | | |
| | 260 | | 265 | | 270 |
| Ser Gly Trp Ala | Gln Asn Pro Asp Glu | Arg Pro Ser Phe Leu | Lys | | |
| | 275 | | 280 | | 285 |
| Cys Leu Ile Glu | Leu Glu Pro Val Leu | Arg Thr Phe Glu Glu | Ile | | |
| | 290 | | 295 | | 300 |
| Thr Phe Leu Glu | Ala Val Ile Gln Leu | Lys Lys Thr Lys Leu | Gln | | |
| | 305 | | 310 | | 315 |
| Ser Val Ser Ser | Ala Ile His Leu Cys | Asp Lys Lys Lys Met | Glu | | |
| | 320 | | 325 | | 330 |
| Leu Ser Leu Asn | Ile Pro Val Asn His | Gly Pro Gln Glu Glu | Ser | | |
| | 335 | | 340 | | 345 |
| Cys Gly Ser Ser | Gln Leu His Glu Asn | Ser Gly Ser Pro Glu | Thr | | |
| | 350 | | 355 | | 360 |
| Ser Arg Ser Leu | Pro Ala Pro Gln Asp | Asn Asp Phe Leu Ser | Arg | | |
| | 365 | | 370 | | 375 |
| Lys Ala Gln Asp | Cys Tyr Phe Met Lys | Leu His His Cys Pro | Gly | | |
| | 380 | | 385 | | 390 |
| Asn His Ser Trp | Asp Ser Thr Ile Ser | Gly Ser Gln Arg Ala | Ala | | |
| | 395 | | 400 | | 405 |
| Phe Cys Asp His | Lys Thr Thr Pro Cys | Ser Ser Ala Ile Ile | Asn | | |
| | 410 | | 415 | | 420 |
| Pro Leu Ser Thr | Ala Gly Asn Ser Glu | Arg Leu Gln Pro Gly | Ile | | |
| | 425 | | 430 | | 435 |
| Ala Gln Gln Trp | Ile Gln Ser Lys Arg | Glu Asp Ile Val Asn | Gln | | |
| | 440 | | 445 | | 450 |
| Met Thr Glu Ala | Cys Leu Asn Gln Ser | Leu Asp Ala Leu Leu | Ser | | |
| | 455 | | 460 | | 465 |
| Arg Asp Leu Ile | Met Lys Glu Asp Tyr | Glu Leu Val Ser Thr | Lys | | |
| | 470 | | 475 | | 480 |
| Pro Thr Arg Thr | Ser Lys Val Arg Gln | Leu Leu Asp Thr Thr | Asp | | |
| | 485 | | 490 | | 495 |
| Ile Gln Gly Glu | Glu Phe Ala Lys Val | Ile Val Gln Lys Leu | Lys | | |
| | 500 | | 505 | | 510 |
| Asp Asn Lys Gln | Met Gly Leu Gln Pro | Tyr Pro Glu Ile Leu | Val | | |
| | 515 | | 520 | | 525 |
| Val Ser Arg Ser | Pro Ser Leu Asn Leu | Leu Gln Asn Lys Ser | Met | | |
| | 530 | | 535 | | 540 |

<210> 7
 <211> 454
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone Number: 2883243

<400> 7
 Met Tyr Asn Thr Val Trp Asn Met Glu Asp Leu Asp Leu Glu Tyr
 1 5 10 15
 Ala Lys Thr Asp Ile Asn Cys Gly Thr Asp Leu Met Phe Tyr Ile
 20 25 30
 Glu Met Asp Pro Pro Ala Leu Pro Pro Lys Pro Pro Lys Pro Thr
 35 40 45
 Thr Val Ala Asn Asn Gly Met Asn Asn Asn Met Ser Leu Gln Asp
 50 55 60
 Ala Glu Trp Tyr Trp Gly Asp Ile Ser Arg Glu Glu Val Asn Glu
 65 70 75
 Lys Leu Arg Asp Thr Ala Asp Gly Thr Phe Leu Val Arg Asp Ala
 80 85 90
 Ser Thr Lys Met His Gly Asp Tyr Thr Leu Thr Leu Arg Lys Gly
 95 100 105
 Gly Asn Asn Lys Leu Ile Lys Ile Phe His Arg Asp Gly Lys Tyr
 110 115 120
 Gly Phe Ser Asp Pro Leu Thr Phe Ser Ser Val Val Glu Leu Ile
 125 130 135
 Asn His Tyr Arg Asn Glu Ser Leu Ala Gln Tyr Asn Pro Lys Leu
 140 145 150
 Asp Val Lys Leu Leu Tyr Pro Val Ser Lys Tyr Gln Gln Asp Gln
 155 160 165
 Val Val Lys Glu Asp Asn Ile Glu Ala Val Gly Lys Lys Leu His
 170 175 180
 Glu Tyr Asn Thr Gln Phe Gln Glu Lys Ser Arg Glu Tyr Asp Arg
 185 190 195
 Leu Tyr Glu Glu Tyr Thr Arg Thr Ser Gln Glu Ile Gln Met Lys
 200 205 210
 Arg Thr Ala Ile Glu Ala Phe Asn Glu Thr Ile Lys Ile Phe Glu
 215 220 225
 Glu Gln Cys Gln Thr Gln Glu Arg Tyr Ser Lys Glu Tyr Ile Glu
 230 235 240
 Lys Phe Lys Arg Glu Gly Asn Glu Lys Glu Ile Gln Arg Ile Met
 245 250 255
 His Asn Tyr Asp Lys Leu Lys Ser Arg Ile Ser Glu Ile Ile Asp
 260 265 270
 Ser Arg Arg Arg Leu Glu Glu Asp Leu Lys Lys Gln Ala Ala Glu
 275 280 285
 Tyr Arg Glu Ile Asp Lys Arg Met Asn Ser Ile Lys Pro Asp Leu
 290 295 300
 Ile Gln Leu Arg Lys Thr Arg Asp Gln Tyr Leu Met Trp Leu Thr
 305 310 315
 Gln Lys Gly Val Arg Gln Lys Lys Leu Asn Glu Trp Leu Gly Asn
 320 325 330
 Glu Asn Thr Glu Asp Gln Tyr Ser Leu Val Glu Asp Asp Glu Asp
 335 340 345

```

Leu Pro His His Asp Glu Lys Thr Trp Asn Val Gly Ser Ser Asn
      350                      355                      360
Arg Asn Lys Ala Glu Asn Leu Leu Arg Gly Lys Arg Asp Gly Thr
      365                      370                      375
Phe Leu Val Arg Glu Ser Ser Lys Gln Gly Cys Tyr Ala Cys Ser
      380                      385                      390
Val Val Val Asp Gly Glu Val Lys His Cys Val Ile Asn Lys Thr
      395                      400                      405
Ala Thr Gly Tyr Gly Phe Ala Glu Pro Tyr Asn Leu Tyr Ser Ser
      410                      415                      420
Leu Lys Glu Leu Val Leu His Tyr Gln His Thr Ser Leu Val Gln
      425                      430                      435
His Asn Asp Ser Leu Asn Val Thr Leu Ala Tyr Pro Val Tyr Ala
      440                      445                      450
Gln Gln Arg Arg

```

<210> 8

<211> 502

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 3173355

<400> 8

```

Met Phe Gly Thr Leu Leu Leu Tyr Cys Phe Phe Leu Ala Thr Val
  1                      5                      10                      15
Pro Ala Leu Ala Glu Thr Gly Gly Glu Arg Gln Leu Ser Pro Glu
      20                      25                      30
Lys Ser Glu Ile Trp Gly Pro Gly Leu Lys Ala Asp Val Val Leu
      35                      40                      45
Pro Ala Arg Tyr Phe Tyr Ile Gln Ala Val Asp Thr Ser Gly Asn
      50                      55                      60
Lys Phe Thr Ser Ser Pro Gly Glu Lys Val Phe Gln Val Lys Val
      65                      70                      75
Ser Ala Pro Glu Glu Gln Phe Thr Arg Val Gly Val Gln Val Leu
      80                      85                      90
Asp Arg Lys Asp Gly Ser Phe Ile Val Arg Tyr Arg Met Tyr Ala
      95                      100                     105
Ser Tyr Lys Asn Leu Lys Val Glu Ile Lys Phe Gln Gly Gln His
      110                     115                     120
Val Ala Lys Ser Pro Tyr Ile Leu Lys Gly Pro Val Tyr His Glu
      125                     130                     135
Asn Cys Asp Cys Pro Leu Gln Asp Ser Ala Ala Trp Leu Arg Glu
      140                     145                     150
Met Asn Cys Pro Glu Thr Ile Ala Gln Ile Gln Arg Asp Leu Ala
      155                     160                     165
His Phe Pro Ala Val Asp Pro Glu Lys Ile Ala Val Glu Ile Pro
      170                     175                     180
Lys Arg Phe Gly Gln Arg Gln Ser Leu Cys His Tyr Thr Leu Lys
      185                     190                     195
Asp Asn Lys Val Tyr Ile Lys Thr His Gly Glu His Val Gly Phe
      200                     205                     210
Arg Ile Phe Met Asp Ala Ile Leu Leu Ser Leu Thr Arg Lys Val

```

| | | | | | |
|-----------------|---------------------|-------------------------|-----|--|-----|
| | 215 | | 220 | | 225 |
| Lys Met Pro Asp | Val Glu Leu Phe Val | Asn Leu Gly Asp Trp Pro | | | |
| | 230 | | 235 | | 240 |
| Leu Glu Lys Lys | Lys Ser Asn Ser Asn | Ile His Pro Ile Phe Ser | | | |
| | 245 | | 250 | | 255 |
| Trp Cys Gly Ser | Thr Asp Ser Lys Asp | Ile Val Met Pro Thr Tyr | | | |
| | 260 | | 265 | | 270 |
| Asp Leu Thr Asp | Ser Val Leu Glu Thr | Met Gly Arg Val Ser Leu | | | |
| | 275 | | 280 | | 285 |
| Asp Met Met Ser | Val Gln Ala Asn Thr | Gly Pro Pro Trp Glu Ser | | | |
| | 290 | | 295 | | 300 |
| Lys Asn Ser Thr | Ala Val Trp Arg Gly | Arg Asp Ser Arg Lys Glu | | | |
| | 305 | | 310 | | 315 |
| Arg Leu Glu Leu | Val Lys Leu Ser Arg | Lys His Pro Glu Leu Ile | | | |
| | 320 | | 325 | | 330 |
| Asp Ala Ala Phe | Thr Asn Phe Phe Phe | Phe Lys His Asp Glu Asn | | | |
| | 335 | | 340 | | 345 |
| Leu Tyr Gly Pro | Ile Val Lys His Ile | Ser Phe Phe Asp Phe Phe | | | |
| | 350 | | 355 | | 360 |
| Lys His Lys Tyr | Gln Ile Asn Ile Asp | Gly Thr Val Ala Ala Tyr | | | |
| | 365 | | 370 | | 375 |
| Arg Leu Pro Tyr | Leu Leu Val Gly Asp | Ser Val Val Leu Lys Gln | | | |
| | 380 | | 385 | | 390 |
| Asp Ser Ile Tyr | Tyr Glu His Phe Tyr | Asn Glu Leu Gln Pro Trp | | | |
| | 395 | | 400 | | 405 |
| Lys His Tyr Ile | Pro Val Lys Ser Asn | Leu Ser Asp Leu Leu Glu | | | |
| | 410 | | 415 | | 420 |
| Lys Leu Lys Trp | Ala Lys Asp His Asp | Glu Glu Ala Lys Lys Ile | | | |
| | 425 | | 430 | | 435 |
| Ala Lys Ala Gly | Gln Glu Phe Ala Arg | Asn Asn Leu Met Gly Asp | | | |
| | 440 | | 445 | | 450 |
| Asp Ile Phe Cys | Tyr Tyr Phe Lys Leu | Phe Gln Glu Tyr Ala Asn | | | |
| | 455 | | 460 | | 465 |
| Leu Gln Val Ser | Glu Pro Gln Ile Arg | Glu Gly Met Lys Arg Val | | | |
| | 470 | | 475 | | 480 |
| Glu Pro Gln Thr | Glu Asp Asp Leu Phe | Pro Cys Thr Cys His Arg | | | |
| | 485 | | 490 | | 495 |
| Lys Lys Thr Lys | Asp Glu Leu | | | | |
| | 500 | | | | |

<210> 9

<211> 282

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 5116906

<400> 9

| | | |
|-----------------|---------------------|-------------------------|
| Met Trp Ala Cys | Gly Val Ile Leu Tyr | Ile Leu Leu Val Gly Tyr |
| 1 | 5 | 10 15 |
| Pro Pro Phe Trp | Asp Glu Asp Gln His | Arg Leu Tyr Gln Gln Ile |
| | 20 | 25 30 |
| Lys Ala Gly Ala | Tyr Asp Phe Pro Ser | Pro Glu Trp Asp Thr Val |
| | 35 | 40 45 |

```
<210> 10
<211> 510
<212> PRT
<213> Homo 'sapiens
```

| | | | | | | | | | | | | | | |
|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| <400> 10 | | | | | | | | | | | | | | |
| Met | Lys | Ala | Asp | Ile | Lys | Ile | Trp | Ile | Leu | Thr | Gly | Asp | Lys | Gln |
| 1 | | | | 5 | | | | | 10 | | | | | 15 |
| Glu | Thr | Ala | Ile | Asn | Ile | Gly | His | Ser | Cys | Lys | Leu | Leu | Lys | Lys |
| | | | | 20 | | | | | 25 | | | | | 30 |
| Asn | Met | Gly | Met | Ile | Val | Ile | Asn | Glu | Gly | Ser | Leu | Asp | Ser | Phe |
| | | | | 35 | | | | | 40 | | | | | 45 |
| Ser | Asn | Thr | Gln | Asn | Ser | Arg | Lys | Glu | Ala | Val | Leu | Leu | Ala | Lys |
| | | | | 50 | | | | | 55 | | | | | 60 |
| Met | Lys | His | Pro | Asn | Ile | Val | Ala | Phe | Lys | Glu | Ser | Phe | Glu | Ala |
| | | | | 65 | | | | | 70 | | | | | 75 |
| Glu | Gly | His | Leu | Tyr | Ile | Val | Met | Glu | Tyr | Cys | Asp | Gly | Gly | Asp |
| | | | | 80 | | | | | 85 | | | | | 90 |

| | | | | |
|---|---|-----|-----|-----|
| Leu Met Gln Lys | Ile Lys Gln Gln Lys Gly Lys Leu Phe Pro Glu | 95 | 100 | 105 |
| Asp Met Ile Leu Asn Trp Phe Thr Gln Met Cys Leu Gly Val Asn | | 110 | 115 | 120 |
| His Ile His Lys Lys Arg Val Leu His Arg Asp Ile Lys Ser Lys | | 125 | 130 | 135 |
| Asn Ile Phe Leu Thr Gln Asn Gly Lys Val Lys Leu Gly Asp Phe | | 140 | 145 | 150 |
| Gly Ser Ala Arg Leu Leu Ser Asn Pro Met Ala Phe Ala Cys Thr | | 155 | 160 | 165 |
| Tyr Val Gly Thr Pro Tyr Tyr Val Pro Pro Glu Ile Trp Glu Asn | | 170 | 175 | 180 |
| Leu Pro Tyr Asn Asn Lys Ser Asp Ile Trp Ser Leu Gly Cys Ile | | 185 | 190 | 195 |
| Leu Tyr Glu Leu Cys Thr Leu Lys His Pro Phe Gln Ala Asn Ser | | 200 | 205 | 210 |
| Trp Lys Asn Leu Ile Leu Lys Val Cys Gln Gly Cys Ile Ser Pro | | 215 | 220 | 225 |
| Leu Pro Ser His Tyr Ser Tyr Glu Leu Gln Phe Leu Val Lys Gln | | 230 | 235 | 240 |
| Met Phe Lys Arg Asn Pro Ser His Arg Pro Ser Ala Thr Thr Leu | | 245 | 250 | 255 |
| Leu Ser Arg Gly Ile Val Ala Arg Leu Val Gln Lys Cys Leu Pro | | 260 | 265 | 270 |
| Pro Glu Ile Ile Met Glu Tyr Gly Glu Glu Val Leu Glu Glu Ile | | 275 | 280 | 285 |
| Lys Asn Ser Lys His Asn Thr Pro Arg Lys Lys Thr Asn Pro Ser | | 290 | 295 | 300 |
| Arg Ile Arg Ile Ala Leu Gly Asn Glu Ala Ser Thr Val Gln Glu | | 305 | 310 | 315 |
| Glu Glu Gln Asp Arg Lys Gly Ser His Thr Asp Leu Glu Ser Ile | | 320 | 325 | 330 |
| Asn Glu Asn Leu Val Glu Ser Ala Leu Arg Arg Val Asn Arg Glu | | 335 | 340 | 345 |
| Glu Lys Gly Asn Lys Ser Val His Leu Arg Lys Ala Ser Ser Pro | | 350 | 355 | 360 |
| Asn Leu His Arg Arg Gln Trp Glu Lys Asn Val Pro Asn Thr Ala | | 365 | 370 | 375 |
| Leu Thr Ala Leu Glu Asn Ala Ser Ile Leu Thr Ser Ser Leu Thr | | 380 | 385 | 390 |
| Ala Glu Asp Asp Arg Gly Gly Ser Val Ile Lys Tyr Ser Lys Asn | | 395 | 400 | 405 |
| Thr Thr Arg Lys Gln Trp Leu Lys Glu Thr Pro Asp Thr Leu Leu | | 410 | 415 | 420 |
| Asn Ile Leu Lys Asn Ala Asp Leu Ser Leu Ala Phe Gln Thr Tyr | | 425 | 430 | 435 |
| Thr Ile Tyr Arg Pro Gly Ser Glu Gly Phe Leu Lys Gly Pro Leu | | 440 | 445 | 450 |
| Ser Glu Glu Thr Glu Ala Ser Asp Ser Val Asp Gly Gly His Asp | | 455 | 460 | 465 |
| Ser Val Ile Leu Asp Pro Glu Arg Leu Glu Pro Gly Leu Asp Glu | | 470 | 475 | 480 |
| Glu Asp Thr Asp Phe Glu Glu Glu Asp Asp Asn Pro Asp Trp Val | | 485 | 490 | 495 |
| Ser Glu Leu Lys Lys Arg Ala Gly Trp Gln Gly Leu Cys Asp Arg | | 500 | 505 | 510 |

<210> 11
 <211> 248
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <223> Incyte Clone Number: 304421

<400> 11
 Met Ala Glu Thr Ser Leu Pro Glu Leu Gly Gly Glu Asp Lys Ala
 1 5 10 15
 Thr Pro Cys Pro Ser Ile Leu Glu Leu Glu Glu Leu Leu Arg Ala
 20 25 30
 Gly Lys Ser Ser Cys Ser Arg Val Asp Glu Val Trp Pro Asn Leu
 35 40 45
 Phe Ile Gly Asp Ala Met Asp Ser Leu Gln Lys Gln Asp Leu Arg
 50 55 60
 Arg Pro Lys Ile His Gly Ala Val Gln Ala Ser Pro Tyr Gln Pro
 65 70 75
 Pro Thr Leu Ala Ser Leu Gln Arg Leu Leu Trp Val Arg Gln Ala
 80 85 90
 Ala Thr Leu Asn His Ile Asp Glu Val Trp Pro Ser Leu Phe Leu
 95 100 105
 Gly Asp Ala Tyr Ala Ala Arg Asp Lys Ser Lys Leu Ile Gln Leu
 110 115 120
 Gly Ile Thr His Val Val Asn Ala Ala Ala Gly Lys Phe Gln Val
 125 130 135
 Asp Thr Gly Ala Lys Phe Tyr Arg Gly Met Ser Leu Glu Tyr Tyr
 140 145 150
 Gly Ile Glu Ala Asp Asp Asn Pro Phe Phe Asp Leu Ser Val Tyr
 155 160 165
 Phe Leu Pro Val Ala Arg Tyr Ile Arg Ala Ala Leu Ser Val Pro
 170 175 180
 Gln Gly Arg Val Leu Val His Cys Ala Met Gly Val Ser Arg Ser
 185 190 195
 Ala Thr Leu Val Leu Ala Phe Leu Met Ile Tyr Glu Asn Met Thr
 200 205 210
 Leu Val Glu Ala Ile Gln Thr Val Gln Ala His Arg Asn Ile Cys
 215 220 225
 Pro Asn Ser Gly Phe Leu Arg Gln Leu Gln Val Leu Asp Asn Arg
 230 235 240
 Leu Gly Arg Glu Thr Gly Arg Phe
 245

<210> 12
 <211> 810
 <212> PRT
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <223> Incyte Clone Number: 1213802

14/64

| | | | | | |
|-----------------|---------------------|-------------------------|-----|--|-----|
| | 410 | | 415 | | 420 |
| Glu Arg Gln Lys | Ser Lys Lys Asp Thr | Thr Cys Ile Lys Leu Lys | | | |
| | 425 | | 430 | | 435 |
| Ile Asp Ser Glu | Ile Lys Lys Thr Val | Val Leu Pro Pro Ile Val | | | |
| | 440 | | 445 | | 450 |
| Ala Ser Arg Gly | Gln Ser Glu Glu Pro | Ala Gly Lys Thr Lys Ser | | | |
| | 455 | | 460 | | 465 |
| Met Gln Glu Val | His Ile Lys Thr Leu | Glu Glu Ile Lys Leu Glu | | | |
| | 470 | | 475 | | 480 |
| Lys Ala Leu Arg | Val Gln Gln Ser Ser | Glu Ser Ser Thr Ser Ser | | | |
| | 485 | | 490 | | 495 |
| Pro Ser Gln His | Glu Ala Thr Pro Gly | Ala Arg Arg Leu Leu Arg | | | |
| | 500 | | 505 | | 510 |
| Ile Thr Lys Arg | Thr Gly Met Lys Glu | Glu Lys Asn Leu Gln Glu | | | |
| | 515 | | 520 | | 525 |
| Gly Asn Glu Val | Asp Ser Gln Ser Ser | Ile Arg Thr Glu Ala Lys | | | |
| | 530 | | 535 | | 540 |
| Glu Ala Ser Gly | Glu Thr Thr Gly Val | Asp Ile Thr Lys Ile Gln | | | |
| | 545 | | 550 | | 555 |
| Val Lys Arg Cys | Glu Thr Met Arg Glu | Lys His Met Gln Lys Gln | | | |
| | 560 | | 565 | | 570 |
| Gln Glu Arg Glu | Lys Ser Val Leu Thr | Pro Leu Arg Gly Asp Val | | | |
| | 575 | | 580 | | 585 |
| Ala Ser Cys Asn | Thr Gln Val Ala Glu | Lys Pro Val Leu Thr Ala | | | |
| | 590 | | 595 | | 600 |
| Val Pro Gly Ile | Thr Arg His Leu Thr | Lys Arg Leu Pro Thr Lys | | | |
| | 605 | | 610 | | 615 |
| Ser Ser Gln Lys | Val Glu Val Glu Thr | Ser Gly Ile Gly Asp Ser | | | |
| | 620 | | 625 | | 630 |
| Leu Leu Asn Val | Lys Cys Ala Ala Gln | Thr Leu Glu Lys Arg Gly | | | |
| | 635 | | 640 | | 645 |
| Lys Ala Lys Pro | Lys Val Asn Val Lys | Pro Ser Val Val Lys Val | | | |
| | 650 | | 655 | | 660 |
| Val Ser Ser Pro | Lys Leu Ala Pro Lys | Arg Lys Ala Val Glu Met | | | |
| | 665 | | 670 | | 675 |
| His Ala Ala Val | Ile Ala Ala Val Lys | Pro Leu Ser Ser Ser Ser | | | |
| | 680 | | 685 | | 690 |
| Val Leu Gln Glu | Pro Pro Ala Lys Lys | Ala Ala Val Ala Val Val | | | |
| | 695 | | 700 | | 705 |
| Pro Leu Val Ser | Glu Asp Lys Ser Val | Thr Val Pro Glu Ala Glu | | | |
| | 710 | | 715 | | 720 |
| Asn Pro Arg Asp | Ser Leu Val Leu Pro | Pro Thr Gln Ser Ser Ser | | | |
| | 725 | | 730 | | 735 |
| Asp Ser Ser Pro | Pro Glu Val Ser Gly | Pro Ser Ser Ser Gln Met | | | |
| | 740 | | 745 | | 750 |
| Ser Met Lys Thr | Arg Arg Leu Ser Ser | Ala Ser Thr Gly Lys Pro | | | |
| | 755 | | 760 | | 765 |
| Pro Leu Ser Val | Glu Asp Asp Phe Glu | Lys Leu Ile Trp Glu Ile | | | |
| | 770 | | 775 | | 780 |
| Ser Gly Gly Lys | Leu Glu Ala Glu Ile | Asp Leu Asp Pro Gly Lys | | | |
| | 785 | | 790 | | 795 |
| Asp Glu Asp Asp | Leu Leu Leu Glu Leu | Ser Glu Met Ile Asp Ser | | | |
| | 800 | | 805 | | 810 |

<211> 549

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 1378134

<400> 13

```

Met Arg Arg Arg Ala Ser Asn Ala Ala Ala Ala His Thr Ile
 1              5              10              15
Gly Gly Ser Lys His Thr Met Asn Asp His Leu His Val Gly Ser
              20              25              30
His Ala His Gly Gln Ile Gln Val Arg Gln Leu Phe Glu Asp Asn
              35              40              45
Ser Asn Lys Arg Thr Val Leu Thr Thr Gln Pro Asn Gly Leu Thr
              50              55              60
Thr Val Gly Lys Thr Gly Leu Pro Val Val Pro Glu Arg Gln Leu
              65              70              75
Asp Ser Ile His Arg Arg Gln Gly Ser Ser Thr Ser Leu Lys Ser
              80              85              90
Met Glu Gly Met Gly Lys Val Lys Ala Thr Pro Met Thr Pro Glu
              95              100             105
Gln Ala Met Lys Gln Tyr Met Gln Lys Leu Thr Ala Phe Glu His
              110             115             120
His Glu Ile Phe Ser Tyr Pro Glu Ile Tyr Phe Leu Gly Leu Asn
              125             130             135
Ala Lys Lys Arg Gln Gly Met Thr Gly Gly Pro Asn Asn Gly Gly
              140             145             150
Tyr Asp Asp Asp Gln Gly Ser Tyr Val Gln Val Pro His Asp His
              155             160             165
Val Ala Tyr Arg Tyr Glu Val Leu Lys Val Ile Gly Lys Gly Ser
              170             175             180
Phe Gly Gln Val Val Lys Ala Tyr Asp His Lys Val His Gln His
              185             190             195
Val Ala Leu Lys Met Val Arg Asn Glu Lys Arg Phe His Arg Gln
              200             205             210
Ala Ala Glu Glu Ile Arg Ile Leu Glu His Leu Arg Lys Gln Asp
              215             220             225
Lys Asp Asn Thr Met Asn Val Ile His Met Leu Glu Asn Phe Thr
              230             235             240
Phe Arg Asn His Ile Cys Met Thr Phe Glu Leu Leu Ser Met Asn
              245             250             255
Leu Tyr Glu Leu Ile Lys Lys Asn Lys Phe Gln Gly Phe Ser Leu
              260             265             270
Pro Leu Val Arg Lys Phe Ala His Ser Ile Leu Gln Cys Leu Asp
              275             280             285
Ala Leu His Lys Asn Arg Ile Ile His Cys Asp Leu Lys Pro Glu
              290             295             300
Asn Ile Leu Leu Lys Gln Gln Gly Arg Ser Gly Ile Lys Val Ile
              305             310             315
Asp Phe Gly Ser Ser Cys Tyr Glu His Gln Arg Val Tyr Thr Tyr
              320             325             330
Ile Gln Ser Arg Phe Tyr Arg Ala Pro Glu Val Ile Leu Gly Ala
              335             340             345
Arg Tyr Gly Met Pro Ile Asp Met Trp Ser Leu Gly Cys Ile Leu

```

| | | |
|---|-----|-----|
| 350 | 355 | 360 |
| Ala Glu Leu Leu Thr Gly Tyr Pro Leu Leu Pro Gly Glu Asp Glu | | |
| 365 | 370 | 375 |
| Gly Asp Gln Leu Ala Cys Met Ile Glu Leu Leu Gly Met Pro Ser | | |
| 380 | 385 | 390 |
| Gln Lys Leu Leu Asp Ala Ser Lys Arg Ala Lys Asn Phe Val Ser | | |
| 395 | 400 | 405 |
| Ser Lys Gly Tyr Pro Arg Tyr Cys Thr Val Thr Thr Leu Ser Asp | | |
| 410 | 415 | 420 |
| Gly Ser Val Val Leu Asn Gly Gly Arg Ser Arg Arg Gly Lys Leu | | |
| 425 | 430 | 435 |
| Arg Gly Pro Pro Glu Ser Arg Glu Trp Gly Asn Ala Leu Lys Gly | | |
| 440 | 445 | 450 |
| Cys Asp Asp Pro Leu Phe Leu Asp Phe Leu Lys Gln Cys Leu Glu | | |
| 455 | 460 | 465 |
| Trp Asp Pro Ala Val Arg Met Thr Pro Gly Gln Ala Leu Arg His | | |
| 470 | 475 | 480 |
| Pro Trp Leu Arg Arg Arg Leu Pro Lys Pro Pro Thr Gly Glu Lys | | |
| 485 | 490 | 495 |
| Thr Ser Val Lys Arg Ile Thr Glu Ser Thr Gly Ala Ile Thr Ser | | |
| 500 | 505 | 510 |
| Ile Ser Lys Leu Pro Pro Pro Ser Ser Ser Ala Ser Lys Leu Arg | | |
| 515 | 520 | 525 |
| Thr Asn Leu Ala Gln Met Thr Asp Ala Asn Gly Asn Ile Gln Gln | | |
| 530 | 535 | 540 |
| Arg Thr Val Leu Pro Lys Leu Val Ser | | |
| 545 | | |

<210> 14

<211> 416

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 1490070

<400> 14

| | | |
|---|-----|-----|
| Met Met Pro Gln Leu Gln Phe Lys Asp Ala Phe Trp Cys Arg Asp | | |
| 1 | 5 | 10 |
| Phe Thr Ala His Thr Gly Tyr Glu Val Leu Leu Gln Arg Leu Leu | | |
| 20 | 25 | 30 |
| Asp Gly Arg Lys Met Cys Lys Asp Met Val Glu Leu Leu Trp Gln | | |
| 35 | 40 | 45 |
| Arg Ala Gln Ala Glu Glu Arg Tyr Gly Lys Glu Leu Val Gln Ile | | |
| 50 | 55 | 60 |
| Ala Arg Lys Ala Gly Gly Gln Thr Glu Ile Asn Ser Leu Arg Ala | | |
| 65 | 70 | 75 |
| Ser Phe Asp Ser Leu Lys Gln Gln Met Glu Asn Val Gly Ser Ser | | |
| 80 | 85 | 90 |
| His Ile Gln Leu Ala Leu Thr Leu Arg Glu Glu Leu Arg Ser Leu | | |
| 95 | 100 | 105 |
| Glu Glu Phe Arg Glu Arg Gln Lys Glu Gln Arg Lys Lys Tyr Glu | | |
| 110 | 115 | 120 |
| Ala Val Met Asp Arg Val Gln Lys Ser Lys Leu Ser Leu Tyr Lys | | |

| | | | | | |
|---|-----|--|-----|--|-----|
| | 125 | | 130 | | 135 |
| Lys Ala Met Glu Ser Lys Lys Thr Tyr Glu Gln Lys Cys Arg Asp | | | | | |
| | 140 | | 145 | | 150 |
| Ala Asp Asp Ala Glu Gln Ala Phe Glu Arg Ile Ser Ala Asn Gly | | | | | |
| | 155 | | 160 | | 165 |
| His Gln Lys Gln Val Glu Lys Ser Gln Asn Lys Ala Arg Gln Cys | | | | | |
| | 170 | | 175 | | 180 |
| Lys Asp Ser Ala Thr Glu Ala Glu Arg Val Tyr Arg Gln Ser Ile | | | | | |
| | 185 | | 190 | | 195 |
| Ala Gln Leu Glu Lys Val Arg Ala Glu Trp Glu Gln Glu His Arg | | | | | |
| | 200 | | 205 | | 210 |
| Thr Thr Cys Glu Ala Phe Gln Leu Gln Glu Phe Asp Arg Leu Thr | | | | | |
| | 215 | | 220 | | 225 |
| Ile Leu Arg Asn Ala Leu Trp Val His Ser Asn Gln Leu Ser Met | | | | | |
| | 230 | | 235 | | 240 |
| Gln Cys Val Lys Asp Asp Glu Leu Tyr Glu Glu Val Arg Leu Thr | | | | | |
| | 245 | | 250 | | 255 |
| Leu Glu Gly Cys Ser Ile Asp Ala Asp Ile Asp Ser Phe Ile Gln | | | | | |
| | 260 | | 265 | | 270 |
| Ala Lys Ser Thr Gly Thr Glu Pro Pro Ala Pro Val Pro Tyr Gln | | | | | |
| | 275 | | 280 | | 285 |
| Asn Tyr Tyr Asp Arg Glu Val Thr Pro Leu Thr Ser Ser Pro Gly | | | | | |
| | 290 | | 295 | | 300 |
| Ile Gln Pro Ser Cys Gly Met Ile Lys Arg Phe Ser Gly Leu Leu | | | | | |
| | 305 | | 310 | | 315 |
| His Gly Ser Pro Lys Thr Thr Ser Leu Ala Ala Ser Ala Ala Ser | | | | | |
| | 320 | | 325 | | 330 |
| Thr Glu Thr Leu Thr Pro Thr Pro Glu Arg Asn Glu Gly Val Tyr | | | | | |
| | 335 | | 340 | | 345 |
| Thr Ala Ile Ala Val Gln Glu Ile Gln Gly Asn Pro Ala Ser Pro | | | | | |
| | 350 | | 355 | | 360 |
| Ala Gln Glu Tyr Arg Ala Leu Tyr Asp Tyr Thr Ala Gln Asn Pro | | | | | |
| | 365 | | 370 | | 375 |
| Asp Glu Leu Asp Leu Ser Ala Gly Asp Ile Leu Glu Val Ile Leu | | | | | |
| | 380 | | 385 | | 390 |
| Glu Gly Glu Asp Gly Trp Trp Thr Val Glu Arg Asn Gly Gln Arg | | | | | |
| | 395 | | 400 | | 405 |
| Gly Phe Val Pro Gly Ser Tyr Leu Glu Lys Leu | | | | | |
| | 410 | | 415 | | |

<210> 15

<211> 425

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 1997814

<400> 15

| | | | |
|---|----|----|----|
| Met Glu Gln Gly Leu Glu Glu Glu Glu Glu Val Asp Pro Arg Ile | | | |
| 1 | 5 | 10 | 15 |
| Gln Gly Glu Leu Glu Lys Leu Asn Gln Ser Thr Asp Asp Ile Asn | | | |
| | 20 | 25 | 30 |
| Arg Arg Glu Thr Glu Leu Glu Asp Ala Arg Gln Lys Phe Arg Ser | | | |
| | 35 | 40 | 45 |

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Leu | Val | Glu | Ala | Thr | Val | Lys | Leu | Asp | Glu | Leu | Val | Lys | Lys |
| | | | 50 | | | | | | 55 | | | | | 60 |
| Ile | Gly | Lys | Ala | Val | Glu | Asp | Ser | Lys | Pro | Tyr | Trp | Glu | Ala | Arg |
| | | | 65 | | | | | | 70 | | | | | 75 |
| Arg | Val | Ala | Arg | Gln | Ala | Gln | Leu | Glu | Ala | Gln | Lys | Ala | Thr | Gln |
| | | | 80 | | | | | | 85 | | | | | 90 |
| Asp | Phe | Gln | Arg | Ala | Thr | Glu | Val | Leu | Arg | Ala | Ala | Lys | Glu | Thr |
| | | | 95 | | | | | | 100 | | | | | 105 |
| Ile | Ser | Leu | Ala | Glu | Gln | Arg | Leu | Leu | Glu | Asp | Asp | Lys | Arg | Gln |
| | | | 110 | | | | | | 115 | | | | | 120 |
| Phe | Asp | Ser | Ala | Trp | Gln | Glu | Met | Leu | Asn | His | Ala | Thr | Gln | Arg |
| | | | 125 | | | | | | 130 | | | | | 135 |
| Val | Met | Glu | Ala | Glu | Gln | Thr | Lys | Thr | Arg | Ser | Glu | Leu | Val | His |
| | | | 140 | | | | | | 145 | | | | | 150 |
| Lys | Glu | Thr | Ala | Ala | Arg | Tyr | Asn | Ala | Ala | Met | Gly | Arg | Met | Arg |
| | | | 155 | | | | | | 160 | | | | | 165 |
| Gln | Leu | Glu | Lys | Lys | Leu | Lys | Arg | Ala | Ile | Asn | Lys | Ser | Lys | Pro |
| | | | 170 | | | | | | 175 | | | | | 180 |
| Tyr | Phe | Glu | Leu | Lys | Ala | Lys | Tyr | Tyr | Val | Gln | Leu | Glu | Gln | Leu |
| | | | 185 | | | | | | 190 | | | | | 195 |
| Lys | Lys | Thr | Val | Asp | Leu | Gln | Ala | Lys | Leu | Thr | Leu | Ala | Lys | |
| | | | 200 | | | | | | 205 | | | | | 210 |
| Gly | Glu | Tyr | Lys | Met | Ala | Leu | Lys | Asn | Leu | Glu | Met | Ile | Ser | Asp |
| | | | 215 | | | | | | 220 | | | | | 225 |
| Glu | Ile | His | Glu | Arg | Arg | Arg | Ser | Ser | Ala | Met | Gly | Pro | Arg | Gly |
| | | | 230 | | | | | | 235 | | | | | 240 |
| Cys | Gly | Val | Gly | Ala | Glu | Gly | Ser | Ser | Thr | Ser | Val | Glu | Asp | Leu |
| | | | 245 | | | | | | 250 | | | | | 255 |
| Pro | Gly | Ser | Lys | Pro | Glu | Pro | Asp | Ala | Ile | Ser | Val | Ala | Ser | Glu |
| | | | 260 | | | | | | 265 | | | | | 270 |
| Ala | Phe | Glu | Asp | Asp | Ser | Cys | Ser | Asn | Phe | Val | Ser | Glu | Asp | Asp |
| | | | 275 | | | | | | 280 | | | | | 285 |
| Ser | Glu | Thr | Gln | Ser | Val | Ser | Ser | Phe | Ser | Ser | Gly | Pro | Thr | Ser |
| | | | 290 | | | | | | 295 | | | | | 300 |
| Pro | Ser | Glu | Met | Pro | Asp | Gln | Phe | Pro | Ala | Val | Val | Arg | Pro | Gly |
| | | | 305 | | | | | | 310 | | | | | 315 |
| Ser | Leu | Asp | Leu | Pro | Ser | Pro | Val | Ser | Leu | Ser | Glu | Phe | Gly | Met |
| | | | 320 | | | | | | 325 | | | | | 330 |
| Met | Phe | Pro | Val | Leu | Gly | Pro | Arg | Ser | Glu | Cys | Ser | Gly | Ala | Ser |
| | | | 335 | | | | | | 340 | | | | | 345 |
| Ser | Pro | Glu | Cys | Glu | Val | Glu | Arg | Gly | Asp | Arg | Ala | Glu | Gly | Ala |
| | | | 350 | | | | | | 355 | | | | | 360 |
| Glu | Asn | Lys | Thr | Ser | Asp | Lys | Ala | Asn | Asn | Asn | Arg | Gly | Leu | Ser |
| | | | 365 | | | | | | 370 | | | | | 375 |
| Ser | Ser | Ser | Gly | Ser | Gly | Gly | Ser | Ser | Lys | Ser | Gln | Ser | Ser | Thr |
| | | | 380 | | | | | | 385 | | | | | 390 |
| Ser | Pro | Glu | Gly | Gln | Ala | Leu | Glu | Asn | Arg | Met | Lys | Gln | Leu | Ser |
| | | | 395 | | | | | | 400 | | | | | 405 |
| Leu | Gln | Cys | Ser | Lys | Gly | Arg | Asp | Gly | Ile | Ile | Ala | Asp | Ile | Lys |
| | | | 410 | | | | | | 415 | | | | | 420 |
| Met | Val | Gln | Ile | Gly | | | | | | | | | | |
| | | | 425 | | | | | | | | | | | |

<210> 16

<211> 1135

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2299715

<400> 16

```

Met Ala Asn Asp Ser Pro Ala Lys Ser Leu Val Asp Ile Asp Leu
 1          5          10          15
Ser Ser Leu Arg Asp Pro Ala Gly Ile Phe Glu Leu Val Glu Val
 20          25          30
Val Gly Asn Gly Thr Tyr Gly Gln Val Tyr Lys Gly Arg His Val
 35          40          45
Lys Thr Gly Gln Leu Ala Ala Ile Lys Val Met Asp Val Thr Glu
 50          55          60

Asp Glu Glu Glu Glu Ile Lys Leu Glu Ile Asn Met Leu Lys Lys
 65          70          75
Tyr Ser His His Arg Asn Ile Ala Thr Tyr Tyr Gly Ala Phe Ile
 80          85          90
Lys Lys Ser Pro Pro Gly His Asp Asp Gln Leu Trp Leu Val Met
 95          100          105
Glu Phe Cys Gly Ala Gly Ser Ile Thr Asp Leu Val Lys Asn Thr
 110          115          120
Lys Gly Asn Thr Leu Lys Glu Asp Trp Ile Ala Tyr Ile Ser Arg
 125          130          135
Glu Ile Leu Arg Gly Leu Ala His Leu His Ile His His Val Ile
 140          145          150
His Arg Asp Ile Lys Gly Gln Asn Val Leu Leu Thr Glu Asn Ala
 155          160          165
Gly Val Lys Leu Val Asp Phe Gly Val Ser Ala Gln Leu Asp Arg
 170          175          180
Thr Val Gly Arg Arg Asn Thr Phe Ile Gly Thr Pro Tyr Trp Met
 185          190          195
Ala Pro Glu Val Ile Ala Cys Asp Glu Asn Pro Asp Ala Thr Tyr
 200          205          210
Asp Tyr Arg Ser Asp Leu Trp Ser Cys Gly Ile Thr Ala Ile Glu
 215          220          225
Met Ala Glu Gly Ala Pro Pro Leu Cys Asp Met His Pro Met Arg
 230          235          240
Ala Leu Phe Leu Ile Pro Arg Asn Pro Pro Pro Arg Leu Lys Ser
 245          250          255
Lys Lys Trp Ser Lys Lys Phe Phe Ser Phe Ile Glu Gly Cys Leu
 260          265          270
Val Lys Asn Tyr Met Gln Arg Pro Ser Thr Glu Gln Leu Leu Lys
 275          280          285
His Pro Phe Ile Arg Asp Gln Pro Asn Glu Arg Gln Val Arg Ile
 290          295          300
Gln Leu Lys Asp His Ile Asp Arg Thr Arg Lys Lys Arg Gly Glu
 305          310          315
Lys Asp Glu Thr Glu Tyr Glu Tyr Ser Gly Ser Glu Glu Glu Glu
 320          325          330
Glu Glu Val Pro Glu Gln Glu Gly Glu Pro Ser Ser Ile Val Asn
 335          340          345
Val Pro Gly Glu Ser Thr Leu Arg Arg Asp Phe Leu Arg Leu Gln

```

| | | | |
|-----------------|---------------------|---------------------|-----|
| | 350 | 355 | 360 |
| Gln Glu Asn Lys | Glu Arg Ser Glu Ala | Leu Arg Arg Gln Gln | Leu |
| | 365 | 370 | 375 |
| Leu Gln Glu Gln | Gln Leu Arg Glu Gln | Glu Glu Tyr Lys Arg | Gln |
| | 380 | 385 | 390 |
| Leu Leu Ala Glu | Arg Gln Lys Arg Ile | Glu Gln Gln Lys Glu | Gln |
| | 395 | 400 | 405 |
| Arg Arg Arg Leu | Glu Glu Gln Gln Arg | Arg Glu Arg Glu Ala | Arg |
| | 410 | 415 | 420 |
| Arg Gln Gln Glu | Arg Glu Gln Arg Arg | Arg Glu Gln Glu Glu | Lys |
| | 425 | 430 | 435 |
| Arg Arg Leu Glu | Glu Leu Glu Arg Arg | Arg Lys Glu Glu Glu | Glu |
| | 440 | 445 | 450 |
| Arg Arg Arg Ala | Glu Glu Glu Lys Arg | Arg Val Glu Arg Glu | Gln |
| | 455 | 460 | 465 |
| Glu Tyr Ile Arg | Arg Gln Leu Glu Glu | Glu Gln Arg His Leu | Glu |
| | 470 | 475 | 480 |
| Val Leu Gln Gln | Gln Leu Leu Gln Glu | Gln Ala Met Leu Leu | His |
| | 485 | 490 | 495 |
| Asp His Arg Arg | Pro His Pro Gln His | Ser Gln Gln Pro Pro | Pro |
| | 500 | 505 | 510 |
| Pro Gln Gln Glu | Arg Ser Lys Pro Ser | Phe His Ala Pro Glu | Pro |
| | 515 | 520 | 525 |
| Lys Ala His Tyr | Glu Pro Ala Asp Arg | Ala Arg Glu Val Pro | Val |
| | 530 | 535 | 540 |
| Arg Thr Thr Ser | Arg Ser Pro Val Leu | Ser Arg Arg Asp Ser | Pro |
| | 545 | 550 | 555 |
| Leu Gln Gly Ser | Gly Gln Gln Asn Ser | Gln Ala Gly Gln Arg | Asn |
| | 560 | 565 | 570 |
| Ser Thr Ser Ile | Glu Pro Arg Leu Leu | Trp Glu Arg Val Glu | Lys |
| | 575 | 580 | 585 |
| Leu Val Pro Arg | Pro Gly Ser Gly Ser | Ser Ser Gly Ser Ser | Asn |
| | 590 | 595 | 600 |
| Ser Gly Ser Gln | Pro Gly Ser His Pro | Gly Ser Gln Ser Gly | Ser |
| | 605 | 610 | 615 |
| Gly Glu Arg Phe | Arg Val Arg Ser Ser | Ser Lys Ser Glu Gly | Ser |
| | 620 | 625 | 630 |
| Pro Ser Gln Arg | Leu Glu Asn Ala Val | Lys Lys Pro Glu Asp | Lys |
| | 635 | 640 | 645 |
| Lys Glu Val Phe | Arg Pro Leu Lys Pro | Ala Asp Leu Thr Ala | Leu |
| | 650 | 655 | 660 |
| Ala Lys Glu Leu | Arg Ala Val Glu Asp | Val Arg Pro Pro His | Lys |
| | 665 | 670 | 675 |
| Val Thr Asp Tyr | Ser Ser Ser Ser Glu | Glu Ser Gly Thr Thr | Asp |
| | 680 | 685 | 690 |
| Glu Glu Asp Asp | Asp Val Glu Gln Glu | Gly Ala Asp Glu Ser | Thr |
| | 695 | 700 | 705 |
| Ser Gly Pro Glu | Asp Thr Arg Ala Ala | Ser Ser Leu Asn Leu | Ser |
| | 710 | 715 | 720 |
| Asn Gly Glu Thr | Glu Ser Val Lys Thr | Met Ile Val His Asp | Asp |
| | 725 | 730 | 735 |
| Val Glu Ser Glu | Pro Ala Met Thr Pro | Ser Lys Glu Gly Thr | Leu |
| | 740 | 745 | 750 |
| Ile Val Arg Gln | Thr Gln Ser Ala Ser | Ser Thr Leu Gln Lys | His |
| | 755 | 760 | 765 |
| Lys Ser Ser Ser | Ser Phe Thr Pro Phe | Ile Asp Pro Arg Leu | Leu |

| | | | |
|---|------|------|-----|
| Gln Ile Ser Pro | 770 | 775 | 780 |
| Ser Ser Gly Thr Thr Val Thr Ser Val Val Gly | | | |
| 785 | 790 | 795 | |
| Phe Ser Cys Asp Gly Met Arg Pro Glu Ala Ile Arg Gln Asp Pro | | | |
| 800 | 805 | 810 | |
| Thr Arg Lys Gly Ser Val Val Asn Val Asn Pro Thr Asn Thr Arg | | | |
| 815 | 820 | 825 | |
| Pro Gln Ser Asp Thr Pro Glu Ile Arg Lys Tyr Lys Lys Arg Phe | | | |
| 830 | 835 | 840 | |
| Asn Ser Glu Ile Leu Cys Ala Ala Leu Trp Gly Val Asn Leu Leu | | | |
| 845 | 850 | 855 | |
| Val Gly Thr Glu Ser Gly Leu Met Leu Leu Asp Arg Ser Gly Gln | | | |
| 860 | 865 | 870 | |
| Gly Lys Val Tyr Pro Leu Ile Asn Arg Arg Arg Phe Gln Gln Met | | | |
| 875 | 880 | 885 | |
| Asp Val Leu Glu Gly Leu Asn Val Leu Val Thr Ile Ser Gly Lys | | | |
| 890 | 895 | 900 | |
| Lys Asp Lys Leu Arg Val Tyr Tyr Leu Ser Trp Leu Arg Asn Lys | | | |
| 905 | 910 | 915 | |
| Ile Leu His Asn Asp Pro Glu Val Glu Lys Lys Gln Gly Trp Thr | | | |
| 920 | 925 | 930 | |
| Thr Val Gly Asp Leu Glu Gly Cys Val His Tyr Lys Val Val Lys | | | |
| 935 | 940 | 945 | |
| Tyr Glu Arg Ile Lys Phe Leu Val Ile Ala Leu Lys Ser Ser Val | | | |
| 950 | 955 | 960 | |
| Glu Val Tyr Ala Trp Ala Pro Lys Pro Tyr His Lys Phe Met Ala | | | |
| 965 | 970 | 975 | |
| Phe Lys Ser Phe Gly Glu Leu Val His Gly Ser Cys Ala Gly Phe | | | |
| 980 | 985 | 990 | |
| His Ala Val Asp Val Asp Ser Gly Ser Val Tyr Asp Ile Tyr Leu | | | |
| 995 | 1000 | 1005 | |
| Pro Thr His Ile Gln Cys Ser Ile Lys Pro His Ala Ile Ile Ile | | | |
| 1010 | 1015 | 1020 | |
| Leu Pro Asn Thr Asp Gly Met Glu Leu Leu Val Cys Tyr Glu Asp | | | |
| 1025 | 1030 | 1035 | |
| Glu Gly Val Tyr Val Asn Thr Tyr Gly Arg Ile Thr Lys Asp Val | | | |
| 1040 | 1045 | 1050 | |
| Val Leu Gln Trp Gly Glu Met Pro Thr Ser Val Ala Tyr Ile Arg | | | |
| 1055 | 1060 | 1065 | |
| Ser Asn Gln Thr Met Gly Trp Gly Glu Lys Ala Ile Glu Ile Arg | | | |
| 1070 | 1075 | 1080 | |
| Ser Val Glu Thr Gly His Leu Asp Gly Val Phe Met His Lys Arg | | | |
| 1085 | 1090 | 1095 | |
| Ala Gln Arg Leu Lys Phe Leu Cys Glu Arg Asn Asp Lys Val Phe | | | |
| 1100 | 1105 | 1110 | |
| Phe Ala Ser Val Arg Ser Gly Gly Ser Ser Gln Val Tyr Phe Met | | | |
| 1115 | 1120 | 1125 | |
| Thr Leu Gly Arg Thr Ser Leu Leu Ser Trp | | | |
| 1130 | 1135 | | |

<210> 17

<211> 228

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 209854

<400> 17

```

Met Pro Thr Asn Cys Ala Ala Ala Gly Cys Ala Thr Thr Tyr Asn
 1          5          10          15
Lys His Ile Asn Ile Ser Phe His Arg Phe Pro Leu Asp Pro Lys
          20          25          30
Arg Arg Lys Glu Trp Val Arg Leu Val Arg Arg Lys Asn Phe Val
          35          40          45
Pro Gly Lys His Thr Phe Leu Cys Ser Lys His Phe Glu Ala Ser
          50          55          60
Cys Phe Asp Leu Thr Gly Gln Thr Arg Arg Leu Lys Met Asp Ala
          65          70          75
Val Pro Thr Ile Phe Asp Phe Cys Thr His Ile Lys Ser Met Lys
          80          85          90
Leu Lys Ser Arg Asn Leu Leu Lys Lys Asn Asn Ser Cys Ser Pro
          95          100          105
Ala Gly Pro Ser Asn Leu Lys Ser Asn Ile Ser Ser Gln Gln Val
          110          115          120
Leu Leu Glu His Ser Tyr Ala Phe Arg Asn Pro Met Glu Ala Lys
          125          130          135
Lys Arg Ile Ile Lys Leu Glu Lys Glu Ile Ala Ser Leu Arg Arg
          140          145          150
Lys Met Lys Thr Cys Leu Gln Lys Glu Arg Arg Ala Thr Arg Arg
          155          160          165
Trp Ile Lys Ala Thr Cys Leu Val Lys Asn Leu Glu Ala Asn Ser
          170          175          180
Val Leu Pro Lys Gly Thr Ser Glu His Met Leu Pro Thr Ala Leu
          185          190          195
Ser Ser Leu Pro Leu Glu Asp Phe Lys Ile Leu Glu Gln Asp Gln
          200          205          210
Gln Asp Lys Thr Leu Leu Ser Leu Asn Leu Lys Gln Thr Lys Ser
          215          220          225
Thr Phe Ile

```

<210> 18

<211> 503

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 1384286

<400> 18

```

Met Ala Thr Thr Val Thr Cys Thr Arg Phe Thr Asp Glu Tyr Gln
 1          5          10          15
Leu Tyr Glu Asp Ile Gly Lys Gly Ala Phe Ser Val Val Arg Arg
          20          25          30
Cys Val Lys Leu Cys Thr Gly His Glu Tyr Ala Ala Lys Ile Ile
          35          40          45
Asn Thr Lys Lys Leu Ser Ala Arg Asp His Gln Lys Leu Glu Arg

```

| | | | | | |
|-----------------|---------------------|-------------------------|-----|--|-----|
| | 50 | | 55 | | 60 |
| Glu Ala Arg Ile | Cys Arg Leu Leu Lys | His Ser Asn Ile Val Arg | | | |
| | 65 | | 70 | | 75 |
| Leu His Asp Ser | Ile Ser Glu Glu Gly | Phe His Tyr Leu Val Phe | | | |
| | 80 | | 85 | | 90 |
| Asp Leu Val Thr | Gly Gly Glu Leu Phe | Glu Asp Ile Val Ala Arg | | | |
| | 95 | | 100 | | 105 |
| Glu Tyr Tyr Ser | Glu Ala Asp Ala Ser | His Cys Ile Gln Gln Ile | | | |
| | 110 | | 115 | | 120 |
| Leu Glu Ala Val | Leu His Cys His Gln | Met Gly Val Val His Arg | | | |
| | 125 | | 130 | | 135 |
| Asp Leu Lys Pro | Glu Asn Leu Leu Leu | Ala Ser Lys Cys Lys Gly | | | |
| | 140 | | 145 | | 150 |
| Ala Ala Val Lys | Leu Ala Asp Phe Gly | Leu Ala Ile Glu Val Gln | | | |
| | 155 | | 160 | | 165 |
| Gly Asp Gln Gln | Ala Trp Phe Gly Phe | Ala Gly Thr Pro Gly Tyr | | | |
| | 170 | | 175 | | 180 |
| Leu Ser Pro Glu | Val Leu Arg Lys Glu | Ala Tyr Gly Lys Pro Val | | | |
| | 185 | | 190 | | 195 |
| Asp Ile Trp Ala | Cys Gly Val Ile Leu | Tyr Ile Leu Leu Val Gly | | | |
| | 200 | | 205 | | 210 |
| Tyr Pro Pro Phe | Trp Asp Glu Asp Gln | His Lys Leu Tyr Gln Gln | | | |
| | 215 | | 220 | | 225 |
| Ile Lys Ala Gly | Ala Tyr Asp Phe Pro | Ser Pro Glu Trp Asp Thr | | | |
| | 230 | | 235 | | 240 |
| Val Thr Pro Glu | Ala Lys Asn Leu Ile | Asn Gln Met Leu Thr Ile | | | |
| | 245 | | 250 | | 255 |
| Asn Pro Ala Lys | Arg Ile Thr Ala His | Glu Ala Leu Lys His Pro | | | |
| | 260 | | 265 | | 270 |
| Trp Val Cys Gln | Arg Ser Thr Val Ala | Ser Met Met His Arg Gln | | | |
| | 275 | | 280 | | 285 |
| Glu Thr Val Glu | Cys Leu Lys Lys Phe | Asn Ala Arg Arg Lys Leu | | | |
| | 290 | | 295 | | 300 |
| Lys Gly Ala Ile | Leu Thr Thr Met Leu | Ala Thr Arg Asn Phe Ser | | | |
| | 305 | | 310 | | 315 |
| Ala Ala Lys Ser | Leu Leu Asn Lys Lys | Ala Asp Gly Val Lys Pro | | | |
| | 320 | | 325 | | 330 |
| His Thr Asn Ser | Thr Lys Asn Ser Ala | Ala Ala Thr Ser Pro Lys | | | |
| | 335 | | 340 | | 345 |
| Gly Thr Leu Pro | Pro Ala Ala Leu Glu | Ser Ser Asp Ser Ala Asn | | | |
| | 350 | | 355 | | 360 |
| Thr Thr Ile Glu | Asp Glu Asp Ala Lys | Ala Arg Lys Gln Glu Ile | | | |
| | 365 | | 370 | | 375 |
| Ile Lys Thr Thr | Glu Gln Leu Ile Glu | Ala Val Asn Asn Gly Asp | | | |
| | 380 | | 385 | | 390 |
| Phe Glu Ala Tyr | Ala Lys Ile Cys Asp | Pro Gly Leu Thr Ser Phe | | | |
| | 395 | | 400 | | 405 |
| Glu Pro Glu Ala | Leu Gly Asn Leu Val | Glu Gly Met Asp Phe His | | | |
| | 410 | | 415 | | 420 |
| Arg Phe Tyr Phe | Glu Asn Leu Leu Ala | Lys Asn Ser Lys Pro Ile | | | |
| | 425 | | 430 | | 435 |
| His Thr Thr Ile | Leu Asn Pro His Val | His Val Ile Gly Glu Asp | | | |
| | 440 | | 445 | | 450 |
| Ala Ala Cys Ile | Ala Tyr Ile Arg Leu | Thr Gln Tyr Ile Asp Gly | | | |
| | 455 | | 460 | | 465 |
| Gln Gly Arg Pro | Arg Thr Ser Gln Ser | Glu Glu Thr Arg Val Trp | | | |

| | | | |
|---|-----|-----|-----|
| | 470 | 475 | 480 |
| His Arg Arg Asp Gly Lys Trp Gln Asn Val His Phe His Cys Ser | | | |
| | 485 | 490 | 495 |
| Gly Ala Pro Val Ala Pro Leu Gln | | | |
| | 500 | | |

<210> 19

<211> 433

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 1512656

<400> 19

| | | |
|---|-----|-----|
| Met Thr Gly Glu Ala Gln Ala Gly Arg Lys Arg Ser Arg Ala Arg | | |
| 1 | 5 | 10 |
| Pro Glu Gly Thr Glu Pro Val Arg Arg Glu Arg Thr Gln Pro Gly | | |
| | 20 | 25 |
| Leu Gly Pro Gly Arg Ala Arg Ala Met Ala Ala Glu Ala Thr Ala | | |
| | 35 | 40 |
| Val Ala Gly Ser Gly Ala Val Gly Gly Cys Leu Ala Lys Asp Gly | | |
| | 50 | 55 |
| Leu Gln Gln Ser Lys Cys Pro Asp Thr Thr Pro Lys Arg Arg Arg | | |
| | 65 | 70 |
| Ala Ser Ser Leu Ser Arg Asp Ala Glu Arg Arg Ala Tyr Gln Trp | | |
| | 80 | 85 |
| Cys Arg Glu Tyr Leu Gly Gly Ala Trp Arg Arg Val Gln Pro Glu | | |
| | 95 | 100 |
| Glu Leu Arg Val Tyr Pro Val Ser Gly Gly Leu Ser Asn Leu Leu | | |
| | 110 | 115 |
| Phe Arg Cys Ser Leu Pro Asp His Leu Pro Ser Val Gly Glu Glu | | |
| | 125 | 130 |
| Pro Arg Glu Val Leu Leu Arg Leu Tyr Gly Ala Ile Leu Gln Gly | | |
| | 140 | 145 |
| Val Asp Ser Leu Val Leu Glu Ser Val Met Phe Ala Ile Leu Ala | | |
| | 155 | 160 |
| Glu Arg Ser Leu Gly Pro Gln Leu Tyr Gly Val Phe Pro Glu Gly | | |
| | 170 | 175 |
| Arg Leu Glu Gln Tyr Ile Pro Ser Arg Pro Leu Lys Thr Gln Glu | | |
| | 185 | 190 |
| Leu Arg Glu Pro Val Leu Ser Ala Ala Ile Ala Thr Lys Met Ala | | |
| | 200 | 205 |
| Gln Phe His Gly Met Glu Met Pro Phe Thr Lys Glu Pro His Trp | | |
| | 215 | 220 |
| Leu Phe Gly Thr Met Glu Arg Tyr Leu Lys Gln Ile Gln Asp Leu | | |
| | 230 | 235 |
| Pro Pro Thr Gly Leu Pro Glu Met Asn Leu Leu Glu Met Tyr Ser | | |
| | 245 | 250 |
| Leu Lys Asp Glu Met Gly Asn Leu Arg Lys Leu Leu Glu Ser Thr | | |
| | 260 | 265 |
| Pro Ser Pro Val Val Phe Cys His Asn Asp Ile Gln Glu Gly Asn | | |

| | | | | | |
|---|-----|--|-----|--|-----|
| | 275 | | 280 | | 285 |
| Ile Leu Leu Leu Ser Glu Pro Glu Asn Ala Asp Ser Leu Met Leu | | | | | |
| | 290 | | 295 | | 300 |
| Val Asp Phe Glu Tyr Ser Ser Tyr Asn Tyr Arg Gly Phe Asp Ile | | | | | |
| | 305 | | 310 | | 315 |
| Gly Asn His Phe Cys Glu Trp Val Tyr Asp Tyr Thr His Glu Glu | | | | | |
| | 320 | | 325 | | 330 |
| Trp Pro Phe Tyr Lys Ala Arg Pro Thr Asp Tyr Pro Thr Gln Glu | | | | | |
| | 335 | | 340 | | 345 |
| Gln Gln Leu His Phe Ile Arg His Tyr Leu Ala Glu Ala Lys Lys | | | | | |
| | 350 | | 355 | | 360 |
| Gly Glu Thr Leu Ser Gln Glu Glu Gln Arg Lys Leu Glu Glu Asp | | | | | |
| | 365 | | 370 | | 375 |
| Leu Leu Val Glu Val Ser Arg Tyr Ala Leu Ala Ser His Phe Phe | | | | | |
| | 380 | | 385 | | 390 |
| Trp Gly Leu Trp Ser Ile Leu Gln Ala Ser Met Ser Thr Ile Glu | | | | | |
| | 395 | | 400 | | 405 |
| Phe Gly Tyr Leu Asp Tyr Ala Gln Ser Arg Phe Gln Phe Tyr Phe | | | | | |
| | 410 | | 415 | | 420 |
| Gln Gln Lys Gly Gln Leu Thr Ser Val His Ser Ser Ser | | | | | |
| | 425 | | 430 | | |

<210> 20

<211> 527

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2098635

<400> 20

| | | | |
|---|-----|-----|-----|
| Met Ser Leu Cys Gly Ala Arg Ala Asn Ala Lys Met Met Ala Ala | | | |
| 1 | 5 | 10 | 15 |
| Tyr Asn Gly Gly Thr Ser Ala Ala Ala Ala Gly His His His His | | | |
| | 20 | 25 | 30 |
| His His His His Leu Pro His Leu Pro Pro Pro His Leu Leu His | | | |
| | 35 | 40 | 45 |
| His His His Pro Gln His His Leu His Pro Gly Ser Ala Ala Ala | | | |
| | 50 | 55 | 60 |
| Val His Pro Val Gln Gln His Thr Ser Ser Ala Ala Ala Ala Ala | | | |
| | 65 | 70 | 75 |
| Ala Ala Ala Ala Ala Ala Ala Ala Met Leu Asn Pro Gly Gln Gln | | | |
| | 80 | 85 | 90 |
| Gln Pro Tyr Phe Pro Ser Pro Ala Pro Gly Gln Ala Pro Gly Pro | | | |
| | 95 | 100 | 105 |
| Ala Ala Ala Ala Pro Ala Gln Val Gln Ala Ala Ala Ala Ala Thr | | | |
| | 110 | 115 | 120 |
| Val Lys Ala His His His Gln His Ser His His Pro Gln Gln Gln | | | |
| | 125 | 130 | 135 |
| Leu Asp Ile Glu Pro Asp Arg Pro Ile Gly Tyr Gly Ala Phe Gly | | | |
| | 140 | 145 | 150 |
| Val Val Trp Ser Val Thr Asp Pro Arg Asp Gly Lys Arg Val Ala | | | |
| | 155 | 160 | 165 |
| Leu Lys Lys Met Pro Asn Val Phe Gln Asn Leu Val Ser Cys Lys | | | |

| | | | | | |
|-----------------|---------------------|---------------------|-----|--|-----|
| | 170 | | 175 | | 180 |
| Arg Val Phe Arg | Glu Leu Lys Met Leu | Cys Phe Phe Lys His | Asp | | |
| | 185 | | 190 | | 195 |
| Asn Val Leu Ser | Ala Leu Asp Ile Leu | Gln Pro Pro His Ile | Asp | | |
| | 200 | | 205 | | 210 |
| Tyr Phe Glu Glu | Ile Tyr Val Val Thr | Glu Leu Met Gln Ser | Asp | | |
| | 215 | | 220 | | 225 |
| Leu His Lys Ile | Ile Val Ser Pro Gln | Pro Leu Ser Ser Asp | His | | |
| | 230 | | 235 | | 240 |
| Val Lys Val Phe | Leu Tyr Gln Ile Leu | Arg Gly Leu Lys Tyr | Leu | | |
| | 245 | | 250 | | 255 |
| His Ser Ala Gly | Ile Leu His Arg Asp | Ile Lys Pro Gly Asn | Leu | | |
| | 260 | | 265 | | 270 |
| Leu Val Asn Ser | Asn Cys Val Leu Lys | Ile Cys Asp Phe Gly | Leu | | |
| | 275 | | 280 | | 285 |
| Ala Arg Val Glu | Glu Leu Asp Glu Ser | Arg His Met Thr Gln | Glu | | |
| | 290 | | 295 | | 300 |
| Val Val Thr Gln | Tyr Tyr Arg Ala Pro | Glu Ile Leu Met Gly | Ser | | |
| | 305 | | 310 | | 315 |
| Arg His Tyr Ser | Asn Ala Ile Asp Ile | Trp Ser Val Gly Cys | Ile | | |
| | 320 | | 325 | | 330 |
| Phe Ala Glu Leu | Leu Gly Arg Arg Ile | Leu Phe Gln Ala Gln | Ser | | |
| | 335 | | 340 | | 345 |
| Pro Ile Gln Gln | Leu Asp Leu Ile Thr | Asp Leu Leu Gly Thr | Pro | | |
| | 350 | | 355 | | 360 |
| Ser Leu Glu Ala | Met Arg Thr Ala Cys | Glu Gly Ala Lys Ala | His | | |
| | 365 | | 370 | | 375 |
| Ile Leu Arg Gly | Pro His Lys Gln Pro | Ser Leu Pro Val Leu | Tyr | | |
| | 380 | | 385 | | 390 |
| Thr Leu Ser Ser | Gln Ala Thr His Glu | Ala Val His Leu Leu | Cys | | |
| | 395 | | 400 | | 405 |
| Arg Met Leu Val | Phe Asp Pro Ser Lys | Arg Ile Ser Ala Lys | Asp | | |
| | 410 | | 415 | | 420 |
| Ala Leu Ala His | Pro Tyr Leu Asp Glu | Gly Arg Leu Arg Tyr | His | | |
| | 425 | | 430 | | 435 |
| Thr Cys Met Cys | Lys Cys Cys Phe Ser | Thr Ser Thr Gly Arg | Val | | |
| | 440 | | 445 | | 450 |
| Tyr Thr Ser Asp | Phe Glu Pro Val Thr | Asn Pro Lys Phe Asp | Asp | | |
| | 455 | | 460 | | 465 |
| Thr Phe Glu Lys | Asn Leu Ser Ser Val | Arg Gln Val Lys Glu | Ile | | |
| | 470 | | 475 | | 480 |
| Ile His Gln Phe | Ile Leu Glu Gln Gln | Lys Gly Asn Arg Val | Pro | | |
| | 485 | | 490 | | 495 |
| Leu Cys Ile Asn | Pro Gln Ser Ala Ala | Phe Lys Ser Phe Ile | Ser | | |
| | 500 | | 505 | | 510 |
| Ser Thr Val Ala | Gln Pro Ser Glu Met | Pro Pro Ser Pro Leu | Val | | |
| | 515 | | 520 | | 525 |
| Trp Glu | | | | | |

<210> 21

<211> 322

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2446646

<400> 21

```

Met Glu Gly Ile Ser Asn Phe Lys Thr Pro Ser Lys Leu Ser Glu
  1          5          10          15
Lys Lys Lys Ser Val Leu Cys Ser Thr Pro Thr Ile Asn Ile Pro
          20          25          30
Ala Ser Pro Phe Met Gln Lys Leu Gly Phe Gly Thr Gly Val Asn
          35          40          45
Val Tyr Leu Met Lys Arg Ser Pro Arg Gly Leu Ser His Ser Pro
          50          55          60
Trp Ala Val Lys Lys Ile Asn Pro Ile Cys Asn Asp His Tyr Arg
          65          70          75
Ser Val Tyr Gln Lys Arg Leu Met Asp Glu Ala Lys Ile Leu Lys
          80          85          90
Ser Leu His His Pro Asn Ile Val Gly Tyr Arg Ala Phe Thr Glu
          95          100          105
Ala Asn Asp Gly Ser Leu Cys Leu Ala Met Glu Tyr Gly Gly Glu
          110          115          120
Lys Ser Leu Asn Asp Leu Ile Glu Glu Arg Tyr Lys Ala Ser Gln
          125          130          135
Asp Pro Phe Pro Ala Ala Ile Ile Leu Lys Val Ala Leu Asn Met
          140          145          150
Ala Arg Gly Leu Lys Tyr Leu His Gln Glu Lys Lys Leu Leu His
          155          160          165
Gly Asp Ile Lys Ser Ser Asn Val Val Ile Lys Gly Asp Phe Glu
          170          175          180
Thr Ile Lys Ile Cys Asp Val Gly Val Ser Leu Pro Leu Asp Glu
          185          190          195
Asn Met Thr Val Thr Asp Pro Glu Ala Cys Tyr Ile Gly Thr Glu
          200          205          210
Pro Trp Lys Pro Lys Glu Ala Val Glu Glu Asn Gly Val Ile Thr
          215          220          225
Asp Lys Ala Asp Ile Phe Ala Phe Gly Leu Thr Leu Trp Glu Met
          230          235          240
Met Thr Leu Ser Ile Pro His Ile Asn Leu Ser Asn Asp Asp Asp
          245          250          255
Asp Glu Asp Lys Thr Phe Asp Glu Ser Asp Phe Asp Asp Glu Ala
          260          265          270
Tyr Tyr Ala Ala Leu Gly Thr Arg Pro Pro Ile Asn Met Glu Glu
          275          280          285
Leu Asp Glu Ser Tyr Gln Lys Val Ile Glu Leu Phe Ser Val Cys
          290          295          300
Thr Asn Glu Asp Pro Lys Asp Arg Pro Ser Ala Ala His Ile Val
          305          310          315
Glu Ala Leu Glu Thr Asp Val
          320

```

<210> 22

<211> 802

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2764911

<400> 22

```

Met Glu Glu Glu Gly Gly Ser Ser Gly Gly Ala Ala Gly Thr Ser
 1          5          10          15
Ala Asp Gly Gly Asp Gly Gly Glu Gln Leu Leu Thr Val Lys His
          20          25          30
Glu Leu Arg Thr Ala Asn Leu Thr Gly His Ala Glu Lys Val Gly
          35          40          45
Ile Glu Asn Phe Glu Leu Leu Lys Val Leu Gly Thr Gly Ala Tyr
          50          55          60
Gly Lys Val Phe Leu Val Arg Lys Ile Ser Gly His Asp Thr Gly
          65          70          75
Lys Leu Tyr Ala Met Lys Val Leu Lys Lys Ala Thr Ile Val Gln
          80          85          90
Lys Ala Lys Thr Thr Glu His Thr Arg Thr Glu Arg Gln Val Leu
          95          100          105
Glu His Ile Arg Gln Ser Pro Phe Leu Val Thr Leu His Tyr Ala
          110          115          120
Phe Gln Thr Glu Thr Lys Leu His Leu Ile Leu Asp Tyr Ile Asn
          125          130          135
Gly Gly Glu Leu Phe Thr His Leu Ser Gln Arg Glu Arg Phe Thr
          140          145          150
Glu His Glu Val Gln Ile Tyr Val Gly Glu Ile Val Leu Ala Leu
          155          160          165
Glu His Leu His Lys Leu Gly Ile Ile Tyr Arg Asp Ile Lys Leu
          170          175          180
Glu Asn Ile Leu Leu Asp Ser Asn Gly His Val Val Leu Thr Asp
          185          190          195
Phe Gly Leu Ser Lys Glu Phe Val Ala Asp Glu Thr Glu Arg Ala
          200          205          210
Tyr Ser Phe Cys Gly Thr Ile Glu Tyr Met Ala Pro Asp Ile Val
          215          220          225
Arg Gly Gly Asp Ser Gly His Asp Lys Ala Val Asp Trp Trp Ser
          230          235          240
Leu Gly Val Leu Met Tyr Glu Leu Leu Thr Gly Ala Ser Pro Phe
          245          250          255
Thr Val Asp Gly Glu Lys Asn Ser Gln Ala Glu Ile Ser Arg Arg
          260          265          270
Ile Leu Lys Ser Glu Pro Pro Tyr Pro Gln Glu Met Ser Ala Leu
          275          280          285
Ala Lys Asp Leu Ile Gln Arg Leu Leu Met Lys Asp Pro Lys Lys
          290          295          300
Arg Leu Gly Cys Gly Pro Arg Asp Ala Asp Glu Ile Lys Glu His
          305          310          315
Leu Phe Phe Gln Lys Ile Asn Trp Asp Asp Leu Ala Ala Lys Lys
          320          325          330
Val Pro Ala Pro Phe Lys Pro Val Ile Arg Asp Glu Leu Asp Val
          335          340          345
Ser Asn Phe Ala Glu Glu Phe Thr Glu Met Asp Pro Thr Tyr Ser
          350          355          360
Pro Ala Ala Leu Pro Gln Ser Ser Glu Lys Leu Phe Gln Gly Tyr
          365          370          375
Ser Phe Val Ala Pro Ser Ile Leu Phe Lys Arg Asn Ala Ala Val
          380          385          390
Ile Asp Pro Leu Gln Phe His Met Gly Val Glu Arg Pro Gly Val

```

| | | | | | |
|-------------------------------------|-----|-------------------------|-----|--|-----|
| | 395 | | 400 | | 405 |
| Thr Asn Val Ala Arg Ser Ala Met Met | | Lys Asp Ser Pro Phe Tyr | | | |
| | 410 | | 415 | | 420 |
| Gln His Tyr Asp Leu Asp Leu Lys Asp | | Lys Pro Leu Gly Glu Gly | | | |
| | 425 | | 430 | | 435 |
| Ser Phe Ser Ile Cys Arg Lys Cys Val | | His Lys Lys Ser Asn Gln | | | |
| | 440 | | 445 | | 450 |
| Ala Phe Ala Val Lys Ile Ile Ser Lys | | Arg Met Glu Ala Asn Thr | | | |
| | 455 | | 460 | | 465 |
| Gln Lys Glu Ile Thr Ala Leu Glu Leu | | Cys Glu Gly His Pro Asn | | | |
| | 470 | | 475 | | 480 |
| Ile Val Lys Leu His Glu Val Phe His | | Asp Gln Leu His Thr Phe | | | |
| | 485 | | 490 | | 495 |
| Leu Val Met Glu Leu Leu Asn Gly Gly | | Glu Leu Phe Glu Arg Ile | | | |
| | 500 | | 505 | | 510 |
| Lys Lys Lys Lys His Phe Ser Glu Thr | | Glu Ala Ser Tyr Ile Met | | | |
| | 515 | | 520 | | 525 |
| Arg Lys Leu Val Ser Ala Val Ser His | | Met His Asp Val Gly Val | | | |
| | 530 | | 535 | | 540 |
| Val His Arg Asp Leu Lys Pro Glu Asn | | Leu Leu Phe Thr Asp Glu | | | |
| | 545 | | 550 | | 555 |
| Asn Asp Asn Leu Glu Ile Lys Ile Ile | | Asp Phe Gly Phe Ala Arg | | | |
| | 560 | | 565 | | 570 |
| Leu Lys Pro Pro Asp Asn Gln Pro Leu | | Lys Thr Pro Cys Phe Thr | | | |
| | 575 | | 580 | | 585 |
| Leu His Tyr Ala Ala Pro Glu Leu Leu | | Asn Gln Asn Gly Tyr Asp | | | |
| | 590 | | 595 | | 600 |
| Glu Ser Cys Asp Leu Trp Ser Leu Gly | | Val Ile Leu Tyr Thr Met | | | |
| | 605 | | 610 | | 615 |
| Leu Ser Gly Gln Val Pro Phe Gln Ser | | His Asp Arg Ser Leu Thr | | | |
| | 620 | | 625 | | 630 |
| Cys Thr Ser Ala Val Glu Ile Met Lys | | Lys Ile Lys Lys Gly Asp | | | |
| | 635 | | 640 | | 645 |
| Phe Ser Phe Glu Gly Glu Ala Trp Lys | | Asn Val Ser Gln Glu Ala | | | |
| | 650 | | 655 | | 660 |
| Lys Asp Leu Ile Gln Gly Leu Leu Thr | | Val Asp Pro Asn Lys Arg | | | |
| | 665 | | 670 | | 675 |
| Leu Lys Met Ser Gly Leu Arg Tyr Asn | | Glu Trp Leu Gln Asp Gly | | | |
| | 680 | | 685 | | 690 |
| Ser Gln Leu Ser Ser Asn Pro Leu Met | | Thr Pro Asp Ile Leu Gly | | | |
| | 695 | | 700 | | 705 |
| Ser Ser Gly Ala Ala Val His Thr Cys | | Val Lys Ala Thr Phe His | | | |
| | 710 | | 715 | | 720 |
| Ala Phe Asn Lys Tyr Lys Arg Glu Gly | | Phe Cys Leu Gln Asn Val | | | |
| | 725 | | 730 | | 735 |
| Asp Lys Ala Pro Leu Ala Lys Arg Arg | | Lys Met Lys Lys Thr Ser | | | |
| | 740 | | 745 | | 750 |
| Thr Ser Thr Glu Thr Arg Ser Ser Ser | | Ser Glu Ser Ser His Ser | | | |
| | 755 | | 760 | | 765 |
| Ser Ser Ser His Ser His Gly Lys Thr | | Thr Pro Thr Lys Thr Leu | | | |
| | 770 | | 775 | | 780 |
| Gln Pro Ser Asn Pro Ala Asp Ser Asn | | Asn Pro Glu Thr Leu Phe | | | |
| | 785 | | 790 | | 795 |
| Gln Phe Ser Asp Ser Val Ala | | | | | |
| | 800 | | | | |

<210> 23
 <211> 641
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone Number: 3013946

<400> 23
 Met Ala Thr Thr Val Thr Cys Thr Arg Phe Thr Asp Glu Tyr Gln
 1 5 10 15
 Leu Tyr Glu Asp Ile Gly Lys Gly Ala Phe Ser Val Val Arg Arg
 20 25 30
 Cys Val Lys Leu Cys Thr Gly His Glu Tyr Ala Ala Lys Ile Ile
 35 40 45
 Asn Thr Lys Lys Leu Ser Ala Arg Asp His Gln Lys Leu Glu Arg
 50 55 60
 Glu Ala Arg Ile Cys Arg Leu Leu Lys His Ser Asn Ile Val Arg
 65 70 75
 Leu His Asp Ser Ile Ser Glu Glu Gly Phe His Tyr Leu Val Phe
 80 85 90
 Asp Leu Val Thr Gly Gly Glu Leu Phe Glu Asp Ile Val Ala Arg
 95 100 105
 Glu Tyr Tyr Ser Glu Ala Asp Ala Ser His Cys Ile Gln Gln Ile
 110 115 120
 Leu Glu Ala Val Leu His Cys His Gln Met Gly Val Val His Arg
 125 130 135
 Asp Leu Lys Pro Glu Asn Leu Leu Leu Ala Ser Lys Cys Lys Gly
 140 145 150
 Ala Ala Val Lys Leu Ala Asp Phe Gly Leu Ala Ile Glu Val Gln
 155 160 165
 Gly Asp Gln Gln Ala Trp Phe Gly Phe Ala Gly Thr Pro Gly Tyr
 170 175 180
 Leu Ser Pro Glu Val Leu Arg Lys Glu Ala Tyr Gly Lys Pro Val
 185 190 195
 Asp Ile Trp Ala Cys Gly Val Ile Leu Tyr Ile Leu Leu Val Gly
 200 205 210
 Tyr Pro Pro Phe Trp Asp Glu Asp Gln His Lys Leu Tyr Gln Gln
 215 220 225
 Ile Lys Ala Gly Ala Tyr Asp Phe Pro Ser Pro Glu Trp Asp Thr
 230 235 240
 Val Thr Pro Glu Ala Lys Asn Leu Ile Asn Gln Met Leu Thr Ile
 245 250 255
 Asn Pro Ala Lys Arg Ile Thr Ala His Glu Ala Leu Lys His Pro
 260 265 270
 Trp Val Cys Gln Arg Ser Thr Val Ala Ser Met Met His Arg Gln
 275 280 285
 Glu Thr Val Glu Cys Leu Lys Lys Phe Asn Ala Arg Arg Lys Leu
 290 295 300
 Lys Gly Ala Ile Leu Thr Thr Met Leu Ala Thr Arg Asn Phe Ser
 305 310 315
 Ala Lys Ser Leu Leu Asn Lys Lys Ala Asp Gly Val Lys Pro Gln
 320 325 330
 Thr Asn Ser Thr Lys Asn Ser Ala Ala Ala Thr Ser Pro Lys Gly
 335 340 345

```

Thr Leu Pro Pro Ala Ala Leu Glu Pro Gln Thr Thr Val Ile His
350 355 360
Asn Pro Val Asp Gly Ile Lys Glu Ser Ser Asp Ser Ala Asn Thr
365 370 375
Thr Ile Glu Asp Glu Asp Ala Lys Ala Pro Arg Val Pro Asp Ile
380 385 390
Leu Ser Ser Val Arg Arg Gly Ser Gly Ala Pro Glu Ala Glu Gly
395 400 405
Pro Leu Pro Cys Pro Ser Pro Ala Pro Phe Gly Pro Leu Pro Ala
410 415 420
Pro Ser Pro Arg Ile Ser Asp Ile Leu Asn Ser Val Arg Arg Gly
425 430 435
Ser Gly Thr Pro Glu Ala Glu Gly Pro Leu Ser Ala Gly Pro Pro
440 445 450
Pro Cys Leu Ser Pro Ala Leu Leu Gly Pro Leu Ser Ser Pro Ser
455 460 465
Pro Arg Ile Ser Asp Ile Leu Asn Ser Val Arg Arg Gly Ser Gly
470 475 480
Thr Pro Glu Ala Lys Gly Pro Ser Pro Val Gly Pro Pro Pro Cys
485 490 495
Pro Ser Pro Thr Ile Pro Gly Pro Leu Pro Thr Pro Ser Arg Lys
500 505 510
Gln Glu Ile Ile Lys Thr Thr Glu Gln Leu Ile Glu Ala Val Asn
515 520 525
Asn Gly Asp Phe Glu Ala Tyr Ala Lys Ile Cys Asp Pro Gly Leu
530 535 540
Thr Ser Phe Glu Pro Glu Ala Leu Gly Asn Leu Val Glu Gly Met
545 550 555
Asp Phe His Arg Phe Tyr Phe Glu Asn Leu Leu Ala Lys Asn Ser
560 565 570
Lys Pro Ile His Thr Thr Ile Leu Asn Pro His Val His Val Ile
575 580 585
Gly Glu Asp Ala Ala Cys Ile Ala Tyr Ile Arg Leu Thr Gln Tyr
590 595 600
Ile Asp Gly Gln Gly Arg Pro Arg Thr Ser Gln Ser Glu Glu Thr
605 610 615
Arg Val Trp His Arg Arg Asp Gly Lys Trp Gln Asn Val His Phe
620 625 630
His Cys Ser Gly Ala Pro Val Ala Pro Leu Gln
635 640

```

<210> 24

<211> 588

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 067967

<400> 24

```

Met Gly Gly Thr Ala Arg Gly Pro Gly Arg Lys Asp Ala Gly Pro
1 5 10 15
Pro Gly Ala Gly Leu Pro Pro Gln Gln Arg Arg Leu Gly Asp Gly
20 25 30
Val Tyr Asp Thr Phe Met Met Ile Asp Glu Thr Lys Cys Pro Pro

```

| | | | | | |
|-----------------|---------------------|---------------------|-----|--|-----|
| | 35 | | 40 | | 45 |
| Cys Ser Asn Val | Leu Cys Asn Pro Ser | Glu Pro Pro Ser Pro | Arg | | |
| | 50 | | 55 | | 60 |
| Arg Leu Asn Met | Thr Thr Glu Gln Phe | Thr Gly Asp His Thr | Gln | | |
| | 65 | | 70 | | 75 |
| His Phe Leu Asp | Gly Gly Glu Met Lys | Val Glu Gln Leu Phe | Gln | | |
| | 80 | | 85 | | 90 |
| Glu Phe Gly Asn | Arg Lys Ser Asn Thr | Ile Gln Ser Asp Gly | Ile | | |
| | 95 | | 100 | | 105 |
| Ser Asp Ser Glu | Lys Cys Ser Pro Thr | Val Ser Gln Gly Lys | Ser | | |
| | 110 | | 115 | | 120 |
| Ser Asp Cys Leu | Asn Thr Val Lys Ser | Asn Ser Ser Ser Lys | Ala | | |
| | 125 | | 130 | | 135 |
| Pro Lys Val Val | Pro Leu Thr Pro Glu | Gln Ala Leu Lys Gln | Tyr | | |
| | 140 | | 145 | | 150 |
| Lys His His Leu | Thr Ala Tyr Glu Lys | Leu Glu Ile Ile Asn | Tyr | | |
| | 155 | | 160 | | 165 |
| Pro Glu Ile Tyr | Phe Val Gly Pro Asn | Ala Lys Lys Arg His | Gly | | |
| | 170 | | 175 | | 180 |
| Val Ile Gly Gly | Pro Asn Asn Gly Gly | Tyr Asp Asp Ala Asp | Gly | | |
| | 185 | | 190 | | 195 |
| Ala Tyr Ile His | Val Pro Arg Asp His | Leu Ala Tyr Arg Tyr | Glu | | |
| | 200 | | 205 | | 210 |
| Val Leu Lys Ile | Ile Gly Lys Gly Ser | Phe Gly Gln Val Ala | Arg | | |
| | 215 | | 220 | | 225 |
| Val Tyr Asp His | Lys Leu Arg Gln Tyr | Val Ala Leu Lys Met | Val | | |
| | 230 | | 235 | | 240 |
| Arg Asn Glu Lys | Arg Phe His Arg Gln | Ala Ala Glu Glu Ile | Arg | | |
| | 245 | | 250 | | 255 |
| Ile Leu Glu His | Leu Lys Lys Gln Asp | Lys Thr Gly Ser Met | Asn | | |
| | 260 | | 265 | | 270 |
| Val Ile His Met | Leu Glu Ser Phe Thr | Phe Arg Asn His Val | Cys | | |
| | 275 | | 280 | | 285 |
| Met Ala Phe Glu | Leu Leu Ser Ile Asp | Leu Tyr Glu Leu Ile | Lys | | |
| | 290 | | 295 | | 300 |
| Lys Asn Lys Phe | Gln Gly Phe Ser Val | Gln Leu Val Arg Lys | Phe | | |
| | 305 | | 310 | | 315 |
| Ala Gln Ser Ile | Leu Gln Ser Leu Asp | Ala Leu His Lys Asn | Lys | | |
| | 320 | | 325 | | 330 |
| Ile Ile His Cys | Asp Leu Lys Pro Glu | Asn Ile Leu Leu Lys | His | | |
| | 335 | | 340 | | 345 |
| His Gly Arg Ser | Ser Thr Lys Val Ile | Asp Phe Gly Ser Ser | Cys | | |
| | 350 | | 355 | | 360 |
| Phe Glu Tyr Gln | Lys Leu Tyr Thr Tyr | Ile Gln Ser Arg Phe | Tyr | | |
| | 365 | | 370 | | 375 |
| Arg Ala Pro Glu | Ile Ile Leu Gly Ser | Arg Tyr Ser Thr Pro | Ile | | |
| | 380 | | 385 | | 390 |
| Asp Ile Trp Ser | Phe Gly Cys Ile Leu | Ala Glu Leu Leu Thr | Gly | | |
| | 395 | | 400 | | 405 |
| Gln Pro Leu Phe | Pro Gly Glu Asp Glu | Gly Asp Gln Leu Ala | Cys | | |
| | 410 | | 415 | | 420 |
| Met Met Glu Leu | Leu Gly Met Pro Pro | Pro Lys Leu Leu Glu | Gln | | |
| | 425 | | 430 | | 435 |
| Ser Lys Arg Ala | Lys Tyr Phe Ile Asn | Ser Lys Gly Ile Pro | Arg | | |
| | 440 | | 445 | | 450 |
| Tyr Cys Ser Val | Thr Thr Gln Ala Asp | Gly Arg Val Val Leu | Val | | |

| | | | | | |
|-----------------|---|--|-----|--|-----|
| | 455 | | 460 | | 465 |
| Gly Gly Arg Ser | Arg Arg Gly Lys Lys Arg Gly Pro Pro Gly Ser | | | | |
| | 470 | | 475 | | 480 |
| Lys Asp Trp Gly | Thr Ala Leu Lys Gly Cys Asp Asp Tyr Leu Phe | | | | |
| | 485 | | 490 | | 495 |
| Ile Glu Phe Leu | Lys Arg Cys Leu His Trp Asp Pro Ser Ala Arg | | | | |
| | 500 | | 505 | | 510 |
| Leu Thr Pro Ala | Gln Ala Leu Arg His Pro Trp Ile Ser Lys Ser | | | | |
| | 515 | | 520 | | 525 |
| Val Pro Arg Pro | Leu Thr Thr Ile Asp Lys Val Ser Gly Lys Arg | | | | |
| | 530 | | 535 | | 540 |
| Val Val Asn Pro | Ala Ser Ala Phe Gln Gly Leu Gly Ser Lys Leu | | | | |
| | 545 | | 550 | | 555 |
| Pro Pro Val Val | Gly Ile Ala Asn Lys Leu Lys Ala Asn Leu Met | | | | |
| | 560 | | 565 | | 570 |
| Ser Glu Thr Asn | Gly Ser Ile Pro Leu Cys Ser Val Leu Pro Lys | | | | |
| | 575 | | 580 | | 585 |
| Leu Ile Ser | | | | | |

<210> 25

<211> 389

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 346275

<400> 25

| | | |
|-----------------|---|---------|
| Met Ser Asp Val | Cys Ser Ser Gln Arg Ala Glu His Glu His Leu | |
| 1 | 5 | 10 15 |
| Pro Gly Leu Val | Pro Pro Ser Gly Met Gly Val Arg Lys Gly | |
| | 20 | 25 30 |
| Ser Ser Pro Leu | Lys Ser His Pro Cys Arg Glu Lys Ser Val Ser | |
| | 35 | 40 45 |
| Asn Arg Arg Ser | Gly Lys Thr Ile Val Arg Ser Ala Val Glu Glu | |
| | 50 | 55 60 |
| Val Arg Thr Ala | Gly Leu Phe Arg Ser Gly Phe Ser Glu Glu Lys | |
| | 65 | 70 75 |
| Ala Thr Gly Lys | Leu Phe Ala Val Lys Cys Ile Pro Lys Lys Ala | |
| | 80 | 85 90 |
| Leu Lys Gly Lys | Glu Ser Ser Ile Glu Asn Glu Ile Ala Val Leu | |
| | 95 | 100 105 |
| Arg Lys Ile Lys | His Glu Asn Ile Val Ala Leu Glu Asp Ile Tyr | |
| | 110 | 115 120 |
| Glu Ser Pro Asn | His Leu Tyr Leu Val Met Gln Leu Val Ser Gly | |
| | 125 | 130 135 |
| Gly Glu Leu Phe | Asp Arg Ile Val Glu Lys Gly Phe Tyr Thr Glu | |
| | 140 | 145 150 |
| Lys Asp Ala Ser | Thr Leu Ile Arg Gln Val Leu Asp Ala Val Tyr | |
| | 155 | 160 165 |
| Tyr Leu His Arg | Met Gly Ile Val His Arg Asp Leu Lys Pro Glu | |
| | 170 | 175 180 |
| Asn Leu Leu Tyr | Tyr Ser Gln Asp Glu Glu Ser Lys Ile Met Ile | |
| | 185 | 190 195 |

```

Ser Asp Phe Gly Leu Ser Lys Met Glu Gly Lys Gly Asp Val Met
      200      205      210
Ser Thr Ala Cys Gly Thr Pro Gly Tyr Val Ala Pro Glu Val Leu
      215      220      225
Ala Gln Lys Pro Tyr Ser Lys Ala Val Asp Cys Trp Ser Ile Gly
      230      235      240
Val Ile Ala Tyr Ile Leu Leu Cys Gly Tyr Pro Pro Phe Tyr Asp
      245      250      255
Glu Asn Asp Ser Lys Leu Phe Glu Gln Ile Leu Lys Ala Glu Tyr
      260      265      270
Glu Phe Asp Ser Pro Tyr Trp Asp Asp Ile Ser Asp Ser Ala Lys
      275      280      285
Asp Phe Ile Arg Asn Leu Met Glu Lys Asp Pro Asn Lys Arg Tyr
      290      295      300
Thr Cys Glu Gln Ala Ala Arg His Pro Trp Ile Ala Gly Asp Thr
      305      310      315
Ala Leu Asn Lys Asn Ile His Glu Ser Val Ser Ala Gln Ile Arg
      320      325      330
Lys Asn Phe Ala Lys Ser Lys Trp Arg Gln Ala Phe Asn Ala Thr
      335      340      345
Ala Val Val Arg His Met Arg Lys Leu His Leu Gly Ser Ser Leu
      350      355      360
Asp Ser Ser Asn Ala Ser Val Ser Ser Ser Leu Ser Leu Ala Ser
      365      370      375
Gln Lys Asp Cys Ala Tyr Val Ala Lys Pro Glu Ser Leu Ser
      380      385

```

<210> 26

<211> 343

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 283746

<400> 26

```

Met Ile Gly Glu Glu Ala Met Ile Asn Tyr Glu Asn Phe Leu Lys
  1      5      10      15
Val Gly Glu Lys Ala Gly Ala Lys Cys Lys Gln Phe Phe Thr Ala
      20      25      30
Lys Val Phe Ala Lys Leu Leu His Thr Asp Ser Tyr Gly Arg Ile
      35      40      45
Ser Ile Met Gln Phe Phe Asn Tyr Val Met Arg Lys Val Trp Leu
      50      55      60
His Gln Thr Arg Ile Gly Leu Ser Leu Tyr Asp Val Ala Gly Gln
      65      70      75
Gly Tyr Leu Arg Glu Ser Asp Leu Glu Asn Tyr Ile Leu Glu Leu
      80      85      90
Ile Pro Thr Leu Pro Gln Leu Asp Gly Leu Glu Lys Ser Phe Tyr
      95      100      105
Ser Phe Tyr Val Cys Thr Ala Val Arg Lys Phe Phe Phe Phe Leu
      110      115      120
Asp Pro Leu Arg Thr Gly Lys Ile Lys Ile Gln Asp Ile Leu Ala
      125      130      135

```

```

Cys Ser Phe Leu Asp Asp Leu Leu Glu Leu Arg Asp Glu Glu Leu
140 145 150
Ser Lys Glu Ser Gln Glu Thr Asn Trp Phe Ser Ala Pro Ser Ala
155 160 165
Leu Arg Val Tyr Gly Gln Tyr Leu Asn Leu Asp Lys Asp His Asn
170 175 180
Gly Met Leu Ser Lys Glu Glu Leu Ser Arg Tyr Gly Thr Ala Thr
185 190 195
Met Thr Asn Val Phe Leu Asp Arg Val Phe Gln Glu Cys Leu Thr
200 205 210
Tyr Asp Gly Glu Met Asp Tyr Lys Thr Tyr Leu Asp Phe Val Leu
215 220 225
Ala Leu Glu Asn Arg Lys Glu Pro Ala Ala Leu Gln Tyr Ile Phe
230 235 240
Lys Leu Leu Asp Ile Glu Asn Lys Gly Tyr Leu Asn Val Phe Ser
245 250 255
Leu Asn Tyr Phe Phe Arg Ala Ile Gln Glu Leu Met Lys Ile His
260 265 270
Gly Gln Asp Pro Val Ser Phe Gln Asp Val Lys Asp Glu Ile Phe
275 280 285
Asp Met Val Lys Pro Lys Asp Pro Leu Lys Ile Ser Leu Gln Asp
290 295 300
Leu Ile Asn Ser Asn Gln Gly Asp Thr Val Thr Thr Ile Leu Ile
305 310 315
Asp Leu Asn Gly Phe Trp Thr Tyr Glu Asn Arg Glu Ala Leu Val
320 325 330
Ala Asn Asp Ser Glu Asn Ser Ala Asp Leu Asp Asp Thr
335 340

```

<210> 27

<211> 184

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2696537

<400> 27

```

Met Gly Asn Gly Met Asn Lys Ile Leu Pro Gly Leu Tyr Ile Gly
1 5 10 15
Asn Phe Lys Asp Ala Arg Asp Ala Glu Gln Leu Ser Lys Asn Lys
20 25 30
Val Thr His Ile Leu Ser Val His Asp Ser Ala Arg Pro Met Leu
35 40 45
Glu Gly Val Lys Tyr Leu Cys Ile Pro Ala Ala Asp Ser Pro Ser
50 55 60
Gln Asn Leu Thr Arg His Phe Lys Glu Ser Ile Lys Phe Ile His
65 70 75
Glu Cys Arg Leu Arg Gly Glu Ser Cys Leu Val His Cys Leu Ala
80 85 90
Gly Val Ser Arg Ser Val Thr Leu Val Ile Ala Tyr Ile Met Thr
95 100 105
Val Thr Asp Phe Gly Trp Glu Asp Ala Leu His Thr Val Arg Ala
110 115 120

```

Gly Arg Ser Cys Ala Asn Pro Asn Val Gly Phe Gln Arg Gln Leu
 125 130 135
 Gln Glu Phe Glu Lys His Glu Val His Gln Tyr Arg Gln Trp Leu
 140 145 150
 Lys Glu Glu Tyr Gly Glu Ser Pro Leu Gln Asp Ala Glu Glu Ala
 155 160 165
 Lys Asn Ile Leu Ala Ala Pro Gly Ile Leu Lys Phe Trp Ala Phe
 170 175 180
 Leu Arg Arg Leu

<210> 29
 <211> 118
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone Number: 619292

<400> 29
 Met Gly Leu Ile Asp Gly Met His Thr His Leu Gly Ala Pro Gly
 1 5 10 15
 Leu Tyr Ile Gln Thr Leu Leu Pro Gly Ser Pro Ala Ala Ala Asp
 20 25 30
 Gly Arg Leu Ser Leu Gly Asp Arg Ile Leu Glu Val Asn Gly Ser
 35 40 45
 Ser Leu Leu Gly Leu Gly Tyr Leu Arg Ala Val Asp Leu Ile Arg
 50 55 60
 His Gly Gly Lys Lys Met Arg Phe Leu Val Ala Lys Ser Asp Val
 65 70 75
 Gly Lys Gln Pro Arg Arg Ser Ile Ser Ala Arg Pro Leu Ser Arg
 80 85 90
 Gly Ala Ala Arg Thr Pro Pro Gln Ala Arg His Pro Val Pro Pro
 95 100 105
 Gly Asp Thr Gly Leu Pro Pro Ala Phe Val Pro Val Leu
 110 115

<210> 30
 <211> 356
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone Number: 2054049

<400> 30
 Met Val Gly Val Ser Gly Lys Arg Ser Lys Glu Asp Glu Lys Tyr
 1 5 10 15
 Leu Gln Ala Ile Met Asp Ser Asn Ala Gln Ser His Lys Ile Phe
 20 25 30
 Ile Phe Asp Ala Arg Pro Ser Val Asn Ala Val Ala Asn Lys Ala
 35 40 45
 Lys Gly Gly Gly Tyr Glu Ser Glu Asp Ala Tyr Gln Asn Ala Glu

| | | |
|---|-------------------------|-----|
| 50 | 55 | 60 |
| Leu Val Phe Leu Asp Ile His Asn Ile | His Val Met Arg Glu Ser | |
| 65 | 70 | 75 |
| Leu Arg Lys Leu Lys Glu Ile Val Tyr Pro Asn Ile Glu Glu Thr | | |
| 80 | 85 | 90 |
| His Trp Leu Ser Asn Leu Glu Ser Thr His Trp Leu Glu His Ile | | |
| 95 | 100 | 105 |
| Lys Leu Ile Leu Ala Gly Ala Leu Arg Ile Ala Asp Lys Val Glu | | |
| 110 | 115 | 120 |
| Ser Gly Lys Thr Ser Val Val Val His Cys Ser Asp Gly Trp Asp | | |
| 125 | 130 | 135 |
| Arg Thr Ala Gln Leu Thr Ser Leu Ala Met Leu Met Leu Asp Gly | | |
| 140 | 145 | 150 |
| Tyr Tyr Arg Thr Ile Arg Gly Phe Glu Val Leu Val Glu Lys Glu | | |
| 155 | 160 | 165 |
| Trp Leu Ser Phe Gly His Arg Phe Gln Leu Arg Val Gly His Gly | | |
| 170 | 175 | 180 |
| Asp Lys Asn His Ala Asp Ala Asp Arg Ser Pro Val Phe Leu Gln | | |
| 185 | 190 | 195 |
| Phe Ile Asp Cys Val Trp Gln Met Thr Arg Gln Phe Pro Thr Ala | | |
| 200 | 205 | 210 |
| Phe Glu Phe Asn Glu Tyr Phe Leu Ile Thr Ile Leu Asp His Leu | | |
| 215 | 220 | 225 |
| Tyr Ser Cys Leu Phe Gly Thr Phe Leu Cys Asn Ser Glu Gln Gln | | |
| 230 | 235 | 240 |
| Arg Gly Lys Glu Asn Leu Pro Lys Arg Thr Val Ser Leu Trp Ser | | |
| 245 | 250 | 255 |
| Tyr Ile Asn Ser Gln Leu Glu Asp Phe Thr Asn Pro Leu Tyr Gly | | |
| 260 | 265 | 270 |
| Ser Tyr Ser Asn His Val Leu Tyr Pro Val Ala Ser Met Arg His | | |
| 275 | 280 | 285 |
| Leu Glu Leu Trp Val Gly Tyr Tyr Ile Arg Trp Asn Pro Arg Met | | |
| 290 | 295 | 300 |
| Lys Pro Gln Glu Pro Ile His Asn Arg Tyr Lys Glu Leu Leu Ala | | |
| 305 | 310 | 315 |
| Lys Arg Ala Glu Leu Gln Lys Lys Val Glu Glu Leu Gln Arg Glu | | |
| 320 | 325 | 330 |
| Ile Ser Asn Arg Ser Thr Ser Ser Ser Glu Arg Ala Ser Ser Pro | | |
| 335 | 340 | 345 |
| Ala Gln Cys Val Thr Pro Val Gln Thr Val Val | | |
| 350 | 355 | |

<210> 31

<211> 453

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2843910

<400> 31

| | |
|---|----|
| Met Ala Gly Ala Gly Gly Phe Gly Cys Pro Ala Gly Gly Asn Asp | |
| 1 | 5 |
| Phe Gln Trp Cys Phe Ser Gln Val Lys Gly Ala Ile Asp Glu Asp | 10 |
| | 15 |

| | | | | | |
|-----|-----|-----|-----|-----|-----|
| | 20 | | 25 | | 30 |
| Val | Ala | Glu | Ala | Asp | Ile |
| | 35 | | 40 | | 45 |
| Gly | Asp | Leu | Leu | Ala | Thr |
| | 50 | | 55 | | 60 |
| Phe | Gln | Arg | Glu | Gln | Glu |
| | 65 | | 70 | | 75 |
| Glu | Tyr | Asn | Val | Tyr | Ser |
| | 80 | | 85 | | 90 |
| Asp | Tyr | Leu | Lys | Ser | Leu |
| | 95 | | 100 | | 105 |
| Arg | Trp | Leu | Pro | Gln | Gln |
| | 110 | | 115 | | 120 |
| Asn | Asp | Lys | Thr | Ile | Lys |
| | 125 | | 130 | | 135 |
| Arg | Ala | Glu | Gly | Tyr | Asn |
| | 140 | | 145 | | 150 |
| Asp | Pro | Phe | Arg | Ile | Thr |
| | 155 | | 160 | | 165 |
| Met | Asp | Leu | Met | Val | Glu |
| | 170 | | 175 | | 180 |
| Ala | His | Thr | Tyr | His | Ile |
| | 185 | | 190 | | 195 |
| Glu | Thr | Tyr | Leu | Ser | Ala |
| | 200 | | 205 | | 210 |
| Leu | Glu | Ile | Thr | Asp | Arg |
| | 215 | | 220 | | 225 |
| Ala | Asn | Met | Glu | Glu | Leu |
| | 230 | | 235 | | 240 |
| His | Pro | His | Gln | Cys | Asn |
| | 245 | | 250 | | 255 |
| Thr | Ile | Arg | Leu | Cys | Asp |
| | 260 | | 265 | | 270 |
| His | Ser | Lys | Phe | Phe | Glu |
| | 275 | | 280 | | 285 |
| Phe | Phe | Ser | Glu | Ile | Ile |
| | 290 | | 295 | | 300 |
| His | Ser | Gly | Arg | Tyr | Met |
| | 305 | | 310 | | 315 |
| Val | Trp | Asp | Leu | Asn | Met |
| | 320 | | 325 | | 330 |
| Val | His | Glu | Tyr | Leu | Arg |
| | 335 | | 340 | | 345 |
| Asp | Cys | Ile | Phe | Asp | Lys |
| | 350 | | 355 | | 360 |
| Ser | Ala | Ile | Met | Thr | Gly |
| | 365 | | 370 | | 375 |
| Asp | Arg | Asp | Thr | Arg | Arg |
| | 380 | | 385 | | 390 |
| Ser | Ser | Lys | Pro | Arg | Ala |
| | 395 | | 400 | | 405 |
| Gly | Gly | Lys | Arg | Arg | Lys |
| | 410 | | 415 | | 420 |
| Phe | Asn | Lys | Lys | Ile | Leu |
| | 425 | | 430 | | 435 |
| Val | Ile | Ala | Val | Ala | Ala |

440 445 450

Lys Ile Asn

<210> 32
 <211> 1221
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone Number: 132240

<400> 32
 cttttcctgg aatttctata atggaaagtc cattagaaag tcagccctta gattcagata 60
 gaagcatcaa agaatcctct tttgaagaat caaatattga agatccactt attgtaacac 120
 cagattgccca agaaaagacc tcacccaaaag gtgtcgagaa ccctgctgta caagagagta 180
 accaaaaaat gttagggtcct cctttggagg tgctgaaaac gttagcctct aaaagaaatg 240
 ctgttgcttt tcgaagtttt aacagtcata ttaatgcata caataactca gaaccatcca 300
 gaatgaacat gacttcttta gatgcaatgg atatttcgtg tgcctacagt ggttcatatc 360
 ccatggctat aacccttact caaaaaagaa gatcctgtat gccacatcag accccaaatc 420
 agatcaagtc gggaactcca taccgaactc cgaagagtgt gagaagaggg gtggcccccg 480
 ttgatgatgg gcgaattcta ggaaccccag actaccttgc acctgagctg ttactaggca 540
 gggcccatgg tcctgcggta gactggtggg cacttggagt ttgcttgttt gaatttctaa 600
 caggaattcc ccctttcaat gatgaaacac cacaacaagt attccagaat attctgaaaa 660
 gagatatccc ttggccagaa ggtgaagaaa agttatctga taatgctcaa agtgcagtag 720
 aaatactttt aaccattgat gatacaaaga gagctggaat gaaagagcta aaacgtcatc 780
 ctctcttcag tgatgtggac tgggaaaatc tgcagcatca gactatgcct ttcatcccc 840
 agccagatga tgaacagat acctcctatt ttgaagccag gaatactgct cagcacctga 900
 ctgtatctgg atttagtctg tagcacaaaa attttcttt tagtctagcc ttgtgttata 960
 gaatgaactt gcataattat atactcctta atactagatt gatctaaggg gaaagatca 1020
 ttatttaacc tagttcaatg tgcctttaat gtacgttaca gctttcacag agttaaaggg 1080
 ctgaaaggaa tatagtcagt aatttatctt aacctcaaaa ctgtatataa atcttcaaa 1140
 cttttttcat ttatttattt tgtttattgc actttatgaa aactgaagca tcaataaaat 1200
 tagaggacac taaaaaaaaa a 1221

<210> 33
 <211> 542
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte Clone Number: 2180116

<400> 33
 tggccaggct gggctccagca gcgcgatggc agctcagcgg ctgggcaagc gcgtgctgag 60
 caagctgcag tctccatcgc gggcccgcgg gccagggggc agtcccgggg ggaatgcagaa 120
 gcggcacgcg cgcgtcaccg tcaagtatga ccggcgggag ctgcagcggc ggcaggacgt 180
 ggagaagtgg atcgacgggc gcctggagga gctgtaccgc ggcatggagg cagacatgcc 240
 cgatgagatc aacattgatg aattgttggg gttagagagt gaagaggaga gaagccggaa 300
 aatccaggga ctctgaagt catgtgggaa acctgtcgag gacttcatcc aggagctgct 360
 ggcaaagctt caaggcctcc acaggcagcc cggcctccgc cagccaagcc cctcccacga 420
 cggcagcctc agccccctcc aggaccgggc cgggactgct caccctgac cctcttgac 480
 tctcctgcc ccccgagcgc cgcccagctt gcttgtgtat aagttgtatt taatggattc 540

tt

542

<210> 34
<211> 2778
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> 2548, 2557, 2645, 2722, 2557, 2762, 2765
<223> Incyte Clone Number: 2197671

<400> 34
cgcggtatcgt cgcgggcccg cgcgtccgct ccaggaagtg gccgtcctga ggcgcatggc 60
tcactccccg gtgcagtcgg gcctgcccgg catgcagaac ctaaaggcag acccagaaga 120
gctttttaca aaactagaga aaattgggaa gggctccttt ggagaggtgt tcaaaggcat 180
tgacaatcgg actcagaaag tgggtgccat aaagatcatt gatctggaag aagctgaaga 240
tgagatagag gacattcaac aagaaatcac agtgctgagt cagtgtgaca gtccatatgt 300
aaccaaatat tatggatcct atctgaagga tacaaaatta tggataataa tggaaatatct 360
tgggtggaggc tccgcactag atctattaga acctggccga ttagatgaaa ccagatcgc 420
tactatatta agagaaatac tgaaaggact cgattatctc cattcggaga agaaaatcca 480
cagagacatt aaagcgcca acgtcctgct gtctgagcat ggcgaggtga agctggcgga 540
ctttggcgtg gctggccagc tgacagacac ccagatcaaa aggaacacct tcgtgggcac 600
cccattctgg atggcaccg aggtcatcaa acagtcggcc tatgactcga aggcagacat 660
ctggtccctg ggcataacag ctattgaact tgcaagaggg gaaccacctc attccgagct 720
gcaccccatg aaagttttat tcctcattcc aaagaacaac ccaccgacgt tggaggaaa 780
ctacagtaaa cccctcaagg agtttgtgga ggctgtttg aataaggagc cgagctttag 840
accactgct aaggagttaa tgaagcacia gtttatacta cgcaatgcaa agaaaacttc 900
ctacttgacc gagtcacgc acaggtacaa gagatggaag gccgagcaga gccatgacga 960
ctcgagctcc gaggtatccg acgcggaaac agatggccaa gcctcggggg gcagtgatc 1020
tggggactgg atcttcacia tccgagaaaa agatcccaag aatctcgaga atggagctct 1080
tcagccatcg gacttggaca gaaataagat gaaagacatc ccaaaggagc ctttctctca 1140
gtgtttatct acaattatct ctctctgtt tgcagagttg aaggagaaga gccaggcgtg 1200
cggagggaac ttgggtcca ttgaagagct gcgaggggcc atctacctag cggaggaggc 1260
gtgccttggc atctccgaca catggtggc ccagctcgtg cagcggctcc agagatactc 1320
tctaagtggg ggaggaaact catcccactg aaattccttt ggcatttggg gttttgtttt 1380
tcttttttct cttcttcac ctcctccttt tttaaaagtc aacgagagcc ttcgctgact 1440
ccaccgaaga ggtgcgccac tgggagccac ccagtgcca ggcgcccgtc caggagacaca 1500
cacagtcttc actgtgctgc agccagatga agtctctcag atgggtgggg agggcagct 1560
ccttcacagc atcattttat tttattttat tacttttgtt ttttaattta accatagtgc 1620
acatattcca ggaaagtgtc tttaaaaaca aaaacaaacc ctgaaatgta tatttgggat 1680
tatgataagg caactaaaga catgaaacct caggtatcct gctttaagtt gataactccc 1740
tctgggagct ggagaatcgc tctggtggat ggggtgtacag atttgtatat aatgtcattt 1800
ttacggaaac cctttcggcg tgcataagga atcactgtgt acaaaactggc caagtgcctc 1860
tgtagataac gtcagtggag taaatatcgc acaggccata acttgagctc attgccttgc 1920
ctttattaca tgtacatttt gaattctgtg accagtgatt tgggttttat tttgtatttg 1980
cagggtttgt cattataat taatgcccc ctcttacaga acactcctat ttgtacctca 2040
acaaatgcaa attttcccg tttgcctac gcccctttg gtacacctag aggttgattt 2100
cctttttcat cgatggtact atttcttagt gttttaaatt ggaacatata ttgcctcatg 2160
aagctttaaa ttataatttt cagtttctcc ccatgaagcg ctctcgtctg acatttgttt 2220
ggaatcgtgc cactgctggc ctgcgccaga tgtaccgtcc tttccaatac gattttctgt 2280
tgcaccttgt agtggattct gcataatc tttccacct aaaaatgtct gaatgcttac 2340
acaaataaat ttataacac gcttattttg catactcctt gaaatgtgac tcttcagagg 2400
acaggttacc tgctgtgtat gtgtggcgt gccgtgtgtac tcgtggctgt gtgtgtgtga 2460

```

tgagacactt tgggaagactc cagggagaag ttcccagggc tggagctgcc gagtgcccag 2520
gtcagcgcgc tgggctgctt gcgcaatngc tcaccngat gatgcattgg aggttgctga 2580
cctgtgcgat tgctgtagcg gttgccaggg accttaaggg gttattttgc ttccctggga 2640
gggncctat gtttctaggc aagcagccat gtgtctaatt ttctgggttt gctgtgggga 2700
cctgattggg ggagggggaa anctttgggg ttcttgaggt gggaggggtc gtgccancaa 2760
tntnctctgg taaaaaag                                     2778

```

<210> 35

<211> 1424

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2594943

<400> 35

```

ggctcagcct ccgaccaggg tgggtctggag cctgccggga gagtgggtggc atctgagagg 60
ctggctcgtgg actgtggttg ggggaggttg gagctgtttt aaccgtgtgc cccctctcct 120
gtgccggcgt gggcatcccc cggggcagtg gaacgcgggc gtcctccag cttccgagtc 180
cagccagcct gggcgcgggg cgccgcccc gagacacccg aggagtccgt tcctccctgg 240
ttacgtggac tgtggagctg gtctcttggt gctcagcgcc gtgcggaggt tgaagcgtac 300
ctgcggaggt cgcaccaggg cgtgaggagg aggaggaaagg gcatgagccg agcttgagga 360
atccgtgctc caaactctac actcaagggt ggcccttggg tagggtgaag atcccctgtc 420
tttaccctag ttccacacct tgggtgtgggt tactgggtgc aggatgaact gtcgctcgga 480
gggtcgtggag gtgtcgggtg aggggcgcca ggtggaggag gccatgctgg ctgtgctgca 540
cacggtgctt ctgcaccgca gcacaggcaa gttccactac aagaaggagg gcacctactc 600
cattggcacc gtgggcaccc aggatgttga ctgtgacttc atcgacttca cttatgtgcy 660
tgtctcttct gaggaactgg atcgtgccct gcgcaagggt gttggggagt tcaaggatgc 720
actgcgcaac tctggtggcg atgggctggg gcagatgtcc ttggagttct accagaagaa 780
gaagtctcgc tggccattct cagacgagtg catcccatgg gaagtgtgga cggccaaggt 840
gcatgtggtg gccctggcca cggagcagga gcggcagatg tgccgggaga aggtgggtga 900
gaaactctgc gagaagatca tcaacatcgt ggaggtgatg aatcgcatg agtacttgcc 960
caagatgccc acacagtcgg aggtggataa cgtgtttgac acaggcttgc gggacgtgca 1020
gccctacctg tacaagatct ccttccagat cactgatgcc ctgggcacct cagtcaccac 1080
caccatgcgc aggtcatca aagacaccct tgccctctga gcgtcgttgg atctctggga 1140
gctccttgat ggctcccaga ctttggtttt tgggaattgc acttttgggc ctttgggttc 1200
tggaacctgc tctgggtcat tgggtgagact tgggaaggggc agccccgct ggcttcttgg 1260
ttttgtggtt gccagcctca ggtcatcctt ttaatctttg ctgatggttc agtccctgcc 1320
ctactgtctc tccatagccc tgggtgggtc ccccttcttt ctccactgta cagaagagcc 1380
accactggga tggggaataa agttgagaac atgaaaaaaa aaaa 1424

```

<210> 36

<211> 1839

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 1513871

<400> 36

```

ctcctcctc gggcagctca ggttgagct tctctgggga actgctcacc tttccggagc 60
aggggaagct gcccctgcc cgggagggag cgggcgcacc gcggcccca ggacacgcgc 120
tgaccgggct gccagtcct tcatgatcat gaacaagatg aagaacttta agcggcgttt 180
ctccctgtca gtgccccgca ctgagaccat tgaagaatcc ttggctgaat tcacggagca 240

```

```

attcaaccag ctccacaacc ggcggaatga gaacttgacg ctcggtcctc ttggcagaga 300
ccccccgag gagtgcagca ccttctcccc aacagacagc ggggaggagc cggggcagct 360
ctcccctggc gtgcagttcc agcggcgga gaaccagcgc cgcttctcca tggaggacgt 420
cagcaagagg ctctctctgc ccatggatat ccgcctgccc caggaattcc tacagaagct 480
acagatggag agcccagatc tgcccagcc gctcagccgc atgtcccgcc gggcctccct 540
gtcagacatt ggctttggga aactggaac atactgaaa ctggacaaac tgggagaggg 600
cacctatgcc acagtcttca aagggcgag caaactgacg gagaaccttg tggccctgaa 660
agagatccgg ctggagcacg aggaggagc gccctgcaat gccatccgag aggtgtctct 720
gctgaagaac ctgaagcacg ccaatattgt gacctgcat gacctcatcc acacagatcg 780
gtccctcacc ctggtgtttg agtacctgga cagtgcacct aagcagtatc tggaccactg 840
tgggaacctc atgagcatgc acaacgtcaa gattttcatg ttccagctgc tccggggcct 900
cgctactgt caccaccgca agatcctgca ccgggacctg aagccccaga acctgctcat 960
caacgagagg ggggagctga agctggcga ctttggactg gccagggcca agtcagtgc 1020
cacaagact tactccaatg aggtgtgac cctgtggtac agggcccccg atgtgtgct 1080
gggatccaca gactactcca cccccattga tatgtggggc gtgggctgca tccactacga 1140
gatggccaca gggaggcccc tcttccggg ctccacagtc aaggaggagc tgcacctcat 1200
ctttcgctc ctcgggaccc ccacagaaga gacgtggccc ggcgtgaccg ccttctctga 1260
gttccgaccc tacagcttcc cctgtacct ccgcagccg ctcatcaacc acgcgccag 1320
gttgatacag gatggcatcc acctcctgag cagcctgctc ctgtatgaat ccaagagtcg 1380
catgtcagca gaggctgccc tgagtcactc ctacttccgg tctctgggag agcgtgtgca 1440
ccagcttgaa gacactgcct ccactcttct cctgaaggag atccagctcc agaaggacc 1500
aggctaccga ggcttgccct tccagcagcc aaggcagagg aagaacaggc ggcagagcat 1560
cttctgagcc acgcccacct tgctgtggcc aagggacaag agatcacatg gagcacaaat 1620
tcgggtagga tggagcctgt gtggccctcg gaggactgaa gaacgagggc tgacagcagc 1680
ctggaagacc gcttggcagg cttttggcca agtgttttct tttgtggttt cgatctgctg 1740
ccagtagttt cagtggatac aacgtgcttt aggagttggg tgggaaagtc ttgctagagg 1800
gtttaggggg aggtttctac cgttgactcg gtttagggc 1839

```

<210> 37

<211> 2024

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 156108

<400> 37

```

gtcagctctg gttcggagaa gcagcggctg gcgtgggcca tccggggaat gggcgccctc 60
gtgacctagt gttgcggggc aaaaagggtc ttgcccgcct cgctcgtgca ggggcgtatc 120
tgggcgcctg agcgcggcgt gggagccttg ggagccgccc cagcaggggg cacaccggga 180
accggcctga gcgcccggga ccatgaacgg ggaggccatc tgcagcggcc tgcccaccat 240
tccctaccac aaactcgccg acctgcgcta cctgagccgc ggcgcctctg gcaactgtgc 300
gtccgcccgc cagcagact ggcgcgtcca ggtggccgtg aagcacctgc acatccacac 360
tccgctgctc gacagtgaag gaaaggatgt cttaagagaa gctgaaattt tacacaaagc 420
tagatttagt tacattcttc caattttggg aatttgcaat gaggctgaat ttttgggaat 480
agttactgaa tacatgcca atggatcatt aaatgaactc ctacatagga aaactgaata 540
tcttgatgtt gcttggccat tgagatttct catcctgcat gaaattgccc ttggtgtaaa 600
ttactgcac aatatgactc ctctttact tcatcatgac ttgaagactc agaatatctt 660
attggacaat gaatttcatg ttaagattgc agattttgtt ttatcaaagt ggcgcatgat 720
gtccctctca cagtacgaa gtagcaaatc tgcaccagaa ggagggacaa ttatctatat 780
gccacctgaa aactatgaac ctggacaaaa atcaagggcc agtatcaagc acgatataata 840
tagctatgca gttatcacat gggaaagtgt atccagaaaa cagccttttg aagatgtcac 900
caatcctttg cagataatgt atagtgtgtc acaaggacat cgacctgtta ttaatagaaga 960
aagtttgcca tatgatatac ctcccgagc acgtatgatc tctctaataa aaagtggatg 1020

```

```

ggcacaaaaa ccagatgaaa gaccatcttt cttaaaatgt ttaatagaac ttgaaccagt 1080
tttgagaaca tttgaagaga taacttttct tgaagctgtt attcagctaa agaaaacaaa 1140
gttacagagt gtttcaagtg ccattcacct atgtgacaag aagaaaatgg aattatctct 1200
gaacatacct gtaaatcatg gtccacaaga ggaatcatgt ggatcctctc agctccatga 1260
aaatagtggg tctcctgaaa cttcaagggt cctgccagct cctcaagaca atgatttttt 1320
atctagaaaa gctcaagact gttattttat gaagctgcat cactgtcctg gaaatcacag 1380
ttgggatagc accattttctg gatctcaaag ggctgcattc tgtgatcaca agaccactcc 1440
atgctcttca gcaataataa atccactctc aactgcagga aactcagaac gtctgcagcc 1500
tggatatagc cagcagtggg tccagagcaa aagggaagac attgtgaacc aaatgacaga 1560
agcctgcctt aaccagtcgc tagatgcctt tctgtccagg gacttgatca tgaaagagga 1620
ctatgaactt gttagtacca agcctacaag gacctcaaaa gtcagacaat tactagacac 1680
tactgacatc caaggagaag aatttgccaa agttatagta caaaaattga aagataacaa 1740
acaaatgggt cttcagcctt acccggaat aactgtggtt tctagatcac catctttaa 1800
tttacttcaa aataaaagca tgtaagtgc tgtttttcaa gaagaaatgt gtttcataaa 1860
aggatattta tatctctgtt gctttgactt tttttatata aaatccgtga gtattaaagc 1920
tttattgaag gttctttggg taaatattag tctccctcca tgacactgca gtattttttt 1980
taattaatac aagtaaaaag tttgaatttt gctacataaa aaaa 2024

```

<210> 38

<211> 1861

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2883243

<400> 38

```

gcttcttagt gaggttggca ttatgttaag gctggtatgg aagacaactg atgaagcagg 60
agtggctctg tgacattttt ctgacttgat tggctggggc gtgtgatgta ataggtttca 120
gtgcagcccc ttataggttt taaaatgaat tccaagacac cattacaaag aaagccggac 180
tcttttctta taactgagct cagccaagga aactcttgca caaatgtaca atactgtttg 240
gaatatggaa gacctggatt tagaatatgc caagacagat ataaattgtg gcacagactt 300
gatgttttat atagaaatgg acccaccagc actgcctcct aaaccaccaa aacctactac 360
tgtagccaac aacggtatga ataacaatat gtccttacia gatgctgaat ggtactgggg 420
agatatctcg aggggaagaag tgaatgaaaa acttcgagat acagcagacg ggaccttttt 480
ggtacgagat gcgtctacta aaatgcatgg tgattatact cttacactaa ggaaaagggg 540
aaataacaaa ttaatcaaaa tatttcacg agatgggaaa tatggcttct ctgacctatt 600
aaccttcagt tctgtggttg aattaataaa ccactaccgg aatgaatctc tagctcagta 660
taatcccaaa ttggatgtga aattacttta tccagtatcc aaataccaac aggatcaagt 720
tgtcaagaa gataatattg aagctgtagg gaaaaaatta catgaatata acactcagtt 780
tcaagaaaa agtcgagaat atgatagatt atatgaagaa tatacccgca catcccagga 840
aatccaaatg aaaaggacag ctattgaagc atttaatgaa accataaaaa tatttgaaga 900
acagtgccag acccaagagc ggtacagcaa agaatacata gaaaagttta aacgtgaagg 960
caatgagaaa gaaatacaaa ggattatgca taattatgat aagttgaagt ctcgaatcag 1020
tgaaattatt gacagtagaa gaagattgga agaagacttg aagaagcagg cagctgagta 1080
tcgagaaatt gacaaacgta tgaacagcat taaaccagac cttatccagc tgagaaagac 1140
gagagaccaa tacttgatgt ggttgactca aaaagggtgt cggcaaaaga agttgaacga 1200
gtggttgggc aatgaaaaca ctggaagacca atattcactg gtggaagatg atgaagattt 1260
gccccatcat gatgagaaga ctggaatgt tgggaagcag aaccgaaaac aagctgataa 1320
cctgttgcca gggaagcgag atggcacttt tctgtccgg gagagcagta aacagggtct 1380
ctatgcctgc tctgtagtgg tggacggcga agtaaaagcat tgtgtcataa acaaaacagc 1440
aactggctat ggctttgccg agccctataa cttgtacagc tctctgaaag aactgggtgt 1500
acattaccaa cacacctccc ttgtgcagca caacgactcc ctcaatgtca cactagccta 1560
cccagtatat gcacagcaga ggcgatgaag cgcttactct ttgatccttc tcctgaagtt 1620

```

cagccaccct gaggcctctg gaaagcaaag ggctcctctc cagtctgata tgtgaattga 1680
 gctgcagaaa cgaagccaac ttttttttga tgggactagt gctttctttc acaaaaaaga 1740
 agtaggggaa gacatgcagc ctaaggctgt atgatgacca cacgttccta agctggagtg 1800
 cttatccctt ctttttcttt ttttcttttg ttttaatttaa agccacaacc acatacaaca 1860
 c 1861

<210> 39

<211> 2045

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 3173355

<400> 39

cttggctgga acctgagacg gattcgctcc caaatgatgc tccagtggca ggagcaactc 60
 aagtcatca ttgtcctgag agagaggagc agcgcggttc tcggccggga cagcagaacg 120
 ccaggggacc ctacctggg cgcgccgggg cacgggcttt gattgtcctg gggtcgcgga 180
 gaccgcgcgc cctgccctgc acgccgggcg gcaacctttg cagtcgcgtt ggctgctgcg 240
 atcgcccggc gggteccctgc cgaaggctcg gctgcttctg tccacctctt acacttcttc 300
 atttatcggt ggatcatttc gagagtccgt cttgtaaatg tttggcactt tgctacttta 360
 ttgcttcttt ctggcgacag ttccagcact cgccgagacc ggccggagaaa ggcagctgag 420
 cccggagaag agcgaaatat ggggacccgg gctaaaagca gacgtcgtcc ttcccgcccg 480
 ctatttctat attcaggcag tggatacatc aggggaataaa ttcacatctt ctccaggcga 540
 aaaggtcttc caggtgaaag tctcagcacc agaggagcaa ttcactagag ttggagtcca 600
 ggttttagac cgaaaagatg ggtccttcat agtaagatac agaagtgtat caagctacaa 660
 aaatctgaag gtggaatta aattccaagg gcaacatgtg gccaaatccc catatatttt 720
 aaaagggcgc gtttaccatg agaactgtga ctgtcctctg caagatagtg cagcctggct 780
 acgggagatg aactgcctcg aaaccattgc tcagattcag agagatctgg cacatttccc 840
 tgctgtggat ccagaaaaga ttgcagtaga aatcccaaaa agatttggac agaggcagag 900
 cctatgtcac tacaccttaa aggataacaa ggtttatata aagactcatg gtgaacatgt 960
 aggttttaga attttcatgg atgccatact actttctttg actagaaagg tgaagatgcc 1020
 agatgtggag ctctttgtta atttgggaga ctggcctttg gaaaaaaga aatccaattc 1080
 aaacatccat ccgatctttt cctgggtgtg ctccacagat tccaaggata tcgtgatgcc 1140
 tacgtacgat ttgactgatt ctgttctgga aaccatgggc cgggtaagtc tggatatgat 1200
 gtccgtgcaa gctaacacgg gtccctccctg ggaaagcaaa aattccactg ccgtctggag 1260
 agggcgagac agccgcaaag agagactcga gctgggttaa ctcagtagaa aacaccacga 1320
 actcatagac gctgctttca ccaacttttt ctcttttaa cacgatgaaa acctgtatgg 1380
 tcccattgtg aaacatattt cattttttga tttcttcaag cataagtatc aaataaatat 1440
 cgatggcact gtagcagctt atcgccctgc atatttgcta gttggtgaca gtgttggtgt 1500
 gaagcaggat tccatctact atgaacattt ttacaatgag ctgcagccct ggaaacacta 1560
 cattccagtt aagagcaacc tgagcgatct gctagaaaaa cttaaattggg cgaaagatca 1620
 cgatgaagag gccaaaaaga tagcaaaagc aggacaagaa tttgcaagaa ataatctcat 1680
 gggcgatgac atattctggt attattttcaa acttttccag gaatatgcca atttacaagt 1740
 gagtgaagccc caaatccgag agggcatgaa aagggtagaa ccacagactg aggacgacct 1800
 ctcccttgt acttgccata ggaaaaagac caaagatgaa ctctgatatg caaaataact 1860
 tctattagaa taatgggtgt ctgaagactc ttcttaacta aaaagaagaa tttttttaag 1920
 tattaattcc atggacaata taaaatctgt gtgattgttt gcagtatgaa gacacatttc 1980
 tacttatgca gtattctcat gactgtactt taaagtacat ttttagaatt ttataataaa 2040
 accac 2045

<210> 40

<211> 1260

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 5116906

<400> 40

```

cgatatTTTT ctttcttagt ttcccatTtc atattgtttt gtcaaatcaa ctgtgactca 60
ttaacatctc ttttccctag gttttgctgg cacacctgga tatctttctc cagaagtttt 120
acgtaaagat ccttatggaa agccagtgga tatgtgggca tgtggtgtca ttctctatat 180
tctacttggt gggatatccac ccttctggga tgaagaccaa cacagactct atcagcagat 240
caaggctgga gcttatgatt ttccatcacc agaatgggac acggtgactc ctgaagccaa 300
agacctcatc aataaaatgc ttactatcaa ccctgccaaa cgcacacag cctcagaggc 360
actgaagcac ccatggatct gtcaacgttc tactgttgct tccatgatgc acagacagga 420
gactgtagac tgcttgaaga aatttaatgc tagaagaaaa ctaaaggggtg ccatcttgac 480
aactatgctg gctacaagga atttctcagc agccaagagt ttgttgaaga aaccagatgg 540
agtaaaggag tcaactgaga gttcaaatac aacaattgag gatgaagatg tgaagcacg 600
aaagcaagag attatcaaag tcaactgaaca actgatcgaa gctatcaaca atggggactt 660
tgaagcctac acaaaaatct gtgacccagg ccttactgct tttgaacctg aagctttggg 720
taatttagtg gaagggatgg attttcaccg attctacttt gaaaatgctt tgtccaaaag 780
caataaacca atccacacta ttattctaaa ccctcatgta catctggtag gggatgatgc 840
cgctgcata gcatatatta ggctcacaca gtacatggat ggacgtggaa tgccaaagac 900
aatgcagtca gaagagactc gtgtgtggca ccgcccggat ggaaagtggc agaattgtca 960
ttttcatcgc tcggggtcac caacagtacc catcaactaa atttcaacag tgccacttct 1020
gcattctctg ttctcaaggc acctggatgg tgacctggg ccgtcctctc ctctcttca 1080
tgcatgtttc tgagtgcatt aagttgtgaa ggtcctacat gtaatgcata tgtgatgcatt 1140
catcttatca tatattcctt cctatacatt gtttacactt caactacggg gatgttccac 1200
acaaacttaa attactgttg gcaaaacaat agggggagat tagacaaaaa aaaaaaaaaa 1260

```

<210> 41

<211> 2059

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 940589

<400> 41

```

aaaccataga aacgctaatt aaagcagaca tcaaaatctg gatccttaca ggggacaagc 60
aagaaactgc cattaacatc ggacactcct gcaaactgtt gaagaagaac atgggaatga 120
ttgttataaa tgaaggctct cttgattctt tctctaatac acagaattct aggaaggagg 180
ctgttctttt agccaaaatg aaacacccta atattgttgc cttcaaagaa tcatttgaag 240
ctgaaggaca cttgtatatt gtgatggaat actgtgatgg aggggatcta atgcaaaaaga 300
ttaaacagca gaaaggaaag ttatttcctg aagacatgat acttaattgg tttacccaaa 360
tgtgccttgg agtaaatcac attcacaaga aacgtgtgct acacagagat atcaagtcca 420
agaatatctt cctcactcag aatggaaaag tgaaattggg agactttgga tctgcccgtc 480
ttctctccaa tccgatggca tttgcttcta cctatgtggg aactccttat tatgtgcctc 540
cagaaatttg ggaaaacctg ccttataaca ataaaagtga catctggtcc ttgggttgca 600
tcctgtatga actctgtacc cttaagcatc catttcaggc aaatagttgg aaaaatctta 660
tcctcaaagt atgtcaaggg tgcacagtc cactgccgtc tcattactcc tatgaacttc 720
agttcctagt caagcagatg tttaaaagga atccctcaca tcgcccctcg gctacaacgc 780
ttctctctcg aggcacgtga gctcggcttg tccagaagtg cttaccccc gagatcatca 840

```



```

tggaatatgg  tgaggaagta  ttagaagaaa  taaaaaatc  gaagcataac  acaccaagaa  900
aaaaaaca    cccagcaga  atcaggatag  ctttgggaaa  tgaagcaagc  acagtgcaag  960
aggaagaaca  agatagaaag  ggtagccata  ctgatttgga  aagcattaat  gaaaatttag  1020
ttgaaagtgc  attgagaaga  gtaaacagag  aagaaaaagg  taataagtca  gtccatctga  1080
ggaaagccag  ttcaccaa    ctccatagac  gacagtggga  gaaaaatgta  cccaatacag  1140
ctcttacagc  tttggaaa    gcacccatac  tcacctccag  tttaacagca  gaggacgata  1200
gaggtgggttc  tgtaataaag  tacagcaaaa  atactactcg  taagcagtgg  ctcaaagaga  1260
ccccggacac  tttgttgaa    atccttaaga  atgctgatct  cagcttggct  tttcaaacat  1320
acacaatata  tagaccaggt  tcagaagggt  tcttgaaagg  cccctgtct  gaagaaacag  1380
aagcatcgga  cagtgttgat  ggaggtcacg  attctgtcat  tttggatcca  gagcgacttg  1440
agcctgggct  agatgaggag  gacacggact  ttgaggagga  agatgacaac  cccgactggg  1500
gttcagagct  gaagaagcga  gctggatggc  aaggcctgtg  cgacagataa  tgcctgagga  1560
aatgttcctg  agtcacgctg  aggagagcct  tcactcagga  gttcatgctg  agatgatcat  1620
gagttcatgc  gacgtatatt  ttcttttga  aacagaatga  agcagaggaa  actcttaata  1680
cttaaaatcg  ttcttgatta  gtatcgtgag  tttgaaaagt  ctagaactcc  tgtaagtttt  1740
tgaactcaag  ggagaaggta  tagtggaatg  agtgtgagca  tcgggctttg  cagtcccata  1800
gaacagaaat  gggatgctag  cgtgccacta  cctacttggt  tgattgtggg  aaattactta  1860
acctcttcaa  gccccaat    cctcaacat  aaaatgaaga  taataatgcc  tacctcagag  1920
ggatgctgac  cacagacctt  tatagcagcc  cgtatgatat  tattcacatt  atgatatgtg  1980
tttattatta  tgtgactctt  ttacatttc  ctaaagggtt  gagaattaa  tatatttaat  2040
tatgaaaaaa  aaaaaaaaaa  2059

```

<210> 42

<211> 1023

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 304421

<400> 42

```

gaggcagagg  ggtgggagg  ctggcccatg  gctgagacct  ctctcccaga  gctgggggga  60
gaggacaaag  ccacgccttg  cccagcagtc  ctggagctgg  aggagctcct  gcgggcaggg  120
aagtcttctt  gcagccgtgt  ggacgaagtt  tggcccaacc  ttttcatagg  agatgcgatg  180
gactcactgc  agaagcagga  cctccggagg  cccaagatcc  atggggcagt  ccaggcatct  240
ccctaccagc  cgcccacatt  ggcttcgctg  cagcgtttgc  tgtgggtccg  tcaggctgcc  300
acactgaacc  atatcgatga  ggtctggccc  agcctcttcc  tgggagatgc  gtacgcagcc  360
cgggacaaga  gcaagctgat  ccagctggga  atcacccacg  ttgtgaatgc  cgctgcaggc  420
aagttccagg  tggacacagg  tgccaaatc  taccgtggaa  tgtccctgga  gtactatggc  480
atcgaggcgg  atgacaaccc  cttcttcgac  ctacgtgtct  actttctgcc  tggtgtctga  540
tacatccgag  ctgccctcag  tgttcccaa  ggccgcgtgc  tggtagactg  tgccatgggg  600
gtaagccgct  ctgccacact  tgtcctggcc  ttctcatga  tctatgagaa  catgacgtg  660
gtagaggcca  tccagacggt  gcaggccac  cgcaatatct  gccctaactc  aggcttcctc  720
cggcagctcc  aggttctgga  caaccgactg  gggcgggaga  cggggcgggt  ctgatctggc  780
aggcagccag  gatccctgac  ccttgccca  accccaccag  cctggccctg  ggaacagcag  840
gctctgctgt  ttctagtac  cctgagatgt  aaacagcaag  tgggggctga  ggcagaggca  900
gggatagctg  ggtggtgacc  tcttagcggg  tggatttccc  tgaccaatt  cagagattct  960
ttatgcaaaa  gtgagttcag  tccatctcta  taataaaata  ttcacgtca  taaaaaaaaa  1020
aaa  1023

```

<210> 43

<211> 4416

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<223> Incyte Clone Number: 1213802

<400> 43

```

gaaatTTTTt tctgcctcat tattattaat tcatggattg agtgttggtt cgacctacag 60
gcgtaataga ttggaactca gtgaagacac agatgttcct gttcagagca accagctaatt 120
gattacagtt taaagacaat ttctgtgatc aagttgtcat ttggaagatt aaacccattt 180
cacgaggact tggagcctgg tccttgcttt gaggaagcag tggcttggtt caagaagcca 240
cttctgatct aagaatctac ccagcatgcc taatcaagga gaagactgct atTTTTTTTT 300
ctattccaca tgtaccaaag gcgacagctg cccattccgt cactgtgaag ctgcaatagg 360
aaatgaaact gtttgcacat tatggcaaga agggcgtgtt tttcgacagg tgtgcagggt 420
tcggcacatg gagattgata aaaaacgcag tgaaattcct tgttattggg aaaatcagcc 480
aacaggatgt caaaaattaa actgcgcttt ccatcacaat agaggacgat atgttgatgg 540
ccttttccta cctccgagca aaactgtgtt gccactgtg cctgagtcac cagaagagga 600
agtgaaggct agccaacttt cagttcagca gaacaaattg tctgtccagt ccaatccttc 660
ccctcagctg cggagcgtta tgaaagtaga aagttccgaa aatgttccta gccccacgca 720
tccaccagtt gtaattaatg ctgcagatga tgatgaagat gatgatgatc agttttctga 780
ggaaggatgt gaaacaaaa caccaccct gcaaccaact cctgaagttc acaatggatt 840
acgagtgact tctgtccgga aacctgcagt caatataaag caaggatgaat gtttgaattt 900
tggaataaaa actcttgagg aaattaagtc aaagaaaatg aaggaaaaat ctaagaagca 960
aggtgagggt tcttcaggag tttccagttt ttactccac cctgagcccg ttcagggtcc 1020
tgaaaaagaa aatgtcagga ctgtggtgag gacagtaact ctctccacca aacaaggaga 1080
agaacccttg gttagattga gtcttactga gagactgggg aaacgaaaat tttcagcagg 1140
cggtgacagt gatcctccat taaagcgtag cctggcacag aggctaggga agaaagtga 1200
agctccagaa actaacattg acaaacacac aaagaaagct caagtttcca agtctcttaa 1260
ggagcgatta ggcattgcag ctgatccaga taatgaggat gcaacagata aagttaataa 1320
agttggttag atccattgta agacattaga agaaattctt ctgaaaagag ccagtcagaa 1380
acgtggagaa ttgcaaaact aactcaagac agaaaggacct tcaaaaactg atgattctac 1440
ttcaggagca agaagctcct ccactatccg tatcaaaacc ttctctgagg tcctggctga 1500
aaaaaaacat cggcagcagg aagcagagag acaaaaaagc aaaaaggata caacttgcatt 1560
caagctaaag attgatagtg aaattaaaaa aacagtagtt ttgccacca ttgttgccag 1620
cagaggacaa tcagaggagc ctgcaggtaa acaaaagtct atgcaggagg tgcacatcaa 1680
gacgctggaa gaaattaaac tggagaaggc actgagggtg cagcagagct ctgagagcag 1740
caccagctcc ccgtctcaac acgaggccac tccaggggca aggcggctgc tgcgaatcac 1800
caaaagaaca gggatgaaag aagagaagaa ccttcaggaa ggaaatgaag ttgattctca 1860
gagcagtatt agaacagaag ctaaaagggc ttcagggtgag accacaggag ttgacatcac 1920
taaaattcaa gtcaagagat gtgagccat gagagagaag cacatgcaga aacagcagga 1980
gagggaaaaa tcagtcttga cacctcttcg gggagatgta gcctcttgca ataccaagt 2040
ggcagagaaa ccagtgtcct ctgctgtgcc aggaatcaca cggcacctga ccaagcggct 2100
tcccacaaag tcatccaga aggtggaggt agaaacctca gggattggag actcattatt 2160
gaatgtgaaa tgtgcagcac agaccttga aaaaaggggt aaagctaaac ccaaagtga 2220
cgtgaagcca tctgtggtta aagttgtgtc atcccccaa ttggcccaa aacgtaaggc 2280
agtggagatg cacgctgtct tcatgtccgc tgtgaagcca ctgagctcca gcagtgtcct 2340
acaggaaccc ccagccaaa aggcagctgt ggctgtgtgc ccgcttgtct ctgaggacaa 2400
atcagtcact gtgctgaag cagaaaatcc tagagacagt cttgtgtctgc ctccaacca 2460
gtcctcttca gattcctcac cccggagggt gtctggccct tctcatccc aaatgagcat 2520
gaaaactcgc cgactcagct ctgctcaac aggaagccc ccactctctg tggaggatga 2580
ttttgagaaa ctaatatggg agatttcagg aggcataatt gaagctgaga ttgacctgga 2640
tcctgggaaa gatgaagatg accttctgct tgagctatca gaaatgattg atagctgaag 2700
gtggtagtga ggacacttta aaaaaaaat cgccaaaaaa ctggacttag tttcatctat 2760
tgtaacattt acctgagatg atcatttctt tagtctagaa tttgccccaa atcagaagta 2820
tacctctgaa ttatctgtat gtgtcctgga ttccttgggg tcagattttt aaagttaact 2880

```

```

tataaccatt ttgtccattt gatgccattg tttatcatct tttgagaaaa aagttctgtc 2940
atacccttct ctccacaaaa aagagactga gagggagatc aagtgaagg gtgcaagcga 3000
acttagtgac tccttgaggt gtttgcagt tttggttttt ttcttctttg ttgtattctt 3060
tatgtattgt cttgatgtac ttaatattac ctgagtttga aatggatgaa gacagctgct 3120
accattaagg accaaatttt atgctaccac taaacaaaaa taccactca gtctgtgtta 3180
aattgtatgt ctttttaaag gtatttaaag attcaactaa gctttaaaga gggctgagca 3240
gctcaggaag cctgtaatgt gggcataact ctttggacct gatcttgatg cttctgtgct 3300
tctgttagcc tctgaagagc aatatctaatt ttattattac tgtaattttt taaaaggctt 3360
taaagtgcct caggggtccc ctgaaactaa ttttctattt ctgggattcc ctggattcat 3420
tatatgagat ggtgacatga ttagaggaat tcttttttag tatgaaaatt gtcccttttc 3480
ttcttcagta cttgcctcct tgctggcatt gaattaacac agggacaaaa tttggttaat 3540
tttttatttc taactctccc aacaaacccc tgttgcccag tatttgtttg gtggccttta 3600
accacctgag ggaaaaaatg agcttattca agctgccaat atttatctat gggctgtagc 3660
agtacactga attgtactgt gccagggata ttgagatgct ctgggggtgt attgtatacc 3720
tgccagtttt cttcatttct gaattgagtt ttcttttctt gatgttggtt tccttcata 3780
cacctcaagg tttagatttg tgaaggaata agcatgatgg aaataatagt cttgaaagga 3840
gatatgttgt atataatcag gaggaagagg aaggaaggac ttaccatttt tgatattttg 3900
ctgtagggtg ccagttttgt ttctcatagg gaaatctgac ccacctgtca tgttggtctc 3960
taaggaactg ctgttgtaag cggctcatca agagttgaac ttcacgtagc cttgttgga 4020
atatggaaga ggaagaaagc cacaggactg cccattcagt cttgggaaga ttgggatgat 4080
tctgcacaag caaaaatgac tgaagtttat ctatagacac acctctacca atccatcttc 4140
agctgactga atgttgtatg atagcccttc tccaaagcag aggtagaatg ttcaggtttc 4200
accatggatt ttctacttat ttctgttttg gaatcagctt acagattcca ggtccctttt 4260
gtatatattc tttattcttt tgctttttta aaaaataatt ttgtttcata tttaaagcac 4320
ttgtattagt caatgtttcg tgttcgcgat tatttgaacc atttgccctt acagaaagag 4380
aaatacttgt ttgtgtttta aataaaactg atgtag 4416

```

<210> 44

<211> 2068

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 1378134

<400> 44

```

gcagtcctac agtccgctga tgcgtcgccg ggccagcaac gctgccgccc cagcccacac 60
gattggcggc agtaagcaca caatgaatga tcacctgcat gtcggcagcc acgctcacgg 120
acagatccag gttecgacagt tgtttgagga taacagtaac aagcggacag tgctcacgac 180
acaaccaaatt gggcttacia cagtgggcaa aacgggcttg ccagtgggtg cagagcggca 240
gctggacagc attcatagac ggcaggggag ctccacctct ctaaaagtcca tggaaaggcat 300
ggggaagggtg aaagccaccc ccatgacacc tgaacaagca atgaagcaat acatgcaaaa 360
actcacagcc ttcgaacacc atgagatttt cagctaccct gaaatatatt tcttgggtct 420
aaatgctaag aagcgccagg gcatgacagg tgggcccac aatggtgggt atgatgatga 480
ccagggatca tatgtgcagg tgccccacga tcacgtggct tacaggtatg aggtcctcaa 540
ggtcattggg aaggggagct ttgggcaggt ggtcaaggcc tacgatcaca aagtcacca 600
gcacgtggcc ctaaaagatg tgcggaatga gaagcgcttc caccggcaag cagcggagga 660
gatccgaatc ctggaacacc tgcggaagca ggacaaggat aacacaatga atgtcatcca 720
tatgtctggg aatttcacct tccgcaacca catctgcatg acgtttgagc tgctgagcat 780
gaacctctat gagctcatca agaagaataa attccagggc ttcagtctgc ctttgggtcg 840
caagtttgcc cactcgattc tgcagtgtt ggatgctttg cacaataaca gaataattca 900
ctgtgacctt aagcccagga acattttgtt aaagcagcag ggtagaagcg gtattaaagt 960
aattgatttt ggctccagtt gttacgagca tcagcgtgtc tacacgtaca tccagtcgag 1020
tttttaccgg gctccagaag tgatccttgg ggccaggatg ggcatgcccc ttgatattgt 1080

```

```

gagcctgggc tgcatttttag cagagctcct gacgggttac cccctcttgc ctggggaaga 1140
tgaaggggac cagctggcct gtatgattga actgttgggc atgccctcac agaaactgct 1200
ggatgcatcc aaacgagcca aaaattttgt gagctccaag gggtatcccc gttactgcac 1260
tgtcacgact ctctcagatg gctctgtggt cctaaacgga ggccgttccc ggagggggaa 1320
actgaggggc ccaccggaga gcagagagtg ggggaacgcg ctgaaggggt gtgatgatcc 1380
ccttttcctt gactttctaa aacagtgttt agagtgggat cctgcagtgc gcatgacccc 1440
aggccaggct ttgcggcacc cctggctgag gaggcggtg ccaaagcctc ccaccgggga 1500
gaaaacgtca gtgaaaagga taactgagag caccggtgct atcacatcta tatccaagtt 1560
acctccacct tctagctcag cttccaaact gaggactaat ttggcgagga tgacagatgc 1620
caatgggaat attcagcaga ggacagtgtt gccaaaactt gttagctgag ctcacgtccc 1680
ctgatgctgg taacctgaaa gatacgacat tctactcatt tactgggttg aaaaggagta 1740
gctcagacct gtttttattt gctcaataac tctactcatt tgatatcttt cagcacttaa 1800
ttttaatgta agaaagtgtt tcattttgtt ttataaaaat acatgaggac aatgctttta 1860
gtttttatac tttcagaaac tttttgtgtt ctaaaagtac aatgagcctt actgtattta 1920
gtgtggcaga ataataacat cagtggcagg ccactgatta cttcatgact gccacgcatt 1980
tacagattgg tgtcaaagac attcactatg tttttatggt tcatgttata tcctccccag 2040
ggtgacagcc ccttaaggcc ctctcttt 2068

```

<210> 45

<211> 1850

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 1490070

<400> 45

```

gggctgcctg cctgcctgcc tgcctgcctg gcccgggccg agctccagcc tgcctcttcc 60
actggccact gcctccacc cagggctggc atccctgctc cctgccctgg gtcccagact 120
gtgtcctcca tcaccgcagg tcggtgaggg gctgggctgg acaccagggc ccgccctccc 180
atcactgagc tccactcctt cctcattttg ctgctgattc tagcccaaaa caaacagggt 240
tgagcttttt cctccctca gaagctctc tctggctcgt ggctgccttc tgagtgttgc 300
agacggcgcc ggccgggaag gggggcctgg gccagccctg ccaggactgg gacgtgctg 360
ctggcgctg gccctccatc aggccagcct gtggcaggag agtgagcttt gcccgggcag 420
acgcctgagg atgatgcccc agctgcagtt caaagatgcc ttttgggtgca gggacttcac 480
agccacacg ggctacgagg tgctgctgca gcggtctctg gatggcagga agatgtgcaa 540
agacatggtg gagtactgt ggcagagggc ccaggcggag gagcggtacg ggaaggagct 600
ggtgcagatc gcacggaagg caggtggcca gacggagatc aactccctga ggcctcctt 660
tgactccttg aagcagcaaa tggagaatgt gggcagctca cacatccagc tggccctgac 720
cctgcgtgag gagctgcgga gtctcgagga gtttcgtgag aggcagaagg agcagaggaa 780
gaagtatgag gccgtcatgg accgggtcca gaagagcaag ctgtcgctct acaagaaggc 840
catggagtcc aagaagacat acgagcagaa gtgccgggac gcggacgacg cggagcaggc 900
cttcgagcgc attagcgcca acggccacca gaagcagggtg gagaagagtc agaacaaagc 960
caggcagtgc aaggactcgg ccaccgaggc agagcgggta tacaggcaga gcattgcgca 1020
gctggagaag gtccgggctg agtgggagca ggagcaccgg accacctgtg aggcctttca 1080
gctgcaagag tttgaccggc tgaccattct ccgcaacgcc ctgtgggtgc acagcaacca 1140
gctctccatg cagtgtgtca aggatgatga gctctacgag gaagtgcggc tgacgttga 1200
aggctgcagc atagacggc acatcgacag tttcatccag gccaaagca cgggcacaga 1260
gcccccgct ccggtgccct accagaacta ttacgatcgg gaggtcacc cgtgaccag 1320
cagccctggc atacagcgt cctgcggcat gataaagagg ttctctggac tgctgcacgg 1380
aagtcccaag accacttcgt tggcagcttc tgctgcgtcc acagagacc tgacccccac 1440
ccccgagcgg aatgaggggt tctacacagc catcgagtg caggagatac agggaaaccc 1500
ggcctcacca gcccgaggat accgggcgct ctacgattat acagcgcaga acccagatga 1560
gctggacctg tccgggggag acatcctgga ggtgatcctg gaaggggagg atggctgggt 1620

```

```

gactgtggag aggaacgggc agcgtggctt cgtccctggg tcctacctgg agaagctttg 1680
aggaaggggc aggagccctt tcggacctgc cctgccagtg gagccagcag tgccccagc 1740
actgtcccca ccttgctagg gccagaacc aagcgtcccc cagccccgag agggagcctg 1800
tcgtctccca gggaataaag gagtgcgttc tgttctcaaa aaaaaaaaaa 1850

```

<210> 46

<211> 2534

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 1997814

<400> 46

```

gaagagggga tggagcaggg gctggaggag gaagaagagg tggatccccg gatccagggg 60
gaactggaga agttaaatca gtccacggat gatatcaaca gacgggagac tgaacttgag 120
gatgctcgtc agaagtcccg ctctgttctg gttgaagcaa cggtgaaact ggatgaactg 180
gtgaagaaaa ttggcaaagc tgtggaagac tccaagccct actgggagggc acggaggggtg 240
gcgaggcagg ctgagctgga agctcagaaa gccacgcagg acttcagag ggccacagag 300
gtgctccgtg ccgccaagga gaccatctcc ctggccgagc agcggctgct ggaggatgac 360
aagcggcagt tcgactccgc ctggcaggag atgctgaatc acgccactca gagggtcatg 420
gaggcggagc agaccaagac caggagcgag ctggtgcata aggagacggc agccaggtac 480
aatgccgcca tgggccgcat gcgacagctg gagaagaaac tcaagagagc catcaacaag 540
tccaagcctt attttgaact caaggcaaag tactatgtgc agctcgagca actgaaaaag 600
actgtggatg acctgcaggc caaactgacc ctggcaaaag gcgagtacaa gatggccctg 660
aagaacctgg agatgatctc agatgagatc cacgagcggc ggcgctccag tgccatgggg 720
cctcggggat gcggtgttgg tgctgagggc agcagcacat ctgtggagga tctgccaggg 780
agcaaacctg agcctgatgc catttctgtg gcctcggagg cctttgaaga tgacagctgt 840
agcaactttg tgtctgaaga tgactcggaa acccagtcgg tgtccagctt tagttcagga 900
ccaacaagcc cgtctgagat gcctgaccag ttccctgcgg ttgtgaggcc tggcagcctg 960
gatctgcccc gccctgtgtc cctgtcagag ttgggatga tgttcccagt gttgggccc 1020
cgaagtgaat gcagcggggc ctccctccct gaatgtgaag tagaacgagg agacagggca 1080
gaaggggcag agaataaaac aagtgacaaa gccaacaaca accggggcct cagcagtagc 1140
agtggcagtg gtggcagcag taagagccaa agcagcacct cccctgaggg ccaggccttg 1200
gagaaccgga tgaagcagct ctccctacag tgctcaaagg gaagagatgg aattattgct 1260
gacataaaaa tgggtgcagat tggctgattc atcctggggc ctggccgatg tgcataatca 1320
catttataca tggaaactgga gaacattgtg ccaataatca tttaatatat gccaaatctt 1380
acacgtctac tctaaactgc tctaatgaag ttccagtgc cttgagggct aaagattgtt 1440
cttctgggta agagctcttg ggctggtttt tcagagcaga gttcttgttg tgggtagact 1500
gtgactaggt tcacagcctt tgtggaacat tccgtataac ggcattgttg aagcaataac 1560
tagttcctat gaaagaacca gagctgggaa gatggctggg aagccaggcc aaagtggggg 1620
caacagcttg cttctcttcc tcttctcacc ctgagtttgt atgggaaaaat ggagatgtcc 1680
tctccacttt atcccacgat atctaaatga aaaagaaaga aaaccacac acaaagcaa 1740
aactcaagta ttaagagcac atatttttga cccagtggag gcttaaaaaa aaaaaatcc 1800
aagaacacaa ttcattttca ccacctctgg tgttcagagg gggcttttaa aaaagcgtgt 1860
atgctgggat acccattaaa accattttct agaaggctac catgagctgc actttttggg 1920
gtgggaaagg tgaatgccag tggggatgcg gggggatgag ggtaggaggg acttatagaa 1980
ggggatttgt ggctgtgggg gagaagggtc tacagcataa gccttatcct gccagccaag 2040
gggatttatt ctaagagaag tgcatgtgaa gaatggttgc cactgttatt agattgacaa 2100
gatgttaatt tctctgtagg ttgtaacttt aaaaataaat gaaattattt aagggttatg 2160
ctgcactagt attccttaga ggaaacagtt ctttaaagtt aggaaaggga gtaggcaggc 2220
atgtgttggc aaaggctgtt aatagtagtt aagtgttaag actgcttttc tttaacgttt 2280
tcatggtaat gcatatttag agcactgtat ttttgtcttg ttaagaaaat ttagcatttc 2340
taaaagaaaa aagcaaccct ctttcaaact gtttaattctg tcacagcctg tatattttag 2400

```

```
tcatttgtaa atctcttcat acaatagtga cttctttttt gactgataca gtatcttaat 2460
tacaagggtta ttttgactt gtcttaatac actaagtgtataaaaaacgg cttgagaaaa 2520
gttaaaaaaa aaaa 2534
```

<210> 47

<211> 3786

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2299715

<400> 47

```
ccgtcctcga ggcgaggaga gtaccggggc ggcccggctg ccgcgcgagg agcgcggctcg 60
gcggcctggg ctgcggctga gatacacaga gcgacagaga catttattgt tatttgtttt 120
ttgggtggcaa aaagggaaaa tggcgaacga cccccctgca aaaagctctgg tggacatcga 180
cctctcctcc ctgcgggatc ctgctgggat ttttgagctg gtggaagtgg ttggaatgg 240
cacctatgga caagtctata agggtcgaca tgtaaaaacg ggtcagttgg cagccatcaa 300
agttatggat gtcactgagg atgaagagga agaaatcaaa ctggagataa atatgctaaa 360
gaaatactct catcacagaa acattgcaac atattatggt gctttcatca aaaagagccc 420
tccaggacat gatgaccaac tctggcttgt tatggagttc tgtggggctg ggtccattac 480
agaccttggt aagaacacca aagggaacac actcaaagaa gactggatcg cttacatctc 540
cagagaaatc ctgaggggac tggcacatct tcacattcat catgtgattc accgggatat 600
caagggccag aatgtgttgc tgactgagaa tgcaggggtg aaacttgttg actttggtgt 660
gagtgtctag ctggacagga ctgtggggcg gagaaatacg ttcataggca ctcctactcg 720
gatggctcct gaggtcatcg cctgtgatga gaaccagat gccacctatg attacagaag 780
tgatctttgg tcttggtggc ttacagccat tgagatggca gaagtgctc cccctctctg 840
tgacatgcat ccaatgagag cactgtttct cattcccaga aacctcctc cccggctgaa 900
gtcaaaaaaa tggtcgaaga agtttttttag ttttatagaa ggggtgcctgg tgaagaatta 960
catgcagcgg cctctacag agcagctttt gaaacatcct tttataaggg atcagccaaa 1020
tgaaaggcaa gttagaatcc agcttaagga tcatatagat cgtaccagga agaagagagg 1080
cgagaaagat gaaactgagt atgagtacag tgggagttag gaagaagagg aggaagtgcc 1140
tgaacaggaa ggagagccaa gttccattgt gaacgtgcct ggtgagtcta ctcttcgccg 1200
agatttcctg agactgcagc aggagaacaa ggaacgttcc gaggtctctc ggagacaaca 1260
gttactacag gagcaacagc tccgggagca ggaagaatat aaaaggcaac tgctggcaga 1320
gagacagaag cggattgagc agcagaaaga acagaggcga cggctagaag agcaacaaag 1380
gagagagcgg gaagctagaa ggcagcagga acgtgaacag cgaaggagag aacaagaaga 1440
aaagaggcgt ctagaggagt tggagagaag gcgcaaagaa gaagaggaga ggagacgggc 1500
agaagaagaa aagaggagag ttgaaagaga acaggagtat atcaggcgac agctagaaga 1560
ggagcagcgg cacttggaa gtccttcagca gcagctgctc caggagcagg ccatgttact 1620
gcatgaccat aggaggccgc accgcagca ctgcgagcag ccgccaccac cgcagcagga 1680
aaggagcaag ccaagcttcc atgctcccga gcccaaagcc cactacgagc ctgctgaccg 1740
agcgcgagag gttcctgtga gaacaacatc tcgctcccct gttctgtccc gtcgagattc 1800
cccactgcag ggcagtgggc agcagaatag ccaggcagga cagagaaact ccaccagtat 1860
tgagcccagg cttctgtggg agagagtggg gaagctgggt cccagacctg gcagtggcag 1920
ctctcaggg tccagcaact caggatccca gcccggtct caccctgggt ctcagagtgg 1980
ctccggggaa cgcttcagag tgagatcatc atccaagtct gaaggctctc catctcagcg 2040
cctggaaaaa ccagtgaaaa aacctgaaga taaaaaggaa gttttcagac ccctcaagcc 2100
tgctgatctg accgcaactg ccaaagagct tcgagcagtg gaagatgtac ggccacctca 2160
caaagtaacg gactactcct catccagtga ggagtgggg acgacggatg aggaggacga 2220
cgatgtggag caggaagggg ctgacgagtc cacctcagga ccagaggaca ccagagcagc 2280
gtcatctctg aatttgagca atggtgaaac ggaatctgtg aaaacctga ttgtccatga 2340
tgatgtagaa agtgagcccg ccatgacccc atccaaggag ggcactctaa tcgtccgccca 2400
gactcagtc gctagtagca cactccagaa acacaaatct tcctcctcct ttacaccttt 2460
```

```

tatagacccc agattactac agattttctcc atctagcgga acaacagtga catctgtggt 2520
gggattttcc tgtgatggga tgagaccaga agccataagg caagatccta cccggaaagg 2580
ctcagtggtc aatgtgaatc ctaccaacac taggccacag agtgacaccc cggagattcg 2640
taaatacaag aagaggttta actctgagat tctgtgtgct gccttatggg gagtgaattt 2700
gctagtgggt acagagagtg gcctgatgct gctggacaga agtggccaag ggaaggtcta 2760
tctcttatac aaccgaagac gatttcaaca aatggacgta cttgagggct tgaatgtctt 2820
ggtgacaata tctggcaaaa aggataagtt acgtgtctac tatttgtcct ggtaagaaa 2880
taaaatactt cacaatgatc cagaagttga gaagaagcag ggatggacaa ccgtagggga 2940
tttggaagga tgtgtacatt ataaagttgt aaaatatgaa agaatcaaatt ttctggtgat 3000
tgctttgaag agttctgtgg aagtctatgc gtgggcacca aagccatatc acaaatttat 3060
ggcctttaag tcatttgagg aattggtaca tggatcctgt gctggattcc atgctgttga 3120
tgtggattca ggatcagttc atgacattta tctaccaaca catatccagt gtagcatcaa 3180
accccatgca atcatcatcc tccccaatc agatggaatg gagcttctgg tgtgctatga 3240
agatgagggg gtttatgtaa acacatatgg aaggatcacc aaggatgtag ttctacagtg 3300
gggagagatg cctacatcag tagcatatat tcatccaat cagacaatgg gctggggaga 3360
gaaggccata gagatccgat ctgtggaaac tggtcacttg gatggtgtgt tcatgcacaa 3420
aagggctcaa agactaaaat tcttgtgtga acgcaatgac aaggtgttct ttgcctctgt 3480
tcggctcgtt ggcagcagtc aggtttatct catgacctta ggcaggactt ctcttctgag 3540
ctggtagaag cagtgtgatc cagggattac tggcctccag agtcttcaag atcctgagaa 3600
cttggaattc cttgtaactg gagctcggag ctgcaccgag ggcaaccagg acagctgtgt 3660
gtgcagacct catgtgttgg gttctctccc ctcttctctg ttctcttat ataccagttt 3720
atccccatcc tttttttttt tcttactcca aaataaatca aggtgcaat gcagctgggtg 3780
ctgtta

```

<210> 48

<211> 1182

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 209854

<400> 48

```

gttgggtgaag tcaagcgaag gcgactagag ctccaggagg gccagttctg tgggctctag 60
tcggccatat taataaagag aaaggggaagg ctgaccgtcc ttcgcctccg cccccacata 120
cacaccctt ctteccactc cgtctctcag actaagctct cacgattaag gcacgcctgc 180
ctcgattgtc cagcctctgc cagaagaaaag cttagcagcc agcgcctcag tagagacct 240
agggcgctga atgagtggga aagggaaatg ccgaccaatt gcgctgcggc gggctgtgac 300
actacctaca acaagcacat taacatcagc ttccacaggt ttctttgga tcctaaaaga 360
agaaaagaat gggttcgctt ggttaggcgc aaaaattttg tgccaggaaa acacactttt 420
ctttgttcaa agcactttga agcctcctgt tttgacctaa caggacaaac tcgacgactt 480
aaaatggatg ctgttccaac catttttgat tttgtaccc atataaagtc tatgaaactc 540
aagtcaagga atcttttgaa gaaaaacaac agttgttctc cagctggacc atctaattta 600
aaatcaaca ttagtagtca gcaagtacta cttgaacaca gctatgcctt taggaatcct 660
atggaggcaa aaaagaggat cattaaactg gaaaaagaaa tagcaagctt aagaagaaaa 720
atgaaaactt gcctacaaaa ggaacgcaga gcaactcgaa gatggatcaa agccacgtgt 780
ttggtaaaag atttagaagc aaatagtgtg ttacctaaag gtacatcaga acacatgtta 840
ccaactgcct taagcagttc tcctttggaa gatttttga tctttgaaca agatcaacaa 900
gataaaacac tgctaagtct aaatctaaaa cagaccaaga gtacctcat ttaaatttag 960
cttgcacaga gcttgatgcc tatccttcat tcttttcaga agtaaagata attatggcac 1020
ttatgccaaa attcattatt taataaagtt ttacttgaag taacattact gaatttgtga 1080
agacttgatt acaaaaagaat aaaaaacttc atatggaaat tttatttgaa aatgagtggg 1140
agtgccttac attagaatta cggactttca aaactatgat aa

```

<210> 49
<211> 1676
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone Number: 1384286

<400> 49
tcgccgagcc cgtccgccgc cgccatggcc accacgggtga cctgcacccg cttcacccgac 60
gagtaccagc tctacgagga tattggcaag ggggctttct ctgtgggtccg acgctgtgtc 120
aagctctgca ccggccatga gtatgcagcc aagatcatca acaccaagaa gctgtcagcc 180
agagatcacc agaagctgga gagagaggct cggatctgcc gccttctgaa gcattccaac 240
atcgtgcgtc tccacgacag catctccgag gagggttcc actacctggt cttcgatctg 300
gtcactgggtg gggagctctt tgaagacatt gtggcgagag agtactacag cgaggctgat 360
gccagtcact gtatccagca gatcctggag gccgttctcc attgtcacca aatgggggtc 420
gtccacagag acctcaagcc ggagaacctg cttctggcca gcaagtgcaa aggggctgca 480
gtgaagctgg cagacttcgg cctagctatc gaggtgcagg gggaccagca ggcattggtt 540
ggtttcgctg gcacaccagg ctacctgtcc cctgagggtcc ttcgcaaaga ggcgtacggc 600
aagcccgtgg acatctgggc atgtgggggtg atcctgtaca tcctgctcgt gggctaccca 660
cccttctggg acgaggacca gcacaagctg taccagcaga tcaaggctgg tgcctatgac 720
ttcccgtccc ctgagtggga caccgtcact cctgaagcca aaaacctcat caaccagatg 780
ctgaccatca accctgccaa gcgcatacaca gcccatgagg ccctgaagca cccgtgggtc 840
tgccaacgct ccacggtagc atccatgatg cacagacagg agactgtgga gtgtctgaaa 900
aagttcaatg ccaggagaaa gctcaaggga gccatcctca ccaccatgct ggccacacgg 960
aatttctcag cagccaagag ttactcaac aagaaagcag atggagtcaa gccccatacg 1020
aatagacca aaaacagtgc agccgccacc agccccaag ggacgcttcc tcctgccgcc 1080
ctggagtctt ctgacagtgc caataccacc atagaggatg aagacgctaa agcccgaag 1140
caggagatca ttaagaccac ggagcagctc atcgaggccg tcaacaacgg tgactttgag 1200
gcctacgca aaatctgtga ccaggggtg acctcgtttg agcctgaagc actgggcaac 1260
ctggttgaag ggatggactt ccacagattc tacttcgaga acctgctggc caagaacagc 1320
aagccgatcc acacgaccat cctgaaccca cactgcacg tcattggaga ggatgccgcc 1380
tgcctcgtt acatccggct cagcagtagc attgacgggc agggccggcc ccgcaccagc 1440
cagtctgagg agaccgcgt gtggcaccgc cgcgacggca agtggcagaa cgtgcacttc 1500
cactgctcgg gcgcgcctgt ggcccgcgtg cagtgaagag ctgcgccctg gtttcgccgg 1560
acagagttgg tgtttgagc ccgactgccc tcgggcacac ggcctgcctg tcgcatgttt 1620
gtgtctgcct cgttccctcc cctgggtgct gtgtctgcag aaaaacaagc ccgact 1676

<210> 50
<211> 1597
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte Clone Number: 1512656

<400> 50
tcggccttcg gaaagacccc cgggccgggg caccggagaga gccgagcgcc gcagccgtga 60
gccgaataga gccggagaga cccgagtatg accggagaag cccaggccgg ccggaagagg 120
agccgagcgc ggccggaagg aaccgagccc gtccgaaggg agcggacgca gcctggcctg 180
gggcccggtc gagcccgcgc catggcggcc gaggcgacag ctgtggccgg aagcggggct 240
gttggcggct gcctggccaa agacggcttg cagcagtcta agtggccgga cactacccca 300
aaacggcggc gcgcctcgtc gctgtcgcgt gacgcgagc gccgagccta ccaatggtgc 360


```

cgggagtact tgggcggggc ctggcgccga gtgcagcccg aggagctgag ggtttacccc 420
gtgagcggag gcctcagcaa cctgctcttc cgctgctcgc tcccggacca cctgcccagc 480
gttggcgagg agccccggga ggtgcttctg cggctgtacg gagccatctt gcagggcgctg 540
gactccctgg tgctagaaag cgtgatgttc gccatacttg cggagcggtc gctggggccc 600
cagctgtacg gagtcttccc agagggccgg ctggaacagt acatcccaag tcggccattg 660
aaaactcaag agcttcgaga gccagtgttg tcagcagcca ttgccacgaa gatggcgcaa 720
tttcatggca tggagatgcc tttcaccaag gagccccact ggctgttttg gaccatggag 780
cggtagcctaa aacagatcca ggacctgccc ccaactggcc tccctgagat gaacctgctg 840
gagatgtaca gcctgaagga tgagatgggc aacctcagga agttactaga gtctaccca 900
tcgccagtcg tcttctgcca caatgacatc caggaaggga acatcttgct gctctcagag 960
ccagaaaatg ctgacagcct catgctggtg gacttcgagt acagcagtta taactatagg 1020
ggctttgaca ttgggaacca tttttgtgag tgggtttatg attatactca cgaggaatgg 1080
cctttctaca aagcaaggcc cacagactac cccactcaag aacagcagtt gcattttatt 1140
cgtcattacc tggcagaggc aaagaaagggt gagaccctct cccaagagga gcagagaaaa 1200
ctggaagaag atttctggtt agaagtcagt cggtatgctc tggcatccca tttcttctgg 1260
ggtctgtggt ccacctcca ggcatccatg tccaccatag aatttggtta cttggactat 1320
gccagtcctc ggttccagtt ctacttccag cagaaggggc agctgaccag tgtccactcc 1380
tcacctgac tccacctcc cactccttg atttctctc gagcctccag ggcaggacct 1440
tggagggagg aacaacgagc agaaggccct ggcgaactgg ctgagcccc aagtgaact 1500
gaggttcagg agaccggcct gttcctgagt ttgagtaggt ccccatggct ggcaggccag 1560
agccccgtgc tgtgtatgta acacaataaa caagctg 1597

```

<210> 51

<211> 2145

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2098635

<400> 51

```

cccacgcgtc cggacagctt gaccagttt gctttccaat caaaggcat ttattttgaa 60
tgtctctttg tggcgcaaga gccaacgcaa aaatgatggc ggcttacaat ggcggtacat 120
ctgcagcagc agcaggtcac caccaccacc atcaccacca ccttcacac ctccctctc 180
ctcacctgct tcaccaccac caccctcaac accatcttca tccggggtcg gctgccgctg 240
tacaccctgt acagcagcac acctcttcgg cagctgcggc agccgcagca gcggctgcag 300
ctgcagccat gttaaaccct gggcaacaac agccatattt cccatcaccg gcaccggggc 360
aggctcctgg accagctgca gcagcccag ctcaggtaca ggctgccgca gctgtacag 420
ttaaggcgca ccatcatcag cactcgcac atccacagca gcagctggat attgagccg 480
atagacctat tggatatgga gcctttgggtg ttgtctggtc agtaacagat ccaagagatg 540
gaaagagagt agcgctcaaa aagatgcccc acgtcttcca gaatctggtc tcttgcaaaa 600
gggtcttcgg ggaattgaag atgttgtgtt tttttaagca tgataatgta ctctctgccc 660
ttgacatact ccaacctcca cacattgact attttgaaga aatatatgtt gtcacagaat 720
tgatgcagag tgacctacat aaaattatcg tctctctca accactcagc tcagatcatg 780
tcaaagtttt tctttatcag attttgcgag gtttgaaata tctccattca gctggcattt 840
tacatcgaga cattaagcca gggaatctcc ttgtgaacag caactgtgtt ctaaagattt 900
gtgatttttg attggccaga gtggaagagt tagatgaatc ccgtcatatg actcaggaag 960
ttgttactca gtattatcgg gctccagaaa tccatgatgg cagccgtcat tacagcaatg 1020
ctattgacat cgtgtctgtg ggatgtatct ttgcagaact actaggacga agaatttgt 1080
ttcaggcaca gagtccatt cagcagttgg atttgatcac ggatctgttg ggcacacct 1140
cactggaagc aatgaggaca gcttgtgaag gcgctaagc acatatactc aggggtcctc 1200
ataaacagcc atctcttct gtactctata ccctgtctag ccaggctaca catgaagctg 1260
ttcatctcct ttgcaggatg ttggtctttg atccatccaa aagaatatcc gctaaggatg 1320
ccttagccca cccctaccta gatgaagggc gactacgata tcacacatgt atgtgtaaat 1380

```

```

gttgcttttc cacctccact ggaagagttt ataccagtga ctttgagcct gtcaccaatc 1440
ccaaatttga tgacactttc gagaagaacc tcagttctgt ccgacagggt aaagaaatta 1500
ttcatcagtt ctttttgaa cagcagaaaag gaaacagagt gcctctctgc atcaaccctc 1560
agtctgctgc ttttaagagc tttattagtt ccactgttgc tcagccatct gagatgcccc 1620
catctcctct ggtgtgggag tgatgggtga agataatgta ctactgaaga tgtaatgtag 1680
ctttccactg gagtctggga tttgcaattc tggagggtta tcatgcttgt actgtaattt 1740
tactaatgaa gttttaaatt aacaaccact acttgatga tatgaataat atttagaaat 1800
gttactagac ttttaatctt gtaaagtggg tgtgctttta gaagaaaaat attttaccac 1860
gagttgcaca tgttttatga atttagtgca gctgttatgg ctcacctcag aacaaaagag 1920
aattgaacca aatttgggag tttgggggtt tatgttttgt ttttcttttc taaaatgaag 1980
tgagattgtt cacacacaca cacacacaca cacacacaca cacaaacaca aaggacagtc 2040
atacattttg atatttgagc cattcctaaa gatttggggg tttctaaaac taaagaatct 2100
aggaaccttg cctgcgacca atcatggagc cacgtgagct gatcg 2145

```

<210> 52

<211> 1454

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2446646

<400> 52

```

gggttcgaat tgcaacggca gctgccgggc gtatgtgttg gtgctagagg cagctgcagg 60
gtctcgctgg gggccgctcg ggaccaattt tgaagaggta cttggccacg acttattttc 120
acctccgacc tttccttcca ggcggtgaga ctctggactg agagtggcct tcacaatgga 180
agggatcagt aatttcaaga caccaagcaa attatcagaa aaaaagaaat ctgtattatg 240
ttcaactcca actataaata tcccggcctc tccgtttatg cagaagcttg gctttggtac 300
tggggtaaat gtgtacctaa tgaaaagatc tccaagaggt ttgtctcatt ctccctgggc 360
tgtaaaaaag attaatccta tatgtaatga tcattatcga agtgtgtatc aaaagagact 420
aatggatgaa gctaagattt tgaaaagcct tcatcatcca aacattgttg gttatcgtgc 480
ttttactgaa gccaatgatg gcagtctgtg tcttgctatg gaatatggag gtgaaaagtc 540
tctaaatgac ttaatagaag aacgatataa agccagccaa gatccttttc cagcagccat 600
aattttaaaa gttgctttga atatggcaag aggggttaaag tatctgcacc aagaaaagaa 660
actgcttcat ggagacataa agtcttcaaa tgttgtaatt aaaggcgatt ttgaaacaat 720
taaaatctgt gatgtaggag tctctctacc actggatgaa aatatgactg tgactgacct 780
tgaggcttgt tacattggca cagagccatg gaaacccaaa gaagctgtgg aggagaatgg 840
tgttattact gacaaggcag acatatctgc ctttggcctt actttgtggg aaatgatgac 900
tttatcgatt ccacacatta atctttcaaa tgatgatgat gatgaagata aaacttttga 960
tgaaagtgat tttgatgatg aagcactata tgcagcgttg ggaactaggc cacctattaa 1020
tatggaagaa ctggatgaat cataccagaa agtaattgaa ctcttctctg tatgcactaa 1080
tgaagaccct aaagatcgtc cttctgctgc acacattgtt gaagctctgg aaacagatgt 1140
ctagtgatca tctcagctga agtgtggcct gcgtaaataa ctgtttatc caaaatattt 1200
acatagttac tatcagtagt tattagactc taaaattggc atatttgagg accatagttt 1260
cttgtaaca tatggataac tatttcta atgaaatatg cttatatttg ctataagcac 1320
ttggaattgt actgggtttt ctgtaaagtt ttagaaacta gctacataag tactttgata 1380
ctgctcatgc tgacttaaaa cactagcagt aaaacgctgt aaactgtaac attaaattga 1440
atgaccatta cttt 1454

```

<210> 53

<211> 3225

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2764911

<400> 53

```

tggagcaggg ggcggtttgg ttgcgcggta ctacgggtgc ccgccgaatg gggaggaggc 60
gaggagcgag ccgtgcggcc agagcgggaa agagactcgt ctttgcgtcc gagttctgga 120
gccgcgcgac cccgactcct ggggcgcgcg cagcggctgc gaggggacgg gcgtccgctg 180
tctcctgggt tcccctcgta gcgacccgcg ggatcgga aaaggagaa gatggaggag 240
gagggtagga gcagcggcgg cgcgcgggg accagcgcg acggcggcga cggaggagag 300
cagctcctca ctgtcaagca cgagctgcgg actgctaatt tgacaggaca tgctgagaag 360
gtgggaatag aaaattttga gtcctgaag gtcctaggaa ctggagctta tggaaaagta 420
tttctagttc gtaaaataag tggccatgat actggaaagc tgtatgccat gaaagttttg 480
aaaaaggcaa caatcgttca aaaggccaaa accacagagc atacaaggac agaacgaca 540
gtcctggaac acattaggca gtcgccattt ttggtaacat tacattatgc tttccagaca 600
gaaaccaaac ttcattctcat tttagattat ataaatggtg gtgaactttt taccatctt 660
tctcaaagag agcgtttcac agagcatgag gtgcagattt atgttgaga gatttgctt 720
gccctcgaac atctccacaa gttggggatt atatcgtg atattaagct tgagaatatt 780
ctacttgatt ctaatggcca tgtggtgctg acagattttg gtctgagtaa ggagtttgtg 840
gtctgatgaaa ctgaaagagc atattccttt tgtggaacta ttgaatacat ggcaccagat 900
attgtcagag ggggagattc aggacatgac aaggcagttg actggtggag ttgggtgtt 960
ctaattgtatg aattactaac tggagcatct cctttcactg ttgatggaga aaaaaattcc 1020
caagctgaga tatctaggag aatattaaaa agtgagcctc catatcccca agaaatgagt 1080
gcttttagcga aagacctaat tcagcgtctt ttgatgaaag atccaagaa gagattggga 1140
tgtggtccac gtgatgcaga tgaaatcaaa gaacatctct tctttcagaa aataaattgg 1200
gatgatttag ccgcaaaaaa agtgcctgca ccatttaagc cagtcattcg agatgaatta 1260
gatgtgagta actttgcaga agagttcaca gaaatggatc ccacttattc tcccgcagcc 1320
ctgccccaga gttctgagaa gctgtttcag ggctattcct ttgttgcctc ttccatccta 1380
ttcaagcgta atgcagctgt catagaccct ctacagtttc acatgggagt tgaacgtcct 1440
ggagtgaaca atgttgccag gagtgcattg atgaaggact ctccattcta tcaacactat 1500
gacctagatt tgaaggacaa acccctggga gaaggtagtt tttcaatttg tcgaaagtgt 1560
gtgcataaaa aaagtaacca agcttttgca gtcaaaaata tcagcaaaag gatggaagcc 1620
aatactcaaa aggaataaac agctctggaa ctctgtgaag gacaccccaa tattgtgaag 1680
ttgcatgaag tttttcatga tcagcttcac acgtttctag tgatggaaact tctgaatgga 1740
ggagaactgt ttgagcgcac taagaaaaag aagcacttca gtgagacgga agccagctac 1800
atcatgagga agcttggttc agctgtaagc cacatgcatg atgttgaggt ggtgcacagg 1860
gatctgaaac ctgagaattt attgttcacc gatgaaaatg acaatttgga aattaaaata 1920
attgttttg gatttgacg gctaaagcca ccgataatc agccctgaa gactccatgc 1980
ttcacccttc attatgccgc ccagagctc ttgaatcaga acggctacga tgagtcctgt 2040
gacctgtgga gcttgggctg cttttgtac acaatgttgt caggacaggt tcccttccaa 2100
tctcatgacc gaagtttgac gtgtaccagc gcggtggaaa tcatgaagaa aattaaaaag 2160
ggagattttc cttttgaagg agaagcctgg aagaatgtat cccaagaggc taaagatttg 2220
atccaaggac ttctcacagt agatccaaac aaaaggctta aaatgtctgg cttgaggtac 2280
aatgaatggc tacaagatgg aagtcagctg tcctccaatc ctctgatgac tccggatatt 2340
ctaggatctt ccggagctgc cgtgcatacc tgtgtgaaag caaccttcca cgcttttaac 2400
aaatacaaga gagaggggtt ttgccttcag aatgttgata agggcccttt ggctaagaga 2460
agaaaaatga aaaagactag caccagtacc gagacacgca gcagttccag tgagagttcc 2520
cattcttctt cctctcattc tcacggtaaa actacacca ccaagacact gcagcccagc 2580
aatcctgccg acagcaataa cccggagacc ctcttccagt tctcggactc agtagcttag 2640
gcatggtagg agtgtatcag tgatccattg cacctttatt cctcagcat atgcctgagg 2700
cgatctttta tgctttttaa aatgtttccc gttggtctca ttggaatctg cctcctaatt 2760
atttttttca ggaaaacctg tttggttatc ctcatcaca agcactggac agagaatgtt 2820
actgtgaata gagcacatat tactcttttt agcaacctag catgatgcca acaagactat 2880
tcttgaaaga gcaaaggttc ctgtaaatat aattagggct agatttgagc tgcttgtaag 2940
tcacagggtt tccagatgtc tgccaacaag aaatgactca tactgtgatg ataccttttg 3000
ctttgccttg tggacaatgt gggtttttga aatttgcacc cttcaacaa tgatttatca 3060

```

gagaaagggg tctgttttca aaaaagattc tgtaaatgaat tttatgtgtg gcatatactt 3120
atctcttgag agaagatttt aacttattgt ttttatttta tggttacata tgatgataac 3180
ctgctattat taaacttttt ctaaaaagtg aaaaaaaaaa aaaaa 3225

<210> 54

<211> 2110

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 3013946

<400> 54

tcgccgagcc cgtccgcgcg cgccatggcc accacgggtga cctgcacccg cttcacccgac 60
gagtaccagc tctacgagga tattggcaag ggggctttct ctgtgggtccg acgctgtgtc 120
aagctctgca ccggccatga gtatgcagcc aagatcatca acaccaagaa gctgtcagcc 180
agagatcacc agaagctgga gagagaggct cggatctgcc gccttctgaa gcattccaac 240
atcgtgcgtc tccacgacag catctccgag gagggcttcc actacctggc cttcgatctg 300
gtcactgggtg gggagctctt tgaagacatt gtggcgagag agtactacag cgaggctgat 360
gccagtcact gtatccagca gatcctggag gccgttctcc attgtcacca aatgggggtc 420
gtccacagag acctcaagcc ggagaacctg cttctggcca gcaagtgcaa aggggctgca 480
gtgaagctgg cagacttcgg cctagctatc gaggtgcagg gggaccagca ggcattggtt 540
ggtttcgctg gcacaccagg ctacctgtcc cctgagggtcc ttcgcaaaga ggcgtatggc 600
aagcctgtgg acatctgggc atgtgggggtg atcctgtaca tcctgtctgt gggctaccca 660
cccttctggg acgaggacca gcacaagctg taccagcaga tcaaggctgg tgcctatgac 720
ttcccgctcc ctgagtggga caccgtcact cctgaagcca aaaacctcat caaccagatg 780
ctgaccatca accctgccaa gcgcatacaca gcccatgagg cctgaagca cccgtgggtc 840
tgccaacgct ccacggtagc atccatgatg cacagacagg agactgtgga gtgtctgaaa 900
aagttcaatg ccaggagaaa gctcaaggga gccatcctca ccaccatgct ggccacacgg 960
aatttctcag ccaagagttt actcaacaag aaagcagatg gagtcaagcc ccagacgaat 1020
agcaccaaaa acagtgcagc cgccaccagc cccaaaggga cgcttctctc tgccgccttg 1080
gagcctcaaa ccaccgtcat ccataaccca gtggacggga ttaaggagtc ttctgacagt 1140
gccaatacca ccatagagga tgaagacgct aaagcccccga gggccccga catcctgagc 1200
tcagtgagga ggggctcggg agccccagaa gccgaggggc ccctgccctg cccatctccg 1260
gtccctcttg gccccctgcc agctccatcc ccaggatct ctgacatcct gaactctgtg 1320
agaaggggtt caggaacccc agaagccgag gggccccctc cagcgggggc cccgccctgc 1380
ctgtctcggg ctctcctagg ccccctgtcc tccccgtccc ccaggatctc tgacatcctg 1440
aactctgtga ggaggggctc agggacccca gaagccaagg gcccctcgcc agtggggccc 1500
ccgccctgcc catctcggac tatcctggc cccctgccca ccccatcccg gaagcaggag 1560
atcattaaga ccacggagca gctcatcgag gccgtcaaca acggtgactt tgaggcctac 1620
gcgaaaatct gtgacccagg gctgacctcg tttagcctg aagcactggg caacctggtt 1680
gaagggatgg acttcacag attctacttc gagaacctgc tggccaagaa cagcaagcca 1740
atccacacga ccatcctgaa cccacacgtg cagtcattg gagaggatgc cgcctgcac 1800
gtttacatcc gggtcacgca gtacattgac gggcagggcc ggccccgcac cagccagtct 1860
gaggagaccc gcgtgtggca ccgcccgcag ggcaagtggc agaattgtgca cttccactgc 1920
tcgggcgcgc ctgtggcccc gctgcagtga agagctgcgc cctgggttctg ccggacagag 1980
ttggtgtttg gagcccgact gccctcgggc acacggcctg cctgtcgcac gtttgtgtct 2040
gcctcgttcc ctccccgtgt gcctgtgtct gcagaaaaac aagaccagat gtgatttgtt 2100
aaaaaaaaaa 2110

<210> 55

<211> 2140

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 067967

<400> 55

```

gtgcgctgag ctgcagtgtc tggctcgagag taccctgtggg agcgtcgcgc cgcggaggca 60
gccgtcccgg cgtagggtggc gtggccgacc ggacccccaa ctggcgccctc tccccgcgcg 120
gggtcccagag ctaggagatg ggaggcacag ctctgtgggcc tgggcggaag gatgcggggc 180
cgctctggggc cgggctcccg ccccgagcgc ggaggttggg ggatggtgtc tatgacacct 240
tcatgatgat agatgaaacc aaatgtcccc cctgttcaaa tgtactctgc aatccttctg 300
aaccaccttc acccagaaga ctaaatatga ccactgagca gtttacagga gatcatactc 360
agcactttttt ggatggaggt gagatgaagg tagaacagct gtttcaagaa tttggcaaca 420
gaaaatccaa tactattcag tcagatggca tcagtgtactc tgaaaaatgc tctcctactg 480
tttctcaggg taaaagttca gattgcttga atacagttaa atccaacagt tcatccaagg 540
caccctaaagt ggtgcctctg actccagaac aagccctgaa gcaatataaa caccacctca 600
ctgcctatga gaaactggaa ataattaatt atccagaaat ttactttgta ggtccaaatg 660
ccaagaaaag acatggaggt attggtggtc ccaataatgg agggatgat gatgcagatg 720
gggcctatat tcatgtacct cgagaccatc tagcttatcg atatgaggtg ctgaaaatta 780
ttggcaaggg gagttttggg caggtggcca gggcttatga tcacaaactt cgacagtacg 840
tggccctaaa aatgggtgcgc aatgagaagc gctttcatcg tcaagcagct gaggagatcc 900
ggatttttga gcatcttaag aaacaggata aaactggtag tatgaacgtt atccacatgc 960
tggaaagttt cacattccgg aaccatgttt gcatggcctt tgaattgctg agcatagacc 1020
tttatgagct gattaaaaaa aataagtttc agggtttttag cgtccagttg gtacgcaagt 1080
ttgcccagtc catcttgcaa tctttggatg cctccacaa aaataagatt attcactgcg 1140
atctgaagcc agaaaacatt ctcttgaaac accacgggcg cagttcaacc aaggtcattg 1200
actttgggtc cagctgtttc gagtaccaga agctctacac atatatccag tctcggttct 1260
acagagctcc agaaatcatc ttaggaagcc gctacagcac accaattgac atatggagtt 1320
ttggctgcag ccttgagaaa cttttaacag gacagcctct cttccctgga gaggatgaag 1380
gagaccagtt ggcctgcatg atggagcttc tagggatgcc accaccaaaa cttctggagc 1440
aatccaaacg tgccaagtac tttattaatt ccaagggcat accccgctac tgctctgtga 1500
ctaccagggc agatgggagg gttgtgcttg tggggggctg ctcacgtagg ggtaaaaagc 1560
ggggctcccc aggcagcaaa gactggggga cagcactgaa aggggtgtgat gactacttgt 1620
ttatagagtt cttgaaaagg tgtcttcact gggaccctc tgcccgttg accccagctc 1680
aagcattaag acacccttg attagcaagt ctgtccccag acctctcacc accatagaca 1740
aggtgtcagg gaaacgggta gttaatcctg caagtgtttt ccagggattg ggttccaagc 1800
tgctccagct tggttgaata gccataagc ttaaagctaa cttaatgtca gaaaccaatg 1860
gtagtatacc cctatgcagt gtattgcaa aactgattag ctagtggaca gagatatgcc 1920
cagagatgca tatgtgtata tttttatgat cttacaaacc tgcaaagga aaaaatgcaa 1980
gccattgggt ggatgttttt gttagagtag acttttttta aacaagacaa aacattttta 2040
tatgattata aaagaattct tcaagggtc attacctaac cagcttgtat tggccatctg 2100
gaatatgcat taaatgactt tttataggtc aaaaaaaaaa 2140

```

<210> 56

<211> 1728

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 346275

<400> 56

```

gacagacaaa gcgccgccac gcgtccgcat gtcggatgtt tgtagcagtc agagagcaga 60

```

```

acatgagcat ctgccaggtc tggttccccc accatcaggg atgggagtga gaaaggggag 120
ttcccctctg aagagccacc cctgcagggg gaaatctgtc tccaacagga gatctgggaa 180
gaccatagtg agaagtgtg tgcgaagaggt ccgcacagcg ggccttttcc gaagtgggtt 240
tagcgaagag aaggcaactg gcaagctctt tgctgtgaag tgtatcccta agaaggcgct 300
gaagggcaag gaaagcagca tagagaatga gatagccgtc ctgagaaaga ttaagcatga 360
aaatattgtt gccctggaag acatttatga aagcccaaat cacctgtact tggcatgca 420
gctgggtgcc ggtggagagc tgtttgaccg gatagtggag aaggggtttt atacagagaa 480
ggatgccagc actctgatcc gccaaagtctt ggacgccgtg tactatctcc acagaatggg 540
catcgtccac agagacctca agcccgaaaa tctcttgtag tacagtcaag atgaggagtc 600
caaaataatg atcagtgtact ttggattgtc aaaaatggag ggcaaaggag atgtgatgtc 660
cactgcctgt ggaactccag gctatgtcgc tcctgaagtc ctgcccaga aaccttacag 720
caaagccgtt gactgtggtt ccctcggagt gattgcctac atcttgctct gcggtaccc 780
tcctttttat gatgaaaatg actccaagct ctttgagcag atcctcaagg cggaatatga 840
gtttgactct ccctactggg atgacatctc cgactctgca aaagacttca ttcggaacct 900
gatggagaag gaccgaata aaagatacac gtgtgagcag gcagctcggc acccatggat 960
cgctggtgac acagccctca acaaaaacat ccacgagtc gtcagcgccc agatccggaa 1020
aaactttgcc aagagcaaat ggagacaagc atttaatgcc acggccgtcg tgagacatat 1080
gagaaaaacta cacctcggca gcagcctgga cagttcaaat gcaagtgttt cgagcagcct 1140
cagtttggtc agccaaaaag actgtgcgta tgtagcaaaa ccagaatccc tcagctgaca 1200
ctgaagacga gcctggggtg gagaggaggg agccggcatc tgccgagcac ctctgtttg 1260
ccaggcgctt tctatactta atcccatgtc atgcgaccct aggacttttt ttaacatgta 1320
atcactgggc cggtgtcagt ggctcacgcc tgtaatccca acactttggg aggtcgaggc 1380
aggaggactg tttgagttca ggagttttaa gaccagcctg accaactatg tgaaacccca 1440
tctctactaa aatataaaaa ttagccgggt gtggtggcga gcacctgtaa tgtcagctac 1500
ttgggaggct gaggcaggag aatcacttga acccaggaag cggaggttgc aatgagctga 1560
gatcacacca ctgcactcca gcctgggtga cagattgaga ctccctctca aaaaaaaaag 1620
ggaaatcatt gaacactcgt ggaaccctag gtattgcata ttccatttac ggtttgggaa 1680
tccagggctc aagtcctcgc aggggtaccg agctcgagat cgtaatca 1728

```

<210> 57

<211> 1610

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 283746

<400> 57

```

gtcgctctg aaggagaacc attttccatc tctttcatag ttttttcccc cagtcagcgt 60
ggtagcggta ttctccgcgg cagtgcagct aattgttttt gcctcttttag ccaagacttc 120
cgccctcgat caagatgggt gttggacggc ctctctaacc tttacggggc ctggcgggtg 180
tgacgcctga gctggtaggg gtggagcagg taggaaacag caaatgcaga agctgctgcg 240
cggaagtccg ccatggactg gaaagaagtt ctctgcggc gcctagcgac gcccaacacc 300
tgtccaaaca ctgcctgctg aagatgaagt ctactacag aaattaagag aggaatcaag 360
agctgtcttt ctacaaagaa aaagcagaga actgttagat aatgaagaat tacagaactt 420
atggtttttg ctggacaaac accagacacc acctatgatt ggagaggaa cgatgatcaa 480
ttacgaaaac tttttgaagg ttggtgaaaa ggctggagca aagtgcgaagc aatttttcac 540
agcaaaagtc tttgttaaac tccttcatac agattcatat ggaagaattt ccatcatgca 600
gttctttaat tatgtcatga gaaaagtttg gcttcatcaa acaagaatag gactcagttt 660
atatgatgtc gctgggcagg ggtaccttcg ggaatctgat ttagaaaact acatattgga 720
acttatccct acgttgccac aattagatgg tctggaaaaa tctttctact ccttttatgt 780
ttgtacagca gttaggaaat tcttctctct ttagatcct ttaagaacag gaaagataaa 840
aattcaagat attttagcat gcagcttcct agatgattta ttggagctaa gggatgagga 900

```

```
actgtccaag gagagtcaag aaacaaattg gttttctgct ccttctgccc taagagtta 960
tggccagtac ttgaatcttg ataaagatca caatggcatg ctcaagtaaag aagaactctc 1020
acgctatgga acagctacca tgaccaatgt cttcttagac cgtgttttcc aggagtgtct 1080
cacttatgat ggagaaatgg actataagac ctacttgac tttgtccttg cattagaaaa 1140
cagaaaggaa cctgcagctc tacaatatat tttcaaactg cttgatattg agaacaaagg 1200
atacctgaat gtcttttcac ttaattatth ctttagggcc atacaggaac taatgaaaat 1260
ccatggacaa gatcctgttt catttcaaga tgtcaaggat gaaatctttg acatggtaaa 1320
accaaaggat cctttgaaaa tctctcttca ggatttaatc aacagtaatc aaggagacac 1380
agtaaccacc attctaactg atttgaatgg cttctggact tacgagaaca gagaggctct 1440
tggtgcaaat gacagtgaag actctgcaga ccttgatgat acatgatctc tgaaagacta 1500
gactgtctta tattatgaga tacttgaatg ctgcatgtaa agcctttaa gcaaaatcct 1560
cagaaatggg ctaaataaaa cacttgatat gcctagagaa aaaaaaaaaa 1610
```

<210> 58

<211> 1290

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2696537

<400> 58

```
ccggctcccc cccggaagtt ctaggccgcc gcacagaaag ccctgccctc cacgcgggt 60
ctctggagcg ccctgggttg cccggccggt ccctgccgct gacttggtga cactgcgagc 120
actcagtcct tcccgcgcgc ctccctcccc cccgccccgc cgtccctcct ccctgtaaca 180
tgccatagtg cgctgcgac cacacggcgg ggcgctagc gttcgcttc agccaccatg 240
gggaatggga tgaacaagat cctgcccggc ctgtacatcg gcaacttcaa agatgccaga 300
gacgcggaac aattgagcaa gaacaagggt acacatatc tgtctgtcca tgatagtgc 360
aggcctatgt tggaggaggt taaataacct tgcattccag cagcggattc accatctcaa 420
aacctgacaa gacatttcaa agaaagtatt aaattcattc acgagtgcgg gctccgcggg 480
gagagctgcc ttgtacctg cctggccggg gtctccagga gcgtgacact ggtgatcgca 540
tacatcatga ccgtcactga ctttggctgg gaggatgcc tgcacaccgt gcgtgctggg 600
agatcctgtg ccaaccccaa cgtgggcttc cagagacagc tccaggagt tggagaagcat 660
gaggtccatc agtatcgcca gtggctgaag gaagaatatg gagagagccc tttgcaggat 720
gcagaagaag ccaaaaacat tctggccgct cccggaattc tgaagtctg ggcctttctc 780
agaagactgt aatgtacctg aagtttctga aatattgcaa acccacagag tttaggctgg 840
tgctgccaaa aagaaaagca acatagagtt taagtatcca gtagtgattt gtaaacttgt 900
tttccatttg aagtgaaata tatacgtagt catgtttatg ttgagaacta aggatattct 960
ttagcaagag aaaatatttt ccccttatcc ccactgctgt ggaggtttct gtacctcgct 1020
tggtatgctg taaggatccc gggagccttg ccgcaactgc ttgtgggtgg cttggcgctc 1080
gtgattgctt cctgtgaacg cctcccaagg acgagcccag tgtagttgtg tggcgtgaac 1140
tctgcccggt tgttctcaa ttccccagct tgggaaatag cccttggtgt gggttttatc 1200
tctggtttgt gttctccgtg gtggaattga ccgaaagctc tatgttttcg ttaataaagg 1260
gcaacttagc caagtttaaa aaaaaaaaaa 1290
```

<210> 59

<211> 2281

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 551178

<400> 59

```

tgatgatcca gatgttaaag cacaagtggga agtgctgtcc gctgcactac gtgcttccag 60
cctggatgca catgaagaga ccatcagtat agaaaagaga agtgatttgc aagatgaact 120
ggatataaat gagctaccaa attgtaaaat aaatcaagaa gattctgtgc ctttaatcag 180
cgatgctgtt gagaatatgg actccactct tcaactatatt cacagcgatt cagacttgag 240
caacaatagc agtttttagcc ctgatgagga aaggagaact aaagtacaag atgttgtagc 300
tcagggcgtt tagatcagt atttatctat gactgaccct tctcgtgcac agacggttga 360
cactgaaatt gctaagcact gtgcatatag cctccctggg gtggccttga cactcggaag 420
acagaattgg cactgcctga gagagacgta tgagactctg gcctcagaca tgcagtggaa 480
agttcgacga actctagcat tctccatcca cgagcttgca gttattcttg gagatcaatt 540
gacagctgca gatctggttc caatttttaa tggattttta aaagacctcg atgaagtcag 600
gatagggtgt cttaaacact tgcagtattt tctgaagctt cttcatattg acaaaagaag 660
agaatatctt tatcaacttc agggattttt ggtgacagat aatagtagaa attggcgttt 720
tcgagctgaa ctggctgaac agctgatttt acttctagag ttatatagtc ccagagatgt 780
ttatgactat ttacgtccca ttgctctgaa tctgtgtgca gacaaagttt cttctgttcg 840
ttggatttcc tacaagttgg tcagcgagat ggtgaagaag ctgcacgcgg caacaccacc 900
aacgttcgga gtggacctca tcaatgagct tgtggagaac tttggcagat gtcccaagt 960
gtctggtcgg caagcctttg tctttgtctg ccagactgtc attgaggatg actgccttcc 1020
catggaccag tttgctgtgc atctcatgcc gcatctgcta accttagcaa atgacagggg 1080
tcctaacgtg cgagtgtctg ttgcaaagac attaagacaa actctactag aaaaagacta 1140
tttcttggcc tctgccagct gccaccagga ggctgtggag cagaccatca tggctcttca 1200
gatggaccgt gacagcgatg tcaagtattt tgcaagcatc caccctgcca gtaccaaagt 1260
ctccgaagat gccatgagca cagcgtcttc aacctactag aaggcttga tctcgtgtgc 1320
tttctgtctt ccatgagagc cgaggttcag tgggcattcg ccacgcagt gacctgggat 1380
agctttcggg ggaggagaga ctttctctc ctgcccactt cattgcaggt gcaagttgcc 1440
tacaccaat accagggatt tcaagagtca agagaaagta cagtaaacac tattatctta 1500
tcttgacttt aaggggaaat aatttctcag aggattataa ttgtcaccga agccttaaat 1560
ccttctgtct tctgactga atgaaacttg aattggcaga gcattttcct tatggaaggg 1620
atgagattcc cagagacctg cattgctttc tcctgggttt atttaacaat cgacaaatga 1680
aattcttaca gcctgaaggc agacgtgtgc ccagatgtga aagagacctt cagtatcagc 1740
cctaactctt ctctcccagg aaggacttgc tgggctctgt ggccagctgt ccagcccagc 1800
cctgtgtgtg aatcgtttgt gacgtgtgca aatgggaaaag gaggggtttt tacatctcct 1860
aaaggacctg atgccaacac aagtaggatt gacttaaaact cttaaagcga gcataattgt 1920
gtacacattt acagaatggg tgctgagtgt ctgtgtctga ttttttcatg ctggtcatga 1980
cctgaaggaa atttattaga cgtataatgt atgtctggtg tttttaactt gatcatgatc 2040
agctctgagg tgcaacttct tcacatactg tacatacctg tgaccactct tgggagtgtc 2100
gcagctttta atcatgctgt ttaaactgtt gtggcacaag ttctcttgtc caaataaaat 2160
ttattaataa gatctataga gagagatata tacacttttg attgttttct agatgtctac 2220
caataaatgc aatttgtgac ctgtattaat gatttaaagt gggaaactag attaaaatat 2280
a
2281

```

<210> 60

<211> 632

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 619292

<400> 60

```

cggacgcgtg gggccagcc gcagctccag caccgaggac ttctgctacg tcttcacggg 60
ggagctggaa cgagggccct ccgggctggg gatgggcctg atcgacggga tgcacacgca 120
cctgggcgcc ccgggctct acatccagac cctgctcccg ggcagccccg cagcgccga 180
cgggcgcctg tcgctggggg accgtatcct ggaggtgaat ggcagcagcc tctgggcct 240

```



```

tggctacctg agagctgtgg acctgatccg tcatggcggg aagaagatgc gggtccctggt 300
cgcgaaagtcc gacgttggga aacagccaag aagatccatt tccgcacgcc ccctctctag 360
gggggctgctg aggcaccccc cacaggcccc gcaccgggtc ccacctgggtg acactgggct 420
tcctcccgcc ttctgccccg ttttgttaact gaccaagtgt ggtccccgggt ggggagcctc 480
acctggggga catgcctgtt gataacatgc atctcagtgt aggttctatt tataatggcag 540
atgacgtgaa attgtgatgt ttgttacaga gcttttatgt ttaaagactt caatggagaa 600
gtacgggttca ataaactatt tttcccgttc tt 632

```

<210> 61

<211> 2347

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2054049

<400> 61

```

cccagtttta tcatggattc atcctgaaag tcaagccaca atcactcggg gtagccagcc 60
catggttgga gtgagtggaa agcgaagcaa agaagatgaa aaataccttc aagctatcat 120
ggattccaat gccagctctc acaaaatctt tatatttgat gcccggccaa gtgttaatgc 180
tgttgccaac aaggcaaagg gtggaggtta tgaaagtgaa gatgcctatc aaaaatgctga 240
actagttttc ctggatatcc acaatattca tgttatgaga gaatcattac gaaaacttaa 300
ggagattgtg taccccaaca ttgaggaaac ccactggttg tctaacttgg aatctactca 360
ttggctagaa catattaagc ttattcttgc aggggctctt aggattgctg acaaggtaga 420
gtcagggaaag acgtctgtgg tagtgcattg cagtgatggg tgggatcgca cagctcagct 480
cacttccctt gccatgctca tgttggatgg atactatcga accatccgag gatttgaagt 540
ccttgtggag aaagaatggc taagtttttg acatcgattt caactaagag ttggccatgg 600
agataagaac catgcagatg cagacagatc gcctgttttt cttcaattta ttgactgtgt 660
ctggcagatg acaagacagt ttcttaccgc atttgaatte aatgagtatt ttctcattac 720
cattttggac cacctataca gctgcttatt cggaacattc ctctgtaata gtgaacaaca 780
gagaggaaaa gagaatcttc ctaaaaggac tgtgtcactg tggctttaca taaacagcca 840
gctggaagac ttactaatc ctctctatgg gagctattcc aatcatgtcc tttatccagt 900
agccagcatg cgccacctag agctctgggt gggatattac ataagggtgga atccacggat 960
gaaaccacag gaacctattc acaacagata caaagaactt cttgctaaac gagcagagct 1020
tcagaaaaaa gttagaggaac tacagagaga gatcttaac cgatcaacct catcctcaga 1080
gagagccagc tctcctgcac agtgtgtcac tcctgtccaa actgttgtat aaaggactgt 1140
aagatcaggg gcatcattgc tatcacctct tgattacact ggcagctcta tgagttagaa 1200
gtcttcggaa tttagaacc atctatgaga gaaagttcag tcactttatt tattttaaat 1260
ctctctagga tgagtttaga actgtagcag tgcaggtggc ttaagtgaag taactccata 1320
tgtaattaca tgattatgat actaatcttt taagtatcca aagaatatta aaatacttca 1380
atcctggatt cacagtggga acaagtttct attaaaaggc aaatgctgtt acaaatTTTT 1440
ggcatctggg aatattaaaa ccatttttaga aatacactct gtgctcactg tgcagaggaa 1500
catcagtttt caaaccaaca ctgaaattct gtggcatcac atatattggg ccttgatgtc 1560
atgacagatc aaaatcattt gatatccctt tctccattct aggtttttct ttttttcagt 1620
aactgattta ccttgatcac ttttcaactt ccatattctt catatagtaa aaggcaaagt 1680
gttgaagata ctacggtgtg gtagtagttg aaaattattg ccgtcattat ttacatactt 1740
aagacatatt agcaagttga tccaaaatgg gaggccttat agatgtgctt gggggaaaaa 1800
gaaggggaga aagttagccat acaggagttc aaagaattcc atgccttca gattagccca 1860
attaccagaa acatcatgaa agatatttta aaaactaatt atttactaca gtgtatttca 1920
cttgtcttgt gtgtctgaac acacagaagc taattagcaa gtttttaaga agtattttaaa 1980
aatcttacta ggattgacat tttttctgaa ttctgtataa atagcttata gtgagaagta 2040
ctgtgtcaa attttacatt tttttccttt gcaaattctg taatttcact caacgattaa 2100
gtctacaaa gaacacactg catgtaaaag atgtattaca atctcaaagc cagtataaaga 2160
aatcttgctt cactgttcac ctgctacaag taagagtttg gtgctggtag aaacatttga 2220

```

ctctgatgtc tattttattc tacataagag ccatatgtaa tgtactgtaa caaaggagct 2280
 tcttgctccc ttggtctttt aattaaaaga aattccaact gacttttaaa ctttaaaaaa 2340
 aaaaaaa 2347

<210> 62

<211> 1737

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte Clone Number: 2843910

<400> 62

ccggggctga gcgctcggct gcagcggcgc ggagggcgtc tccctggtct gccgcggtcc 60
 ccgcccgtcc cgccgccggc tgccatggca ggagccggag ggttcggctg ccccgcgggc 120
 ggcaacgact tccagtggcg cttctcgag gtcaaggggg ccatcgacga ggacgtggcc 180
 gaagcggaca tcatttccac cgttgagttt aattactctg gagatcttct tgcaacagga 240
 gacaagggcg gcagagttgt tatttttcag cgtgaacaag agaataaaag ccgccctcat 300
 tctaggggag aatataatgt ttacagcacc tttcaaagtc atgaaccgga gtttgactat 360
 ttgaaaagtc tagaaattga ggaaaaaatt aataaaatta ggtgggtacc acaacagaat 420
 gctgctcatt ttctactgtc tacaaatgat aaaactataa aattatggaa aataagtga 480
 cgggataaaa gagcagaagg ttataacctg aaagacgaag atggaagact tcgagaccca 540
 tttaggatca cggcgctacg ggtcccaata ttgaagccca tggatcttat ggtagaagcg 600
 agtccacggc gaatttttgc aaatgctcac acatatcata taaattccat ttcagtaa 660
 agtgatcatg aaacatatct ttctgcagat gacctgagaa ttaatttatg gcacttagaa 720
 atcacagata gaagctttaa catcgtggac atcaagcctg ctaacatgga ggagctgacc 780
 gaagtcacga ctgcagccga gttccacccg caccagtga acgtgttcgt ctacagcagt 840
 agcaaaggga ccatccgcct gtgtgacatg cgctcctcgg ccctgtgcga cagacactcc 900
 aagttttttg aagagcctga agatcccagc agtaggtcct tcttctcaga aataatttca 960
 tccatatccg atgtaaaatt cagtcatagt gggcggtaca tgatgaccag agactacctg 1020
 tcggtgaagg tgtgggacct caacatggag agcaggccgg tggagaccca ccagggtccac 1080
 gagtacctgc gcagcaagct ctgctctctc tatgagaacg actgcatctt tgacaagttt 1140
 gagtgttgct ggaacgggtc ggatagcgcc atcatgaccg ggtcctataa caacttcttc 1200
 aggatgtttg atagagacac gcggagggat gtgaccctgg aggcctcgag agagagcagc 1260
 aaaccgcgcg ccagcctcaa accccggaag gtgtgtacgg ggggtaagcg gaggaagac 1320
 gagatcagtg tggacagtct ggacttcaac aagaagatcc tgcacacagc ctggcacccc 1380
 gtggacaatg tcattgccgt ggctgccacc aataacttgt acatattcca ggacaaaatc 1440
 aactagagac gcgaacgtga ggaccaagtc ttgtcttgca tagttaagcc ggacattttt 1500
 ctgtcagaga aaagcatca ttgtccgctc cattaaagaac agtgacgcac ctgctacttc 1560
 ctttcacaga cacaggagaa agcgcctcc gctggaggcc cgggtgtggt ccgcctcggc 1620
 gaggcgcgag acaggcgctg ctgctcacgt ggagacgctc tcgaagcaga gttgacggac 1680
 actgctccca aaaggtcatt actcagaata aatgtattta tttcaaaaaa aaaaaa 1737

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.